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CHAPTER I 
INTRODUCTION 
Retinoids are a relatively new class of compounds which 
have attracted considerable attention in the fields of 
dermatology9,16,22,23,33,43,47,66,82,86,87,88,100,132 and 
oncology.l4,15,23,34,47,69,71,82,91,97 An excellent in 
depth review was recently published on this dynamic topic 
and brought together in two volumes the vast amount of data 
reported up to 1984.l09,llO Originally, these compounds 
were compared to retinol (la) in terms of structure (as 
shown for la-li below) and biological activity. Thus, a 
general definition for this class of compounds was there-
fore based on these two intrinsic properties. However, in 
the search for new retinoids with medicinal applications, 
many compounds have been prepared which possess structures 
of dramatic variation. Consequently, the resemblance of 
many to retinol (la) is remote, and a new definition seems 
necessary. Sporn and Roberts realized that research on 
retinoids had exceeded the original scope of studies in 
terms of significance for nutrition and vision. Thus, in a 
1984 symposium on retinoids a new definition for retinoids 
evolved. 113 They proposed the following: "A retinoid is a 
1 
R 
C02H 
1g 
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1a CH20H ~ C02H 
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1e CH20C (CH2 )14CH3 
- 0 
1f CH20C (CH2 )15CH3 ,..... 
1h HO 
-
co2~H 
0 OH 
C02H 
eubstance that can elicit specific biological responses by 
binding to and activating a specific receptor or set of 
receptors". 113 The two classic retinoids which have been 
examined in binding studies are retinol (la)l09,llO and 
retinoic acid (lb).l09,1lO,lZl However, the experimental 
studies of the binding process developed by Sporn and 
Roberts, to determine if a compound was truely a 
"retinoid", constitute elaborate processes.l09,llO More-
over, Schiff recently reported in a comparison between five 
retinoids that no correlation existed between biological 
2 
activity and binding sites for cellular retinoic acid 
binding protein (CRABP).78 Therefore, in this text a 
specific definition for retinoids will not be cited since 
at this time there is insufficient evidence to invalidate 
the candidacy of any synthetic "retinoid" for possible 
binding studies. 
Historical 
The historical scenario of retinol [la or vitamin A], 
the parent compound of retinoids, begins at the turn of 
this century. In 1909, Stepp,ll6,ll 7 a professor in 
Germany, revealed a lipid-soluble material that he proved 
to be essential for sustaining life in laboratory animals. 
Stepp performed a critical experiment by extracting animal 
feed with ether or alcohol, and, after using this feed for 
his test mice, discovered that the mice died. Thereafter, 
McCollum and Davis 74 • 75 reported the presence of a 
substance which they termed "Fat Soluble A" that occurred 
in butterfat and egg yolk. They were able to demonstrate 
that this "Fat Soluble A" promoted life in rats fed fat-
deficient diets. Then in 1920, Drummond 35 named this 
important nutrient "vitamin A". Eleven years later, the 
structure of vitamin A (la) was elucidated by Karrer and 
Morf63 by using structural information for S-carotene 
(2)61,62,73 established several years earlier. 
In experiments that followed, many biological and 
physiological aspects of vitamin A were uncovered. One 
3 
B-Carotene (2) 
important accomplishment by Wald in 1935 linked vitamin A 
to the vision process.125,126 He was able to prove that 
retinal (lc), an oxidatized derivative of vitamin A, was 
vital in the visual pigments of the eye. 
R 
1c R = CHO 
In 1946, Aren and van Dorp1 synthesized retinoic acid 
(lb), a derivative of vitamin A, and illustrated its 
biological importance in the promotion of growth in rats. 
Several groups directed considerable effort to the total 
synthsis of vitamin A (la), but the most important 
4 
contributions were made by two commerial groups, namely 
those at Hoffmann-La Roche and Company Ltd 56 (1947) and at 
Badische Anilin und Sodafabrik (BASF)89 (1960). Isler, of 
the La Roche group, reported the complete synthesis of 
vitamin A as shown in Figure 1. 5 6 The first step was the 
cyclization step involving pseudoionone (3) with acid to 
give S-ionone (4). To S-ionone (4) was added a one carbon 
fragment using Darzens glycidic ester condensation which 
gave the B-c 14 aldehyde 5. This aldehyde was in turn 
treated with cis-3-methyl-2-penten-4-yn-1-ol.(6) which gave 
dial 7; the latter was subjected to partial hydrogenation 
over Lindlar catalyst affording the dial 8. Dial 8 was 
mono acetylated to 9, which, after dehydration followed by 
a rearrangment, gave crystalline vitamin A acetate (1d). 
The final step was achieved smoothly by saponifying 1d to 
vitamin A (1a). 
In 1953, Wittig 131 reported an olefination method which 
was so efficient that in 1979 he was awarded the Nobel 
Prize in chemistry. This olefination process prompted 
Pommer of BASF to attempt another synthesis of vitamin A 
acetate (1d) utilizing the newly discovered Wittig re-
action131 (Figure 2). The key material in this process was 
B-ionone (4) as was true in the Hoffmann-La Roche process. 
Addition of an acetylene to 4 followed by hydrogenation 
gave vinyl S-ionol (11). The desired phosphonium salt 12 
was obtained by treating alcohol 11 with triphenylphosphine 
and hydrochloric acid. The final step proceeded smoothly 
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Figure 1. Hoffmann-La Roche Commercial Synthesis 
of Retinol (la) and Retinyl Acetate 
(ld). 
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Figure 2. BASr Commerical Synthesis of Vitamin A 
through a Wittig type reaction with the anion of 12 and w-
acetoxytiglic aldehyde (13) to give vitamin A acetate (ld). 
The biological interrelationship between certain natural 
retinoids is shown in Figure 3 and involves retinol (la), 
retinal (lc), and retinoic acid (lb). Dietary 6-carotene 
(2) was shown by Goodman 45 to be cleaved enzymatically in 
the intestinal mucosa into two equivalents of retinal (lc). 
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Figure 3. Biological Connection of Vitamin A 
Moreover, in the intestinal mucosa retinal (lc) was reduced 
to retinol (la). Retinol (la) was in turn esterified with 
a long chain fatty acid, usually palmitic acid, and carried 
in the chylomicrons to the liver for storage. 44 
Retinol (la) is then mobilized from the liver and trans-
ported in the plasma while being bound specifically to a 
transport protein called retinol binding protein (RBP). 
This protein was first isolated by Goodman 46 and commonly 
found to be a 1:1 complex with transthyretin (TTR). The 
primary structures of RBP 93 and TTR 60 are known. TTR is 
one of the most completely characterized human proteins 
known, the three-dimensional structure being resolved to 
1.8 A in 1978.11 In contrast, the three-dimensional 
structure of RBP, however, eluded researchers until 
recently when the structure was refined to 3.0 A. 80 RBP is 
defined as containing a B-barrel core as in Figure 4. 80 
145 
Retinol 
;a 
Figure 4. Three Dimensional Structure of RBP 80 
This barrel is open at one end and closed at the opposite 
end which engulfs the B-ionone ring. The latter eliminates 
the unfavorable interaction in the polar transporting 
media. 
Ret1nol (la) is transported in the TTR-RBP complex to 
peripheral target tissues. 84 The process that governs this 
mobilization is highly regulated and depends heavily upon 
RBP synthesis and secretion by the liver. Furthermore, 
9 
10 
there is considerable evidence indicating that the trans-
location of retinol (la) to a cell might also involve 
recognition of RBP by a specific surface receptor. 54 ,SS,9Z 
Once retinol (la) enters the cell, it complexes with a 
cellular retinol binding protein (CRBP). 84 This complex is 
presumed to activate gene expression for cell differentia-
tion and proliferation.95 
Retinoic acid (lb), a biologically active metabolite of 
retinol (la), is delivered to a cell as a complex with 
albumin.lOS Once in the cell, lb is bound to a new protein 
known as cellular retinoic acid binding protein (CRABP). 121 
In addition to retinol (la) being metabolized by alcohol 
dehydrogenase at varioui locations in the body, it is con-
ceivable that metabolism of la, once delievered by RBP to 
the cell, occurs to give retinoic acid (lb) in many target 
cells. 31 Retinoic acid (Ib) in a cell can participate in 
differentiation and growth. It is plausible that a combin-
ation of these two processes might be operating independ-
ently. 
Metabolism of Retinol {la) and 
Retinoic Acid (lb) 
Since 1931, when the structure of retinol was eluci-
dated, a large number of publications have appeared 
concerning the metabolism of the natural retinoids.l09,llO 
Initial investigations were laborious and time-consuming 
processes which yielded modest results in terms of 
resolving the metabolic pathway of retinoids. With the 
advent of high-pressure liquid chromatography (HPLC) also 
came quantum leaps in this area affording highly purified 
retinoids for improved structural diagnosis. 
The need to understand the metabolic pathways of 
retinoids has important ramification regarding active 
form(s) responsible for the biological activity. In addi-
tion, identification of the specific structural sites most 
vulnerable to biological degradation in a retinoid could 
afford insight for the medicinal chemist to develop active 
synthetic analogues. 
Metabolism of Retinol (1a) 
11 
Retinol (1a) has been studied extensively in an effort 
to determine its physiological mode of action. A portion 
of one important metabolic pathway was determined early, 
and revealed the active form in the visionary process as 
11-cis-retinaldehyde (14). 127 The suggested routes and 
other metabolites are shown in Figure 5. Metabolites 1b, 
1c, 1e and 1f have been discussed earlier. Surprisingly, 
an extremely non-polar hydrocarbon was isolated by Bhat in 
1979. 10 He reported the identification of anhydoretinol 
(15) as the metabolite of retinol (1a) from cultures of 
spontaneously-transformed, mouse fibroblasts. 
Several derivatives are apparently formed intracellu-
larly.41•8 Retinol (la) can be phosphorylated to retinyl 
phosphate (16a), which in turn is converted to retinyl-
12 
" " 
~ R 
0 
II 
1$ R =OCICH2114cH3 
ll 0 II 1f R = OCICH2116CH3 -J 
~ ::;;..-- '7 ~~ 
""" 
~ 
""" 
OH 
~ 
15 ? 
,.-..../ 
1l 
1a 
~ 
"':::: ""= ~ CHO L-
~ 
14 1c 
.-....J l ,..... CHO 
~ 
"" "" 
C02H 
1b ,..... 
Figure 5. Metabolites of Retinol 
mannosyl hydrogen phosphate (16b)4l via the involvment of 
the cofactor quanosine-5'-diphosphomannose (Figure 6). 
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Figure 6. Retinol Metabolites 
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Metabolism of Retinoic Acid (lb) 
Retinoic acid (lb) is apparently not reduced biological-
ly to retinol (la) but, lb is absorbed unchanged by the 
blood from the intestine. 3 9 Moreover, retinoic acid (1b) 
is not stored in appreciable quantities in the body. 
Kalin59 determined the distribution of acid (1b) in 
selected mice tissue after a single 10 mg/kg dose. The 
levels in twelve tissues analyzed reached a maximum between 
30 to 120 min and declined after 3 hours. Brain tissue 
seem to retain retinoic acid (lb) longer than the other 
tissues (i.e. small intestine, liver, lung, fat, kidney 
heart, spleen, large intestine, muscle, testes, and 
bladder). 
Three metabolites (17,18 and 19) were observed and 
identified in the urine of rats given a 27 mg dose of 
retinoic acid (1b) intraperitioneally (Figure 7). 52 All 
0 0 
0 0 
Figure 7. Urinary Metabolites of Retinoic Acid5 2 
14 
three of the isolated compounds had a carbonyl group at 
C(4) and two were lactones with 18 being hydroxylated at 
C(l7). Lactone 17 is apparently a precursor to 18. The 
remaining isolated metabolite 19 was a nonconjugated keto 
acid. Logically, 19 can be 1actonized to 18 with 
concomitant restoration of conjugation. 
Rietz9 4 reported four other metabolites from rat urine 
after a pharmacological dose of retinoic acid (1b). The 
metabolites were derivatized with diazomethane to give 
esters which were characterized (Figure 8). The common 
19 20 
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0 0 
C02 Me ~ 
COzH 
0 0 
~ ~ ~ 
COzMe 
-...;;:: ~ ~ COzH 
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Figure 8. 94 Urinary Metabolites of Retinoic Acid (1b) 
in Rats. (Left) Metabolites After Diazo-
methane Treatment. (Right) Assumed Struc-
tures of Metabolites Before Derivatization. 
position metabolized in acid lb is C(4) and, to some 
extent C(16). 
15 
An interesting comparison between the studies of Hanni5 2 
and Rietz9 4 is the extent of oxidation of the geminal 
dimethyls [i.e. at C(16)]. At a pharmacological dose 
level, the metabolic alcohols experienced additional oxida-
tion to the carboxylic acids with no chain cleavage. With 
an intraperitioneal dose of 27 mg of lb to rats, Hanni 52 
observed extensive chain shortening and diminished meta-
bolic oxidation. 52 A plausible conclusion might be that at 
high levels of retinoic acid (lb) the normal pathways are 
altered to facilitate the excretion of metabolites and lb 
thereby diminishing the latter in the body. 
Other metabolites of acid (lb) are shown in Figure 9. 11 0 
Several of these natural retinoids have shown biological 
activity similiar to that of retinoic acid (lb). 76,11S One 
retinoid, namely 13-cis-retinoic acid (lg), was thought 
initially to be an artifact of the isolation process. But 
in 1980, Frolik 40 established that isomerization of acid 
lb to isomeric acid lg occurs in the normal metabolic 
sequence. The importance of this phenomenon was shown in 
an in vitro "liver-metabolizing" system. Using only all-
trans-retinoic acid (lb), the metabolites 20a and 20b 
furnished isomeric 4-oxoretinoic acids 21a and 2lb whose 
distribution is concentration dependent. In three tissues 
studied, at a low initial concentration administered for 
lb, the 13-cis-4-oxoretinoic acid (2lb) was generally the 
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Figure 9. Metabolites of Retinoic Acid (lb)llO 
major form while at higher initial concentrations the all-
trans-acid 21a dominated (Table 1). The exact physiologi-
cal significance of these observation remains unknown. 
However, since 13-cis-retinoic acid (lg) is biologically 
equivalent to all-trans-retinoic acid (lb) in terms of 
TABLE 1 40 
CONCENTRAION DEPENDENCE OF ALL TRANS-RETINOIC 
ACID ON AN IN VITRO CONVERSION TO 
4-0XORETINOIC ACID. 
Percent 
17 
of 
Initial All-Trans- 4-0xoretinoic Acid 
Retinoic Acid 
Tissue Concentration (M) 13-Cis Trans 
Liver 10-7 27 74 
10-8 59 41 
Intestine 10-7 86 14 
10-8 87 13 
Testis 10-6 76 24 
10-7 66 34 
growth promotion in rats, it is possible, in a manner 
analogous to the visual process, that isomerization at 
C(13) is needed for epithelial differentiation. 
Another retinoid isolated from metabolism of acid lb is 
retinoyl-S-glucuronide (lh). First identified in 1964,36 
ester lh was reported to be water soluble and to have 
biological activity ranging from 30-100% compared to 
retinoic acid (Ib) in terms of a growth assay. In the rat 
vaginal smear assay, r~tinoyl-S-glucuronide (lh) is more 
active that retinoic acid (lb).115 
In the remaining metabolites from acid lb, the common 
oxidative site is C(4), being oxidized either to a hydroxyl 
18 
or to a carbonyl group. Another site attacked is the 5,6 
double bond which leads to 5,6-epoxy-5,6-dihydroretinoic 
acid (li). Preliminary data on epoxide li appeared extreme-
ly promising, 76 but it was later determined to possess 
only 1% of the activity of trans-retinoic acid (lb) as 
evaluated by the tracheal organ culture assay. 81 This 
assay will be discussed briefly in a later section. 
19 
CHAPTER II 
RETINOIDS IN CHEMOTHERAPY 
Cell differentiation by retinol (la) was first described 
in 1925 by Wolback. 130 The study revealed that 
deficiencies of retinol (la) led to changes from normal 
epithelium to squamous keratinization in mucus mem-
branes.130 Later, the interrelationship between retinol 
(la) and cancer was demonstrated by Fujimaki 42 in 1926. He 
showed that rats fed a vitamin-A deficient diet developed 
stomach carcinomas. Another study using Syrian golden 
hamsters linked vitamin A (la) with the inhibition of 
tracheobronchial tumors.9 8 The carcinogen employed was 
benzo[~]pyrene which was suspended in saline before intra-
tracheal installation. Exposure to such a carcinogen 
normally produces up to 100% formation of respiratory tract 
tumors. Of the 46 hamsters treated with vitamin A (la), 
only two developed detectable tumors. 
Another natural retinoid, retinoic acid (lb), has been 
extensively studied. 109 • 110 Bollag showed that acid lb 
exerted a prophylactic effect on papillomas (originally 
induced by 7,12-dimethylbenz[a]anthrene) by delaying or 
diminishing the occurrence of the latter as compared to a 
control. 12 -l4 Retinoic acid (lb) also accelerated the 
20 
healing of wounds in rats. 64 • 65 These early studies hinted 
at the overall importance of ret~noids in the possible 
prevention and treatment of certain tissue disorders 
including cancer. It appeared that the family of natural 
retinoids might contain significant chemotherapeutic agents 
to combat the high percentages of deaths from malignancies 
in the epithelium of patients. 2 Unfortunately, because 
vitamin A (la) and it esters are stored in the liver, a 
regulatory process strictly prevents the level of la in the 
bloodstream from rising proportionally with even massive 
doses. 84 Moreover, at higher concentrations, natural 
retinoids become toxic. It is because of this toxicity 
(known as "hypervitaminosis") that the clinical uses of 
these natural retinoids are limited. Thus the search for 
modified retinoids seems a worthy goal. Since the exact 
mode of action and mechanism of cell differientation is 
unclear, 104 the question arises as to what structural 
modifications are likely required to give less toxic 
retinoids with improved efficacy. 
In the search for retinoids with enhanced activity and 
low toxicity, metabolic pathways and structure-activity 
relationships of known anticancer agents can serve as 
guidelines. One might consider three regions in retinol 
(la) for modification: 1) the trimethylcyclohexenyl or 
hydrocarbon ring, 2) the polyene or hydrocarbon side chain 
and 3) the polar terminal group (Figure 10). These regions 
might be altered in order to accomplish these goals. The 
21 
first is to increase the hydrophilicity and overall 
polarity of the synthetic retinoid. Since both the all-
trans-acid lb and 13-cis-acid lg show acitivity higher than 
most retinoids in many assays, it is likely that the 
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Figure 10. Regions of Structural Modification in Retinol 
overall polarity of modified retinoids should be greater 
than retinoic acid (lb) while retaining the same overall 
geometry and size. 
The second objective for structural change is to vary 
the metabolic oxidative pathway. The oxidation of retinoic 
acid (lb) is known to occur at C(4) to give either the 
hydroxyl system 20a or the carbonyl-containing system 2la 
(see also Figure 9). 52 ,9 4 , 110 In addition, epoxidation of 
C(5)-C(6) to give li and hydroxylation of C(16) to give 20c 
are known. 52 • 76 Modifying these positions could allow the 
modified retinoid to proceed through a different metabolic 
pathway which might enhance the activity due to higher 
1b ,.., 
20a 
- 0 
concentrations at the target site, for instance, from 
improved distribution. 
22 
Finally, the structure of new retinoids might be changed 
to block the potential oxidation sites. For instance, if 
the postion of normal metabolism in acid lb is blocked by 
the presence of a group resistant to oxidation, the usual 
metabolic path for a retinoid might also be disrupted. 
This alteration from normal oxidative metabolism could lead 
to improved effectiveness of the drug. 
Assay of Retinoids-The Biological Method 
In order to assess the usefulness of a test retinoid, a 
variety of assays have been developed. Two forms of 
testing activity of retinoid~ are available, the in vivo 
and in vitro methods. Since these analyses vary in 
accuracy, speed and cost, a full evaluation of new retinoid 
analogues require at least two separate assays. Some are 
described below.112 
In Vivo Methods 
23 
The in vivo methods are extremely important for 
measuring the biological activity of new retinoids. 
Results from such an assay can reveal potential use of a 
test retinoid in chemotherapy. Two common screens are the 
mouse papilloma assay 14 , 73 and the ornithine decarboxylase 
(ODC) assay.lZZ,lZ 3 However, a third but less popular 
method, is the rat vaginal smear assay.ZS,l06,115 Each of 
these tests require only small amounts of retinoid which 
allows for rapid screening of new synthetic systems. 
The mouse papilloma assay is based on a two-stage pro-
cess involving the dorsal skin with specific initiation and 
promotion to a carcinogenic state. 32 The test entails use 
of the initiator 7,12-dimethylbenz[~]anthracene (DMBA) 
which is applied to the shaven backs of mice twice at 2 
week intervals. The promoter croton oil is applied three 
weeks later and twice a week for 3-8 months which promotes 
generation of multiple papillomas averaging 3 mm in 
diameter. 14 , 73 Treatment with a test retinoid then begins, 
and, after two weeks, the papillomas are remeasured and the 
ED 50 is determined. The ED 50 is the effective dose 
required to cause a 50% regression of the papillomas. Some 
of the important results are shown in Tables II and II[. 
TABLE II 
THE BIOLOGICAL EVALUATION OF RETINOIDS USING 
THE IN VIVO MOUSE PAPILLOMA ASSAY 
Retinoid 
~ """= 
22c F 
........... 
Antipapilloma 
Activity 
ED 50 (mg/kg)/day 
400 
800 
C02H 
<80 
24.3 
C02H >20 
25 
Hyper-
vitaminosis 
(mg/kg)/Day 
80 
400 
200 
100 
100 
50 
24 
Ref. 
73 
84 
83 
83 
83 
73 
TABLE III 
THE BIOLOGICAL EVALUATION OF RETINOIDS USING 
THE lR VIVO MOUSE PAPILLOMA ASSAY 
Retinoid 
27 
"-/ 
Antipapilloma 
Activity 
ED50 (mg/kg)/day 
CONEt 
H 
12.5 
50.0 
2.7 
7. 1 
19.2 
so 
75 
Hyper-
vitaminosis 
(mg/kg)/Day 
100 
100 
25 
so 
so 
100 
200 
Ref. 
83 
73 
83 
83 
83 
73 
84 
One obvious weakness with this assay is the long time 
required for results. Moreover, the therapeutic efficacy 
25 
of 13-cis-retinoic acid (lg) is not revealed in this assay 
as seen in Table II. Acid lg has been shown in other 
assays to be quite active.8• 26 • 27 ,Sl,l08 Thus employing 
26 
two assays for each new retinoid seems crucial to ascertain 
the level of activity of a potential viable candidate. 
A method derived from the mouse papillomas assay is the 
ornithine decarboxylase assay (ODC) as cited previously. 109 
The major advantage of the latter assay is the short time 
needed to evaluate a retinoid. Verma·and Boutwe11 122 • 123 
demonstrated that TPA (Figure 11) is an intense promoter of 
the enzyme ornithine decarboxylase but retinoids were able 
to inhibit the action of this enzyme. The results of this 
assay correlate well with the inhibition of papilloma 
development in the long term experiments with mice.l 22 ,1 2 4 
Figure 11. Structure of 12-0-Tetradecanoylphorbol-
13-Acetate (TPA) 
The procedure used in the quick ODC assay is as follows. 
To a mouse pretreated with DMBA is applied a test retinoid 
27 
at a desired concentration 1 hour before application of 17 
nmols of TPA. After 4.5 hours, the mouse is sacrificed and 
the epidermis is separated and homogenized. The release of 
labeled C0 2 from [ 14c]ornithine is determined from 
homogenized solution. Results for new retinoids are 
compared to a control and the percent inhibition is 
determined. Several retinoids are shown in Table IV using 
the ODC assay. 
TABLE IV 
ACTIVITY OF RETINOIDS IN THE ORNITHINE 
DECARBOXYLASE ASSAY 
Retinoid Dose (nmol) 
C02H 
1.7 
1.7 
1.7 
17.0 
1.7 
COzH 
~C02H 17.0 CJ:<l· 1.7 .. """ 3! 
% Inhibition 
of control Ref. 
88 ± 1 29 
92 ± 2 27 
92 ± 2 26 
96 ± 1 27 
96 ± 1 26 
80 ± 1 29 
77 ± 0 29 
TABLE V 
ACTIVITY OF RETINOIDS IN THE ORNITHINE 
DECARBOXYLASE ASSAY 
% Inhibition 
28 
Retinoid Dose (nmol) of Control Ref. 
COzH 
17.0 
17.0 
17.0 
17.0 
17.0 
1.7 
17.0 
1.7 
72 ± 2 
67 ± 2 
80 
82 ± 2 
77 
67 
9 
9 
27 
27 
28 
26 
28 
28 
28 
28 
29 
The final in vivo assay discussed herein is the rat 
vaginal smear assay.25,106,115 Developed in 1932 by 
Baumann and Steenbock 7 to determine the presence of 
retinol (Ia), the method has become somewhat obsolete with 
the advent of modern quantitative analytical techniques. 
However, in 1982, DeLuca 106 was able to increase the 
sensitivity that had plagued this assay and thereby revived 
interest in the method for testing new retinoids. 
This assay measures the changes in the sensitive vaginal 
epithelium. Rats used in the assay are vitamin A-deficient 
and ovariectomized, the latter being done to alleviate the 
interference from hormonal cycling. 90 The test retinoid 
is applied topically to the cornified vaginal epithelium 
and the response is monitored. 106 The response is deter-
mined from the vaginal smear by scoring the cells in terms 
of the presence or absence of three basic cell types. 
These types are non cornified epithelial cells, cornified 
epithelial cells and leukocytes. The scores are plotted 
against concentrations of retinoid used and the ED 50 values 
are determined as the dose observed to give a 50% reversal 
in cornification 106 (Table VI). Attention should be 
directed to retinoid lh, which is one of the few natural 
retinoids that posesses biological activity greater than 
retinoic acid (Ib). The biological activity of ester lh is 
believed to be the result of the enhanced polarity of the 
terminal group increasing the concentration of the retinoid 
at the site of action. 1 06 
TABLE VI 
ACTIVITY OF RETINOIDS IN THE RAT 
VAGINAL SMEAR ASSAY 
Retinoid ED 50 (mol/vagina) 
1 x 1o- 10 
OH 8 X 1o-10 
""'= co2~H 
2 0 OH 
1h C02H 
-
C~H 2 X 1o-10 ~ 
1i 
-
1. 3 X 1o-8 
/,~ 
~co2Et 
2.3 X 10-S 
ND (a) 
ND (a) 
a Not determined, inactive at doses up to 10-7 
mol/vagina. 
Ref. 
25,106 
106 
106 
25 
25 
25 
25 
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In Vitro Methods 
The in vitro methods are extremely valuable for 
screening large numbers of compounds and, unlike in vivo 
methods, exact biological end points are available.111 The 
two increasingly important assays are the hamster tracheal 
organ culture (TOC) assay, 28 • 2 9• 81 ,99 and the assay 
involving the human promyelocytic leukemia cell line (HL-
60).8•108•119 The TOC assay measures the aptitude of 
retinoids to maintain epithelial cell differentiation in 
tracheas of hamsters fed a vitamin-A deficient diet.81 A 
retinoid is considered active if neither keratin or 
kertohyaline granules are observed and inactive if both 
keratin and keratohyaline are present. 81 Dose response 
curves are then tabulated to determine the ED 50 
(suppression of keratinization in 50 percent of the 
cultures). In 1980, Sporn and coworkers reported a 
collaborative body of data on 87 retinoids from eleven 
sources around the world. 81 Shown in Table VII are 
results of important retinoids from Sporn 81 and others 
more recently published.28,29,99 
Another in vitro method is the use of the human 
leukemia-60 cell line (HL-60). This cell line, derived 
from a patient with acute promyelocytic leukemia, is an 
excellent system for the determination of the activity of a 
retinoid. 8 Leukemia is believed to prevent normal 
differentiation and therefore retinoids active in this 
Retinoid 
CH3 
MeO 
MeO 
TABLE VII 
ACITIVITY OF RETINOIDS DETERMINED 
BY HAMSTER TRACHEAL ORGAN 
CULTURE 
EDso (M) 
3 X Io- 11 
co2H 
1 X Io- 7 
In active in 
12/13 cultures 
C02H 5 X Io-9 
~C02H 
~---~ 3 X 1o-1o 
C02Et 1 X Io
-10 
1 x 1o-10 
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Ref 
29 
81 
81 
81 
81 
29 
28,99 
99 
81 
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assay are good candidates for further study. The procedure 
for this method involves treatment of HL-60 cells with a 
test retinoid and nitroblue tetrazolium (NBT), a water-
soluble dye, followed by incubation for 4 to 5 days. The 
differentiated cells produce a superoxide anion reducing 
NBT to an insoluble dark formazan. Therefore, the per-
centage of the differentiated cells are easily determined 
visually. Results are measured by calculating the percent 
of NBT redution which is directly related to differentia-
tion.4 The ED 50 is determined in a similar manner as in 
the TOC assay. The results with all trans-lb and 13-cis-lg 
acids are available in Table VIII. 
Retinoid 
-...;::: 
""' 
TABLE VIII 
BIOLOGICAL ACTIVITY OF lb AND 1g 
ACIDS IN THE HL-60 CELL LINE 
ED so (M) 
1 X 10-8 
C02H 1 X 10- 7 
-...;::: 
"" 
Je 
1 X 10-8 
1 10- 7 X 
1g 
~ 
C02H 
Ref 
8 
108,119 
8 
108 
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Arotinoids And Heteroarotinoids. 
A New Generation of Active 
Retinoids 
Although a large number of modified retinoids have been 
synthesized and screened for biological activity, only a 
few have shown promise in pharmacological application. Two 
basic requirements (discussed earlier) for a retinoid to be 
potentially useful are activity similiar to retinoic acid 
(1b) and diminished toxicity. 
A significant achievement to satisfy the first require-
ment concerning activity appeared in 1980. 68 Loeliger 
reported a new class of active retinoids he labeled as 
"arotinoids". These arotinoids had one common structural 
feature in that an aromatic ring was fused to the 
cyclohexyl system and the C(4) position substituted with 
two methyl groups (Figure 12). These structural modifica-
tions block several metabolic sites known to exist for 
trans-retinoic acid ( 1 b). 
R R 
Figure 12. The Conceptual Development in the Conversion 
of Retinoids to Arotinoids, Blocking the 
Major Metabolic Postions: C(4) and the 
C(5)-C(6) Double bond. 
35 
The synthesis of these compounds proceeded through two 
efficient steps, the first being the formation of the 
appropriate phosphonium bromide as shown below. The second 
major step was achieved by a Wittig type reation as shown 
in Figure 13. 
R~o ;Ph3Br-
___ a_.b_.c __ ~(CH~ 
R A 
R 
n=1.R=H 
n: 1 . R =!VIe 
n:2.R:Me 
R 
a. NaBH4 
R R 
Figure 13. The General Synthetic Route to Arotinoids 
Several arotinoids have proven to be extremely active in 
the mouse papillomas, 68 the TOC, 29 • 81 the ODC 29 and HL-
60 assays.ll9 However, the toxicity of these compounds 
appears to be severe. Thus these synthetic retinoids 
showed promise in terms of high activity but the toxicity 
is above an acceptable level. 
36 
A new alteration has been the incorporation of a hetero-
atom at C(4) to replace the geminal dimethyl group while 
maintaining the fused aromatic ring (Figure 14). These new 
retinoids were termed as "heteroarotinoids". The 
synthesis and biological activities of these new compounds 
R 
X= 0, S, S+O 
Figure 14. General Structure of Heteroarotinoids. 
were reported by two groups independently, namely by 
Berlinl28 and Dawson.29 These heteroarotinoids appear 
from preliminary data to have met the two basic require-
ments described earlier, namely high activity and low 
toxicity, although the latter is based upon only qualita-
tive observations. 
37 
The syntheses of these compounds was accomplished by two 
separate methods independently. Dawson's synthesis is 
shown in Figure 15 29 while Berlin's synthetic scheme 128 
will be briefly discussed later. The biological data for 
these compounds are shown in Table IX along with trans-
retinoic acid (lb) and 13-cis-retinoic acid (lg) as the 
standards for comparison. 
co:J 
0 
a. NaH. ~CI 
b. AICI3 
Figure 15. 29 
g. SnC14 
h. AcCI. Lewis Acid 
Dawson's Synthesis of the Oxa and Thia-
Substituted Heteroarotinoids 
TABLE IX 
THE BIOLOGICAL ACTIVITY OF SELECTED AROTINOIDS 
AND HETEROAROTINOIDS VIA TOC, ODC 
AND HL-60 ASSAYS. 
ODC % INHIBIT. 
TOC 
38 
Retinoid ED so (ref.) 
OF CONTROL (ref.) 
(1.7 nmol dose) HL-60 (M) (Ref.) 
lb 1 X lo-ll (29) 88 ± 1 (29) 1 X 10-7 (119) 
lh 3 X lo-ll (81) 92 (a) 
89 (a) 
40 1 x lo-12 (29) 89 ± 1 (29) 3 X 10-7 (119) 
41 3 X lo-12 (29) 56 ± 1 (29) c 
42 6 X lo- 11 (128) c c 
43 5 x lo-ll (29) 68 ± 4 (29) c 
44 1 x lo- 10 (128) 43b )3 X lo- 6 (a)b 
45 6 X lo-10 (128) 42 ± 6 (29) )3 X 10-6 (a) 
45 2 x Io- 10 (29) c c 
46 1 x lo- 10 (128) c c 
a Unpublished results, Berlin et. al. b Methyl ester tested 
c Not tested 
~oo,, ~"'" ~co2et ....;: -...;: 
s 
~ 
.!!. .s. 
~co2H ~co2et ~co2H 
....;: 
" 
-..;: 
s 0 0 
.2 ~ ~ 
~co2et 
-..;: 
b 2 
The major difference in the activity of the hetero-
arotinoids is the dramatic results in the preliminary 
toxicity screening with Swiss mice (Table X). The non-
TABLE X 
TOXICITY OF RETINOIC ACID AND SELECTED AROTINOIDS 
AND HETEROAROTINOIDS IN SWISS MICE. 
Dose % Survivors Mortality 
Retinoid umol/kg day Day 8 Day 15 Range, Days 
Control 0 100 100 
Retinoic 600 95 0 7-13 
Acid (I b) 300 100 0 10-14 
200 100 63 14-15 
100 100 100 
67 100 100 
40 30 50 0 6-8 
10 87 0 7-10 
3.3 97 0 7-11 
1.0 100 30 10-15 
41 100 100 0 8 
30 100 0 9-12 
10 100 68 10-15 
3.3 100 100 
43 600 100 0 9-10 
300 100 80 14-15 
100 100 100 
30 100 100 
45 600 70 0 7-10 
300 100 so 12-15 
200 100 90 14 
100 100 100 
30 100 100 
39 
heterocyclic arotinoid 40 is extremely toxic even at 1.0 
umol/kg day which gave a mortality range of 10-15 days.29 
In contrast, with heteroarotinoid 43 (at 300 umol/kg day) 
the mortality range was 14-15 days. Obviously, if one 
considers life extension only, 43 is better than 40. This 
40 
initial toxicity indicated that arotinoid 40 is greater 300 
times more toxic than 43. A useful comparison is between 
43 and trans-retinoic acid (1b). The data in Table IX 
indicates retinoic acid (lb) is slightly greater in 
toxicity than 43. At a common dose of 300 umol/kg day for 
both retinoic acid (lb) and for 43, there were no survivors 
from the experiment with retinoic acid lb at the end of two 
weeks. However, 80% of the animals survived after -treatment 
with heteroarotinoid 43. 29 The structures of arotinoid 40 
and 41 and heteroarotinoids 42 and 46 are shown in Figure 
16. 
The relationship of retinoids to cancer109,110 and to 
epiderma1 109 • 110 disorders is well documented. However, 
only two retinoids are used in the United States for the 
treatment of dermatogical conditions but not for cancer. 
Accutane®, the trade name for 13-cis-retinoic acid (lg), is 
the only retinoid approved for oral use. The other is 
Tr.etinoin® [all trans-retinoic acid (lb)], but due to its 
inherent toxicity the use has been accepted for only 
topical treatment as an ointment. In Europe, Tigason®, a 
synthetic retinoid, has received considerable attention for 
treatment of a large number of previously very resistant 
Figure 16. 
skin disorders.17 
in Figure 17. 
42 
~
44 
...._ 
43 
........, 
45 
...._, 
Structures of Reported Arotinoids and 
Heteroarotinoids 
The appropriate structures are shown 
Retinoids used today for the treatment of skin abnor-
malities have been know for many years. These compounds 
have been tested by the guidelines set down by the FDA for 
drug approval in the clinics. Due to the constraints 
placed on the new retinoids, the usefulness of these 
compounds is limited for current cancer patients. For 
41 
"""" """ """" 
~ 
"" "" 
C02H 
1g C02H 1b 
r-.J ,.-..J 
Accutane Tretinoin 
CH3 
CH3 
"" 
C02Et 
MeO ~ 
Tigason 
Figure 17. Retinoids used Clinically. 
instance, the efficacy of !-(4-hydroxyphenyl)retinamide 
(47) was first reported in 1979 by Moon.79 This retinoid 
!-(4-Hydroxyphenyl)retinamide (47) 
has been cited as being useful towards dermatogical 
conditions, bladder papillomas and in women in a high risk 
class for developing premenopausal breast cancer or fibro-
cystic disease of the breast.82 It wasn't, however, until 
late in 1984 that !-(4-hydroxyphenyl)retinamide (47) 
42 
43 
started its clinical trials. Therefore, new retinoids that 
show promise today in preliminary biological screens might, 
at the earliest, get approval late in this decade or in the 
early 1990s. 
CHAPTER III 
RESULTS AND DISCUSSION 
Several heteroarotinoids reported by Berlin128 and 
Dawson29 have shown preliminary activity for possible uses 
in pharmacology. It appears that the sulfur analogues 42 
(ester) and 43 (acid) are the most promising due to the 
diminished toxicity of acid 42 in Swiss mice29 as compared 
to several arotinoids and retinoic acid (lb). We report 
herein the syntheses and partial activity of fourteen new 
heteroarotinoids in which all but two contain a sulfur 
heteroatom in the ring system. The structures (48-50) are 
shown in Figure 18 and 19. 
12 17 
14 
48a 
8 
48d 
Figure 18. Structures of New Heteroarotinoids. 
44 
45 
17 17 
18 
18 
" 
"18 
'',,, 19 
48e C02H 48f C02H 19 
3 
2 
Figure 19. Structures of New Heteroarotinoids 
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The objectives of this work have been to develop 
methodology to make very specific ~Iterations in the 
structures of compounds which could be labeled "hetero-
arotinoids". As a first step, we have been able to insert 
a heteroatom at the 4-position along with the incorporation 
of an aryl ring fused to the cyclohexyl system as shown in 
members 48a-f. This type of molecule retains the side 
chain as in retinoic acid (lb) except for that portion 
incorporated into the aryl ring. Thus, heterocycles 48-49 
allow an assessment of activity in terms of a relationship 
to block the 4-position which could alter metabolism at 
that site as well as prevent epoxidation by the presence of 
the aryl ring. As will be recalled, epoxidation occurs at 
C(5)-C(6) in retinoic acid (lb). 
A second group of molecules selected for synthesis 
involved replacement of part of the side chain with a 
benzene ring and replacement of the three protons by three 
fluorine atoms at C(12) as shown in 50a-f. The presence of 
a benzene ring in the side chain results in a cisoid 
arrangement in that portion of the chain. This cisoid 
arrangement in the side chain has produced useful activity 
as in 13-cis-retinoic acid (lg).8,26,27,81,108 Thus, the 
presence of the aryl ring in the side chain of 49a-b and 
50a-f is reminiscent of that in 28,29 31-34,26,28 and 42-
46.29,128 Fluorine atoms at C(l2) certainly will alter the 
electron density in the double bond at C(ll)-C(13) without 
47 
a 20 
" 
~ 
9 
" 
u 
2 ~10 ~ ~~ 
3 1b ~ C02H "' 4 ~ . 
co~ 
7 
s 
TTNPB 
co~ 
making a significant change in the overall geometry at 
C(l2). In view of the known activity of 42-46, it should 
now·be possible to compare the real effect of the presence 
of the fluorine atoms in the specific assays. 
The third and final change was effected by incorporating 
a gem dimethyl group at C(2) [this is at C(3) in retinoic 
acid (lb) while the heteroatom occupies the 4-position of 
retinoic acid (lb) in all of these systems] which should 
also influence the metabolism at that positon and of the 
heteroatom. Essentially, this later modification simply 
moves the gem dimethyl group one position from that in (E)-
[tetrahydrotetramethyl-2-napthalenyl-1-propenyl]-benzoic 
acid [TTNPB, (40)] followed by adding the heteroatom at the 
4-position. The compounds described are 48c, 49a, 49b, SOc 
and SOd. Moreover, it has been possible to insert fluorine 
atoms at the C(l2)-position in an effort to evaluate a 
second variable within the structure (in terms of effect on 
48 
activity) since the proton counterparts were already known. 
Although we have been successful in the sythnetic 
strategies which we shall delineate herein, the biological 
testing data has not been completed. Dr. A. Verma has 
several of the compounds under examination for activity in 
the ornithine decarboxylase (ODC) assay 122 , 123 at the 
University of Wisconsin, Clinical Cancer Center in Madison, 
Wisconsin. Dr. T. Breitman, of the National Cancer 
Institute in Bethesda, Maryland, has several members under 
investigation in terms of evaluation for these hetero-
arotinoids to influence cell differentiation in the HL-60 
cell line. The latter is a cell system derived from a 
patient with acute promyelocytic leukemia. 8 
Synthesis of the New Heteroarotinoids 
The fourteen new heteroarotinoids reported herein can be 
categorized into two groups. One group (48a-f) has a 
triene side chain similar to natural retinoids and the 
remaining compounds (49a-b, SOa-f) have incorporated an 
aryl moiety to give a locked cisoid rotameric conformation 
at C(l5)-C(l6). The aryl group inherently prevents free 
rotation around C(l5)-C(l6), fixing the conformation in a 
cis geometry. This geometry is believed to be partially 
responsible for biological activity in similar sytems such 
as acids 40 or 43 (Figure 20). 30 
Analogues 48a-f were designed to evaluate the activity 
of heteroarotinoids with the same general side-chain length 
as that of retinoic acid (lb). The synthesis of these 
compounds originated from either ketone Sla or Slb, the 
synthesis of which is shown in Figure 21. 
3 
Figure 20. 
12 
8 
16 
1,9. X = C ICH3l2 
43 X= S 
,......-
Locked Cisoid Conformation of 
Acids 40 and 43 
49 
In one of the earliest publications on heteroarotinoids, 
Berlinl28 first synthesized ketone 5la by the route shown 
below. This synthesis began with the condensation of thio-
phenol (52) and ethyl acrylate (53) using triethylamine 
(TEA) as a base to give ester 54. In the orginal 
synthesis, sodium ethoxide was employed as the base and 
gave ester 54 in a yield of 82.5%. In a recent report,6 
triethylamine was used and gave a quantitative conversion. 
In our hands, however, this was not observed, but yields of 
approximately 96% were common. Ester 54 was then treated 
with two equivalents of freshly prepared methylmagnesium 
iodide, and, after hydroylysis, gave alcohol 55. 
( C02Et, TEA, CHCI:J 
2 
©..- 5 -""../co2et 
51 a 
-
52 
-
0 )l..., TEA 
A£ 
CHCI3, !::. 
~ . 0 
~5~ 
51b 
,....._ 
58 
-
MeMgl 
Et20 
0 
Figure 21. Reaction Sequence for Ketones Sla and Slb. 
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Cyclization of 55 was achieved with polyphosphoric acid 
generated in situ from phosphorous pentoxide and 85% 
phosphoric acid in boiling dry benzene. Dimethylthiochro-
man 56 was obtained after distillation. Acetylation of 56 
was effected by treating a solution of the thioether with 
acetyl chloride in carbon disulfide which gave ketone 5la. 
In parallel fashion, unknown ketone 51b was acquired as 
illustrated. Thiophenol (52) and mesityl oxide (57) were 
51 
condensed using TEA, but, due to the steric hindrence at 
the S-position of ketone 57, a higher reaction temperature 
was required. The reaction gave the desired 4-methyl-4-
thia-phenyl-2-pentanone (58) which was treated with methyl-
magnesium iodide to give alcohol 59. Cyclization of 59 was 
achieved by a slightly different method, namely by boiling 
a suspension of aluminum chloride in cs2 to which was added 
alcohol 59. This led to 2,2,4,4-tetramethylthiochroman 
( 60). Unfortunately, acetylation of 60 did not proceed as 
cleanly as expected. Similiar reaction conditions used to 
obtain ketone 5la gave only a mixture of unidentifiable 
products. Several reaction conditions were scrutinized and 
are shown in Table XI. The best results employed aluminum 
chloride and acetyl chloride in nitromethane with 60, and 
gave ketone 51b in a yield of 68.1%. One benefit in the 
use of nitromethane over carbon disulfide is the formation 
of a homogenous mixture with aluminum chloride. 
The novel synthesis of 48b and 48c was accomplished 
through reaction conditions utilizing ketones Sla and Slb, 
TABLE XI 
ACETYLATION CONDITIONS FOR THIOCHROMAN 60 
LEWIS ACID SOLVENT 
AlC1 3 cs 2 
A1Cl 3 cs 2 
AlCl3 CH 3No 2 
SnC1 4 cs 2 
* Incomplete reaction, 
CH3COCI 
lewis Acid ) 
Solvent 
Temperature 
TEMPERATURE TIME 
(oC) 
25 8 h 
0 2 h 
25 12 h 
25 14 d 
approximately SO% 
remained unreacted. 
RESULTS 
mixture 
Slb (65.0%) 
Slb (68.0%) 
.... 
..... 
thiochroman 60 
as shown in Figure 22. The appropriate ketone (either Sla 
or Slb) was treated with freshly prepared vinylmagnesium 
bromide in THF and, after hydrolysis, gave the alcohol 6la 
or 6lb. Treatment of the proper alcohol with triphenyl-
phosphine hydrobromide (62) 24 led to phosphonium salts 63a 
52 
or 63b. In the next step, a Wittig type reaction proceeded 
smoothly by generation of the ylide of 63a (or 63b) with ~-
butyllithium followed by treatment of the ylide with ethyl 
S-formyl-crotonate (64) at -78°C. The isomeric mixture 
R 
R 
~ §.!!! 
a R=H 
b R=CH3 
R 
R 
R 
R 
Figure 22. 
~MgBr, THF 
R 
+ 
P Ph3 Br 
2. -78° 
4. AT 
'-':: '-':: C 02 E t 
4§.3 R = H & isomers 
§.§ R = CH3 & isomers 
KOH, EtOHiH20 f::::. 
Fractional Recrystallization 
C02H 
48b R = H 
---
Synthesis of Acids 48b and 48c. 
53 
54 
(48a or 65 plus isomers) of esters produced in this 
reaction was unresolved by normal chromatographic methods 
and crystallization techniques. Consequently, this 
isomeric mixture was saponified using aqueous ethanolic KOH 
which gave isomerically pure acid 48b or 48c after 
fractional recrystallization. 
Esters 48a and 48d were prepared from acid 48b in order 
to assess the activity imparted by groups on the terminus 
of the triene side chain. The synthesis of 48a and 48d is 
shown in Figure 23. The all trans-~cid 48b was treated 
~ ~ C02H 
48b 
--
l SOCI2 , Et20. Pyridine [ ~ ~ COCI ] §§ 
l ROH. Pymllne 
~ ~ C02 R 
0 
48a A = Et 48d R=~N~ 
- --
0 
Figure 23. Synthesis of Esters 48a and 48d. 
with thionyl chloride and pyridine in ether at -10°C. The 
resulting acid chloride 66 was then allowed to react with 
the desired alcohol at -20°C and, after chromatography, 
gave either ester 48a or 48d. 
Heteroarotinoids 48e and 48f were designed to determine 
if alterations on the C(l6)-C(l8) double bond would change 
biological activity with respect to that of 48b (Figure 
24). The incentive for the synthesis of 48f was, 
hopefully, to retain the inherent biological character-
istics common to 13-cis-retinoic acid (lg) while keeping 
the useful properties of certain sulfur heteroarotinoids, 
namely ester 42 and acid 43 (Figure 25). Both 48e and 48f 
12 17 
14 16 19 
3 
'-'::: -...:::· C02 H 
13 15 18 
2 
8 48b .......... 
17 
17 
16 
"'-':: '-'::: 18 
48f C02H 
__, 19 
Figure 24. Heteroarotinoid Modifications at the 
C(l6)-C(l8) Double Bond. 
55 
56 
£ R=Et 
43 R= H 
......., 
Figure 25. Structures of Heteroarotinoids 42 and 43 
were synthesized from the phosphonium salt 63a as 
illustrated in Figure 26. The phosphonium salt 63a was 
allowed to react with ~-butyllithium giving the appropriate 
ylide. The ylide of 63a was cooled to -78°C and ethyl 
trans-2-formylcyclocarboxylate (67) was added resulting in 
an isomeric mixture of esters 68. Purification of the all 
trans-ester 68 was unsuccessful and so the mixture was 
saponified using aqueous methanolic KOH with mild heating. 
After acidification, the mixture was concentrated to an oil 
which was crystallized (H 20:ethanol) to give the all trans-
cyclopropanoic acid 48e. Recently, Curly, DeLuca and Silva 
reported 24 the synthesis of four cyclopropyl retinoids 35-
38 (Figure 27). They indicated later 25 that extensive 
degradation occurred with these compounds under mildly 
basic conditions. A major concern of using a base with 
these esters, as well as with 68, was the possiblity of 
epimerzation at the carbon alpha to the C0 2Et group. If 
this did occur with 68, then in the crystallization step, 
1. .!!•BuU, Et20 
2. • 7a"c 
~ p,,, 
OHC £ ''co,er 
2 C02Et j I. KOH, MeOH!H20 mold tl. 
2. Fr:JctJOn~l Recrystallization 
+ 
PPh Br 
I. 2 KH. THF 
2
.Hoho !l2. 
0 
J. HJO+ 
4. Frac~1onal Rec:"JStJIIizatlon 
Figure 26. Synthetic Routes to Heterarotinoids 48e 
and 48f. 
the unwanted epimer of acid 48e was apparently removed 
selectively. The evidence for only one isomer of 48e was 
13 based on C NMR analysis which contained the expected 
number of signals for only 48e without a duplicate set of 
signals expected for the other isomer(s). This will be 
discussed in detail later. 
57 
R1 R2 R3 
35 C02Et H H 
-.J 
36 H C~Et H ,...., 
£ C02Et H CH3 
~ H C~Et CH3 
Figure 27. Cyclopropane Retinoids. 
The synthesis of acid 48f was accomplished by a dif-
ferent method. The cis double bond at C(l6)-C(l8) was 
created by treating 4-hydroxy-3-methylbut-2~enolide (69) 
with one equivalent of potassium hydride which led to 
potassium cis-3-formylcrotonate (70). Another equivalent 
of potassium hydride w1as consumed to form the ylide of 63a 
which attacked the aldehyde group of 70 and produced the 
58 
precursor salt of 48f (Figure 28). After neutralization, a 
Figure 28. Base Initiated Potassium cis-3-Formyl-
crotonate (70) Formation:-
brief iodine treatment of the reaction mixture was 
implemented to equilibrate the mixture of 14,16-dicis-acid 
71 and 16-cis-acid 48£ presumably formed (Figure 29). 
After fractional recrystallization (ethanol) of the solid 
product, acid 48£ was obtained. Unlike acid 48b, the 16-
cis isomer 48£ appears to be extremely sensitive to 
isomerization. It is imperative that, after partial 
isomerization with iodine, sodium thiosulfate be used to 
59 
remove any trace of iodine to prevent further isomerization 
of 48£ to all trans-acid 48b. The two important reactants 
(67 85 and 69 21 ) used in the synthesis of 48e and 48£ were 
Figure 29. 
48b 
-
Isomerization of 14,16-dicis-Acid 71, 
16-cis-Acid 47£ and All-trans-
Acid47b. 
either not available commerically (i.e. 69) or available 
only as isomeric mixtures (i.e. 67). Aldehyde 67 could 
be purchased but was a mixture of cis/trans isomers which 
had to be separated, a process not cost effective. 
Th f th . 1 h . t 85 1 d ere ore, e org1na synt etlc rou e was emp oye to 
attain sufficient quantities of pure 67 which is shown in 
Figure 30. The trans-isomer 67 was separated via a 
Figure 30. 
1. (CH3~s. Acetone 
2. NaOH. K2C03 
CHCI3 
~ Na8H4 
Ho_/''•,,co2Et ~-------
74 
..-v 
· (CHO. Acetone. C. 
A 
OHC C02Et 
£ & isomer 
Synthesis of Ethyl Trans-2-Formylcyclopropan-
carboxylate (67). 
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61 
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chemical means from a reported process. This entailed 
treatment of the cis/trans mixture of aldehydes with sodium 
borohydride followed by distillation of the resulting 
liquid. Isomerically pure ethyl trans-2-hydroxymethyl-
cyclopropanecarboxylate (74) was obtained in a yield of 
41.5%. Presumably, the cis isomer of 74 may suffer an 
intramolecular transesterification and removed in the 
distillation along with other rearranged products. Treat-
ment of pure 74 with pyridinium chlorochromate (PCC, 75) 
gave the desired aldehyde 67. 
The synthesis of the lactol 69 was accomplished by a 
known procedure involving the treatment of ethyl B-trans-
formylcrotonate (64) with boiling 6 N HC1. 21 After distil-
lation of the oily product and recrystallation of the 
solidified distillate, a low melting (mp 42-43°C) solid was 
isolated (Figure 31) which proved to be lactol 69. 
~C02Et 
OHC ' 
HCII-H201 
Figure 31. Sythnesis of Lactol 69 
Retinoid 43 has aroused interest in its potential use in 
chemotherapy.29,30,128 Previousily unknown but related 
62 
trans-ester 49a and trans-acid 49b were designed to assess 
the effect on activity of geminal methyl groups at the C(2) 
position. This change should serve to inhibit catabolic 
degradation of the sulfur atom which probably occurs more 
easily with acid 43. Thus, 49a and 49b are probes for 
steric requirements at C(2). Biological information gained 
from this structural modification might lead to future 
retinoid~ with efficacy similiar to acid 40 (known to be 
. ) 29 . h d d . . tox~c w~t re uce tox~c1ty. 
43 X= S 
,.-..../ 49a R =Me ......._,. 
45 x =o 
......._, 49b R = H 
---...; 
The incorporation of an aromatic ring into the side 
chain has produced compounds with useful biological activi-
h ·1 . bl" 68 F · ty w ~ e possess~ng greater sta 1ty. or 1nstance 
acids 43 and 45 had toxicity less than 40. 29 As a result of 
the presence of the aromatic ring, the diene portion in the 
ring is locked into a planar, cisoid conformation. Struc-
tural comparison between retinoic acid (lb) and acid 40 
revealed remarkable similiarity in the geometrical shapes 
and suggested a reason why the activities might be similar 
which has been substantiated (see Figure 32). 119 
Figure 32.119 Superimposed Structures of (~)-[Tetrahydro­
tetramethyl-2-napthalenyl-1-propenyl]-
benzoic Acid (TTNPB, 40) and Retinoic 
acid (1b). 
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New retinoid 49a was prepared by a modified Horner-
Emmons reaction. 114 Treatment of ketone Slb with the anion 
of dimethyl (4-carbomethoxybenzyl)phosphonate (76) in THF 
in the presence of 15-crown-5 (77) afforded ester 49a. The 
crude ester was purified by chromatography and fractionally 
crystallized to give the pure.§. isomer 49a as shown in 
Figure 33. The isomeric purity was assessed by 1 H and 13c 
64 
NMR analyses which revealed only one signal for the vinylic 
methyl protons and corresponding carbon. Conversion of 
ester 49a to acid 49b proceeded smoothly by treatment with 
ethanolic KOH in water at reflux. After neutralization, 
acid 49b was isolated and determined by NMR analysis to be 
the (~)-isomer. Phosphonate 76 was made readily available by 
the Arbuzov reaction 3 as shown in Figure 34. Treatment 
0 
51b 
,....._,_ 
1. NaH. THF. AT 
CCJ:!M:6 + 77 
_, ,...., 
PfQM~Il 
II 
0 
49a 
..-... 
49b 
,...___. 
KCH. EtCH. HzO 
L 
Figure 33. Synthesis of Retinoids 49a and 49b. 
of ester 78 with !-bromosuccinimide (79) in boiling CC1 4 
gave bromide 80. A reaction of trimethyl phosphite (81) 
with 80 gave the important intermediate phosphonate 76. 
The introduction of fluorine for hydrogen is known to 
65 
~Me . NBS, CCI4, 6. §Me 
79 
80 Br 
78 roJ ,_, 
l (MeOI3P, ~ ~ 
C02 Me 
~PIOMel2 
76 II 
,.,., 0 
Figure 34. Synthesis of Phosphonate 76. 
4 
alter activity in medicinal agents. The trifluoromethyl-
substituted retinoids SOa-f were of interest because the 
geometry of the system should not be altered much and yet 
the electron density will be reduced in the double bond. 
The impact of such a change on biological activity is 
unknown in these systems, although some data have been 
. . . 51 53 77 120 129 
reported J.n related famJ.lJ.es. ' ' ' ' All of these 
known trifluoro-substituted retinoids were synthetic 
analogues of natural retinoids with hydrogens on one methyl 
group [C(12)] being substituted with fluorines atoms. 
Generally, the purpose of a structural modification of this 
type is two fold. As stated previously, fluorines atoms 
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change the electronic environment in nearby atoms without 
appreciable changes in the steric environment, and this 
could lead to enhanced efficacy. Also, fluorine can be 
used as a 19F NMR biological probe. Recently, fluorine has 
been employed as a potential probe in studies on the action 
of two anesthetics in hopes of revealing drug distribution 
19 in tissue and for monitoring metabolic processes. 
Utilization of fluorine in this manner could lead to 
information on the mechanism of action by retinoids in cell 
differentiation. 
The synthesis of these previousily unknown, fluorinated 
retinoids proceeded through the common scheme shown in 
Figure 35. Similar to the synthesis of ketones 51a and 
Sib, an acid chloride was required. Trifluoroacetyl 
chloride (82), a gas at room temperature, was distilled 
into a suspension of aluminium chloride in cs2 containing 
thiochroman 56 to give the desired ketone 83. Ketone 83 
was then treated with the anion of phosphonate 76 to give 
retinoid SOa. 19 NMR analysis ( F) of ester SOa revealed the 
presence of only one isomer and suggested that the aryl 
moieties were ~ with respect to each other. This 
stereochemical designation must be considered tentative in 
view of a lack of adequate models in this family. The 
arguments for this assignment are in the NMR section. 
Ester SOa was easily converted to acid SOb with aqueous 
ethanolic KOH and heat. 
Supporting evidence for the conformational assignment 
R 
·{)§J 
R 
56 X = S. R=H 
"'-J 
60 X= S. R = CH3 ~
~ X:: 0. R=H 
SOb X = S . R :: H 
........_, 
~ X= S. R = CH3 
SOf X :: 0. R :: H 
83 X= S. R = H 
-"J 
85 X:: S. R = CH3 ~ 
86 
"-' 
x= o. R :: H 
1. NaH. THF. RT 
I' 
soa X= S. 
..--.._, 
R ::H 
soc X:: S. R = CH3 ,.._, 
soe X:: C. ,..... R = H 
Figure 35. Synthesis of Trifluoromethyl-Substituted 
Heteroarotinods. 
of ester 50a and acid 50b was reported by Kossmehl in the 
synthesis of (~)-( tri fl uoromethy 1) stilbene ( 8 7). 96 The 
67 
(E)-isomer 87, confirmed by X-ray anaylsis, was reported as 
68 
the dominate isomer (86:14) with respect to the (Z)-isomer 
88 (Figure 36). Also, Liu reported the stablity of the 
CF. ~3 <±J CF3 ~ 0 + IPhl3Pl§J ---7 @@+ 0 
£, ~ 
86% IE I 14% I Z I 
Figure 36. Isomeric Ratio of Trifluoromethyl Stilbenes.Dll 
(!)-isomer with the presence of a vinyl trifluoromethyl 
group. 5 The remaining trifluoromethyl-substituted 
retinoids (SOc-f) were prepared in a manner similar to that 
of ester 50a and acid SOb. 
Chroman 84 was prepared by a route similar to that 
reported by Berlin in 1985 129 (Figure 37). The first step, 
unlike the orginal reaction sequence, started with phenol 
(89) and ethyl acrylate (53) eliminating one step in the 
orginal scheme. This reaction presumably involved a Michael 
type addition of phenol (89) with ethyl acrylate (53) to 
50 give ester 90. Treatment of 90 with methylmagnesium 
iodide gave 2-methyl-4-phenoxy-2-butanol (91). The 
cyclization of alcohol 91 was then achieved by treatment 
69 
~OH Na, D. ~0~CO,Et (C02Et 
89 53 90 
- -
"'"'"-" 
2 MeMgl 
Et20 
00 SnCI4 ~O~OH CH3N02 
84 91 ,....._, ,....... 
Figure 37. Synthetic Scheme of 4,4-Dimethylchroman (84). 
with SnC1 4 in nitromethane at room temperature to give 4,4-
dimethylchroman (84). 
Structural Elucidation of New 
Heteroarotinoids Via 
Natural retinoids characteristically have side chains 
that consist of a conjugated polyene system. For example, 
retinoic acid (lb), a tetraene, has potentially 16 dif-
ferent (!,Z)-isomers. The stereochemical nature of these 
d bl b d . •t• 1 f b" 1 . 1 . . 27,81 au e on s ~s crl ~ca or ~o og~ca act~v~ty. 
Therefore, elucidation of the structures for each new 
retinoid, prior to biological analyses, is essential. 
70 
Heteroarotinoids 48a-f resemble natural retinoids more than 
do 49a-b and SOa-f (Figures 38 and 39). High isomeric 
17 
14 16 19 
~ ~ C02Et 
15 18 
2 4Ba 
48d 
17 17 
16 
18 
'-': 
""" 18 ----,19 
48e CO:zH 48f C02H 
19 
Figure 38. Structures of New Heteroarotinoids 48a-f, 
49a-b and SOa-b. 
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3 
z' 
Figure 39. Structures of New Heteroarotinoids SOc-f. 
purity of 48a-f proved difficult to attain compared to that 
of the remaining new heteroarotinoids 49a-b and SOa-f. 
Discussion of these two groups of retinoids will be 
conducted separately. 
The exact arrangment of a group around the double bond 
in 48a-f was determined via NMR spectroscopy. 1 Both H and 
13 C analyses were employed along with a HETCOR 2-dimen-
sional NMR 49 analyses for specific acids 48b and 48e. 
Table XII contains the 13c signals for retinoids 48a-f. 
CARBON 
2 
2 I 
3 
4 
4a 
5 
6 
7 
8 
Sa 
9' 10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
TABLE XII 
13c NMR SIGNALS FOR HETEROAROTINOIDS 48a-f 
48a 
23.1 
37.6 
33.1 
141.7 * 
123.6 
48b 
23.0 
37.5 
33.0 
* 141.7 
123.6 
HETEROAROTINOIDS 
48c 48d 48e 
35.7§ 
32.6cp 
54.4 
42.2§ 
* 142.5 
124.1 
23.1 
37.6 
33.1 
* 141.8 
123.6 
23.1 
37.7 
33.1 
141.6 
123.6 
..... 
... 
7'2 
47f 
23.1 
37.6 
33.1 
* 141.7 
123.6 
* * * * * * 138.2 138.1 139.0 138.2 138.8 138.0 
123.4 
126.4 
;~ 
131.7 
30.1 
139.9 
16.2 
125.5 
131.1 
135.5 
152.3 
13.8 
118.7 
167.1 
123.3 
126.4 
* 131.5 
30.1 
140.2 
16.1 
125.4 
131.7 
135.4 
154.0 
13.8 
118.3 
170.8 
123.5 
127.9 
132.9 -·-
.,, 
123.4 
126.5 
131.8 
31.7¢ 30.2 
140.7 140.1 
16.3 16.2 
125.7 125.5 
132.0 132.0 
135.4 134.4 
155.1 153.5 
14.1 13.9 
117.8 117.7 
170.8 166.6 
123.3 
126.4 
130.7 
30.2 
135.2 
16.9 
125.0 
128.1 
133.1 
26.8 
15.8 
22.4 
179.5 
..... 
... , 
123.5 
126.4 
131. 9 
30.2 
140.9 
16.2 
126.0 
133.4 
129.2 
153.7 
21.3 
115.9 
172.1 
~:: 
* § cp Signals may be interchanged in the vertical column. 
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The all-trans stereochemistry in the side chain of retin-
aids 48a-d is supported in terms of reported ppm values for 
1H3s,1os d 13c37,67 . 1 . d' an s1gna s 1n correspon 1ng, known 
natural retinoids. Although these new members have similar 
spectra with natural reinoids, a portion of the side chain 
in 48a-f has been incorporated into an aryl ring. Con-
sequently, there is sufficient variation in the NMR signals 
to warrant further analyses. Therefore, a HETCOR 2-D 
plot 49 was employed to verify signal assignments. Analysis 
of the NMR spectral data and HETCOR plot for acid 48b 
established the all-trans stereochemistry which was used as 
a model for 48a and 48c-d. 3 The JHH values were very 
helpful in assessing the stereochemistry about the double 
bonds, particularly isomeric systems related to retinoic 
acid (1b). 101 Coupling constants for all-trans-retinoic 
acid (lb) are 11.5 Hz and 15.0 Hz for H(10,11) and 
H(11,12), respectively. 101 11-cis-Retinoic acid (92) is 
similiar to compound 93 which is presumed to be one of the 
isomers formed in the Wittig reaction as a side product, 
leading to acid 48b. Isomer 93 is likely to be present 
since double bond C(14)-C(15) is formed in this Wittig 
olefination reaction, but to date however, we have not 
isolated 93. Coupling constants for 11-cis-retinoic acid 
(92) are 11.5 Hz and 11.5 Hz for H(10,11) and H(11,12), 
. 1 101 Cl 1 respect1ve y. ear y, a difference exists between the 
3 J 11 , 12 value for the two isomers of lb and 92. For 
3 
related acid 48b, the J 14 , 15 value 
3 [similar to J 11 , 12 
74 
C02H 
92 ,.._, 
12 17 C02H 
16 C02H 
18 
48b 
-- co~ 
for acid (lb)] is 15.0 Hz supporting the trans juncture in 
the side chain. Interestingly, the coupling constant for 
H(13,14) was 12.0 Hz in acid 48b which corresponds to 
3 J 10 , 11 in lb which is 11.5 Hz. The HETCOR 2-D plot (Figure 
40) for 48b allows unequivocal correlation of 1H signals to 
th d . 13c . 1 e correspon 1ng s1gna s. The NMR peaks for groups 
around the thiochromanyl moiety in 48b are also in 
agreement with the 1H and 13c signals reported earlier by 
Waugh and co-workers for 42 and 44-46. 129 Therefore, the 
13c signals for acid 48b serve as a basis to assign 
resonances in heteroarotinoids 48a and 48c-d. 
The 13c assignments for heteroarotinoid 48e were not 
readily obvious in comparison to the 13c signals for acid 
48b. Therefore, to elucidate the 13c signals for the two 
double bonds, a HETCOR 2-D was again used for 48e (Figure 
41). The 1H signal at 6 6.61 was easily assigned as H(14) 
in view of it splitting pattern (dd, J = 12.0 Hz, J = 15.0 
Hz) which is reminiscent of that in acid 48b for the 
cr-
CIJ 
U"l 
CD 
3 
2 
U1 r-
~ ru 
ru U1 
r- l11 
llD 
Figure 40. 
12 t7 
,. 16 t!l 
-...::: -...::: C02H 
15 18 
8 
48b 
--
11.1 
l11 1.1'! c m ~ m ~ 
-
ru 
..a 
ru ..a - r-!T1 
m ru 
U1 
m 
m ..a 
<:D 
<:D 
:r m 
IYO liD 
HETCOR-2D Plot of Acid (48b). 
75 
l."iB 
1.1 b 
b.S'i 
b."iY 
l.OB 
s.a'i 
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corresponding H(14). Although the 1H signal at o 5.34 in 
48e had a similar splitting pattern, the magnitude of the 
coupling constants (J = 9.0 Hz, J = 15.0 Hz) indicated that 
this signal was associated with H(15). 3 The smaller JHH 
value of o 5.34 arises from the coupling of H(15) with 
H(16) of the cyclopropyl moiety. Finally, the signal at o 
6.34 is a doublet with a coupling constant of 12.0 Hz for 
H(l3). Clearly, the coupling constants de£ ine the 
correctness of the assignments. Moreover, the trans 
stereochemistry of the double bonds in 48e is established 
as identical to that observed in acid 48b. In addition, 
the 13c assignments could be obtained from the HETCOR 2-D 
plot. These values are shown in Table XII. The 13c values 
for the cyclopropyl portion of acid 48e paralleled those 
for ethyl trans-2-formylcyclopropanecarboxylate (67). An 
off-resonance spectrum of ester 67 clearly made the assign-
ments easy (Table XIII). Interestingly, C(2) in ester 67 
was a doublet of doublets. This observation was surprising 
in view of the fact the 13 c decoupled spectra clearly gave 
only one set of signals for the expected isomerically pure 
ester 67. Since both C(2) and C(4) gave similar 
multiplicities, it is apparent that these carbons are 
adjacent to each other. A splitting of this type was 
reported by Gray 48 in 1969 for simple acetyl compounds 
(i.e. acetaldehyde). Therefore, the assigned values for 
acid 48e are shown in Table XII. 
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l.'iO 
5.30 
Carbon 
1 
2 
3 
4 
5 
6 
7 
TABLE XIII 
13c DATA FOR ETHYL 
TRANS-2-FORMYLCYCLOPROPANECARBOXYLATE (67) 
3 
;61 
4 '\s s 7 
H~ C02CH2CH3 
0 67 
-../ 
13c (ppm) Multiplicity 
22.2 d 
30.7 dd 
14.8 t 
198.3 dd 
171.1 s 
61.3 t 
14.2 q 
Finally, the 13c assignments for 16-cis acid 48f were 
based on similar values found for acid 48b and 13-cis-
retinoic acid (lg). 37 Figure 42 shows the similarities in 
13c resonances that exist between these retinoids. 
Predictably, certain signals closer to the terminus (the 
five carbons of the chain) of acid 48f coincide with those 
values of acid lg while certain signals for 48f show 
78 
similarities in the signals in the thiochromanyl portion as 
23.1 
37.5~ 
23.3 _.-7 
137.4 
12.9 l 132.9 
"140.3) 
T 
129.9 
130.3 
1g 
--
48f ,.......,_, 
J 16· 7 131.7 
~~····· ~ 
48b 
-..../ 
[,/" 21.3 
153.3 
[,/"I? 115.9 
~ 
C02H 
\ 
171.4 
~21.3 
~153.7 
~ ~ 115.9 
118.3 
Figure 42. Comparison Between lg, 48b and 48f. 
found in acid 48b. The reliability of the 13c values for 
acid lg was established by Englert through the use of a 
79 
lanthanide shift reagent and selective 1H decoupling 
. t 37 exper1.men s. 
Heteroarotinoids 49a-b are very close in structure to 
ester 42 previously reported by our group. The 1H, 13c 
20 
12 C02R C02Et 
2' 
a 
49a R =Me 42 
--
,....., 
49b R=H 
~
and X-ray data revealed a trans arrangement for the iso-
lated double bond [C(ll)-C(l3)] in 42. 129 In general, the 
13 c assignments for ester 49a and acid 49b were made by 
comparison to ester 42 as shown in Table XIV. 
The determination of the stereochemistry for compounds 
SOa-f is tentative and awaiting an X-ray analysis of SOc. 
However, several arguments can be made to deduce the group 
orientation about the isolated double bond. In the 
retinoids previously discussed (48a-f, 49a-b), all 
possessed an allylic carbon and hydrogens. Initially, NMR 
analysis gave an indication of the number of isomers pre 
80 
2' 
Carbon 
2 
2' 
3 
4 
5 
7 
8 
9' 10 
12 
13 
15' 19 
16, 18 
20 
21 
nonprotonated 
Carbons 
TABLE XIV 
13c NMR RESONANCES FOR 
HETEROAROTINOIDS 49a AND 49b 
49a R =Me ,..._, 
49b R = H 
--
Heteroarotinoids (ppm) 
49a 49b 42 
42.1§ 42.2§ 23.0 
32.6¢ 32.7¢ 
54.4 54.4 37.6 
35.6§ 35.7§ 33.1 
124.2 124.4 124.0 
123.7 123.7 123.7 
127.9 128.0 126.4 
31.6¢ 31.7¢ 30.2 
17.6 17.7 17.6 
125.9 125.8 125.7 
* 
.... 
~· 128.9 129.2 128.9 
w }~ .,. 
129.1 130.1 129.4 
167.0 171.7 166.5 
52.1 160.8 
132.4 126.9 143.0 
139.5 132.5 141.7 
139.6 139.9 139.3 
140.1 140.1 139.2 
142.5 142.5 131.4 
143.2 144.1 128.0 
§ <P * May be interchanged in the vertical column. 
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.... 
.... 
* 
sent (if two 13 c signals were present for one allylic 
carbon, two isomers were present and the same was true for 
1 H analysis). In retinoids SOa-f, the trifluoromethyl 
group complicated the analysis because of coupling between 
fluorine and the alpha and beta carbons. However, the 
isomeric purity of these compounds was easily verified by 
19 F NMR analysis. The presence of only ~ 19F signal 
indicated with a high degree of certainty that only one 
isomer was present. The 19p NMR data for heteroarotinoids 
SOa-f are shown in Table XV along·with that for the 
starting ketones 83, 85 and 86. 
There are a few known trifluoromethyl-subsitituted 
retinoids,77 but the similarities to SOa-f are only 
82 
peripheral. However, valuable information can be obtained 
from the 19p analysis of the reported isomeric systems 94-
97 (Table XVI).77 A comparison between 94 and 96 indicated 
that 6.2 ppm separated the two 19p signals. Therefore, a 
large scan was made from -50.0 to -75.0 ppm (upfield from 
FCC1 3 ) for the 19p NMR signals in heteroarotihoids SOa-f. 
All of our samples displayed resonances within this range 
although the data did not substantiate specific 
sterochemistry in the side chain. 
As mentioned previously, the trifluoromethyl group on 
a vinyl carbon (examples are 94-97)5 could influence the 
stereochemistry dramatically. In reported5 systems 
containing a CF3 group, the (E)-isomer dominated (the CF3 
group has priority over the carbon side carbon side chain, 
§ 
TABLE XV 
19F NMR DATA FOR 
HETEROAROTINOIDS SOa-f AND KETONES 83, 85-86. 
R 
X R 
C02R 
R X R 
~ s CH3 SOc CH3 
-----;.Q9 s H SOd H 
~ 0 CH3 ----SOf 0 H 
~ S H 
M s CH3 
~ 0 H 
............ 
Heteroarotinoid 19F (ppm)§ Ketone 
SO a -66.60 83 -71.72 
SOb -66.61 
SOc -66.59 85 -71.74 
SOd -66.61 
SOe -66.80 86 -71.53 
SOf -66.82 
F3cco 2H was the external standard which was referenced 
to FCC1 3 • 
83 
* 
Retinoid 
~ 
CF3 
~ 
95 
......... 
TABLE XVI 
TRIFLUOROMETHYL-SUBSTITUTED 
RETINOIDS AND 19F NMR SIGNALSS 
.... 19F (ppm)"' 
CF3 
-58.1 
~ ~ CHO 
92 
-
~ ~ CHO 
-59.3 
~ 
-65.3 
~ 
~ CHO 
-64.3 
CHO 
Referenced to FCC1 3 • 
indicating the ! designation). However, it seems logical 
84 
that in retinoids 50a-f in which the aryl rings syn to each 
85 
other there would be conformation restrictions and the (E)-
isomer might slowly isomerize to the spatially more 
accommodating (Z)-isomer as illustrated. In the solid 
. 
R 
Solution 
state, there appears to be minimal isomerization but in 
solution, isomerization took place. For example, in 
heteroarotinoid SOc such isomerization was observed by lH 
NMR analysis of H(l5,19) and H(l6,18) in DCC1 3 , and after 
approximately 7 days, the isomerized ratio of (!)/(~) was 
87:13. Surprisingly, this final ratio was very similar to 
that reported for 87 and 88 in Figure 36 [i.e 
86(E):l4(~)].96 The tentative basis for the assignment of 
the stereochemistry for ester SOc as being the (E)-isomer 
(the two aryl rings syn about the double bond) rests on the 
1H shifts for H(15,19) and H(l6,18) compared to those in 
ester 42 (Figure 43). Our contention is that the dramatic 
shifts in H(l5,19) and H(l6,18) occur because of the 
stereochemistry about the double bond and to a lesser 
H 115,191 
H 116,181 
Z isomer 
8.4 8.2 8.0 7.8 7.6 7.4 7.2 7.0 6.8 6.6 
Figure 43. lH NMR of Ester 42 and E/Z Mixture 
of Ester SOc. 
86 
87 
extent because of the fluorine atoms. Since ester 42 was 
confirmed as the (E)-isomer by X-ray analysis, 128 but yet 
the heteroarotinoids 50a-f have considerably different 1H 
spectra, it is presumed that 50a-f exist as (E)-isomers 
(aryl rings are syn about the double bond in contrast to an 
anti arrangment as in 42). The supposition awaits 
confirmation. 
The l3c NMR spectra for heteroarotinoids 50a-f were not 
useful in elucidating the stereochemistry about the double 
bond at C(ll)-C(13). Two carbons that were of particular 
interest, however, were C(ll) [the vinyl carbon bonded to 
the trifluoromethyl group] and C(l2) [the carbon bonded to 
the three fluorine atoms]. In the 1 3c spectra of 50a-f, 
these two carbons were not resolved. Presumably, the 
fluorine atoms alter the relaxation mechanism for these 
carbons, thus diminishing the signal intensities. 
Furthermore, since C(ll), and possibly C(l2), could be 
coupled with fluorine, the l3c signal multiplicity will be 
a quartet with a large J value which could be buried in the 
baseline noise. Efforts to increase the signal intensity 
(NMR delay at 10 seconds, normal is 4.0 seconds) proved 
unsucessful. All the 13c signals are shown in the 
experimental with lH NMR signals. A sample of SOc is 
currently being examined by X-ray diffraction analysis. 
The stereochemical nature of the double bonds present in 
these newly synthesized heteroarotinoids 48a-f, 49a-b and 
50a-f may be critical for biological activity. Thus the 
elucidation of structures for these new retinoids is 
essential if a correlation is to be made with biological 
activity. 
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CHAPTER IV 
PHARMACOLOGICAL ACTIVITY OF 
HETEROAROTINOIDS 
Although the synthetic objectives of this project were 
successful, the complete biological analysis of the 
heteroarotinoids is being conducted in terms of ODC 
activity by Dr. A. K. Verma at the Department of Human 
Oncology, University of Wisconsin and activity toward 
diffeTentiation of HL-60 cells by Dr. T. R. Breitman at the 
National Cancer Institute. To date, three of the 
heteroarotinoids (48a, b, and d) have been tested, and the 
biological analyses for ornithine decarboxylase (ODC) 
activity 12 Z,lZ4 are shown in Table XVII. The results of 
this assay correlate well with the inhibition of papilloma 
development in the long term experiments with mice. 124 The 
procedure used for these retinoids was slightly different 
from that described earlier. For completeness, the 
procedure will be reiterated with small changes. The test 
retinoids were applied to the shaven backs of the mice 1 
hour before application of 10 nmols of TPA (refer to Figure 
11). After 5 hours, the mice were killed and the epidermus 
was separated and homogenized. The release of labeled C0 2 
from [ 14co 2 ] ornithine was determined from this solution. 
TABLE XVII 
ODC ACTIVITY OF 
HETEROAROTINOIDS 48a, 48b and 48d 
48a R :Et 
--48b 
......._, ::~N~ 48d ......._, 
0 
Test Retinoid ODC Percent 
System Dose, nmol Activity Inhibition 
Acetone o.o 0.00 ± o.oo* 
~-
Acetone + TPA 0.0 0.90 ± 0.31-~ Control 
lg¢ 
..,_ 
+ TPA 17.0 0.10 ± 0.01 .... 89 
,,, 
48a + TPA 17.0 0.00 ± 0.00 .... 100 
-·-48b + TPA 17.0 0.10 ± 0.01''' 89 
Acetone 0.0 0.00 ± o.oo§ 
Acetone + TPA o.o 1. 67 ± 0.14§ Control 
lg¢ + TPA 17.0 0.14 ± 0.04§ 92 
48d + TPA 34.0 0.97 ± 0.13§ 42 
* nmol COz/30 min/mg protein 
§ 
nmol COz/60 min/mg protein 
¢ 13-cis-retinoic acid 
" " 
~ 
C02H 
1g 
-
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The greater the amount of 14co2 released the lower the 
activity of the test retinoid. The retinoids were 
evaluated in three separate experiments, and the results 
from the experiments were normalized (% inhibition). This 
should allow for comparison with the results from other 
research groups in this field. 
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Results in Table XVII clearly indicate the importance of 
this family of retinoids. Ester 48a at a 17 nmol dose 
completely inhibited ODC activity. Even acid 48b was 
extremely active at the same dose. However, with the 
incorporation of a large bulky group at the terminus as in 
48d, the activity dropped sharply. 
Acid 48b was also tested in the HL-60 cell line.l08,119 
The procedure is identical to that described in an earlier 
section (pp. 31-34). The dose-response curve of the HL-60 
cell line with the standard trans-retinoic acid (lb) and 
acid 48b is shown in Figure 44. The ED 50 for trans-
retinoic acid (lb) was 4.1 x 10-8 M and for acid 48b, it 
was 7.2 x 10- 8 M. 
Heteroarotinoids, 48a and 48b, show signs of a bright 
future in the area of cancer chemotherapy. The incorpora-
tion of the sulfur atom in the cyclohexyl ring was shown by 
Dawson 2 9 to reduce the toxicity normally associated with 
this class of compounds. In the ODC assay, both 48a and 
48b at equivalent doses were at least as potent as 13-cis-
retinoic acid (lg). Since acid lg is clinically being used 
for treament of cystic acne, it seems logical that both 48a 
and 48b might someday be used in chemotherapy as well. 
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Figure 44. Dose Response Curve For trans-Retinoic Acid 
(lb) ( o ) And Heteroarotinoid 48b ( lJ ) 
In The HL-60 Cell Line. 
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CHAPTER V 
SUGGESTIONS FOR FUTURE WORK 
Two main objectives upon which synthetic medicinal 
chemists have focused with retinoids are activity and 
toxicity. A major draw back with retinoids .appears to be 
associated with the inherent toxicity. As disclosed herin, 
there are many retinoids that exist which have good 
biological activity. Several have activities that are 
equal to trans-retinoic acid (lb) and 13-cis-retinoic acid 
(lg). However, attention needs to be directed at reducing 
the overall toxicity with these medicinally important 
compounds. Until the mechanism on epitheal differentiation 
and cancer is unveiled, one approach to reducing the 
toxicity is structural modifications, perhaps similar to 
those of retinoid metabolites. A structural alteration 
that could prove useful is shown below with the 
heteranapthyl moiety as a building block leading to 
retinoids 98 and 99. There exists many useful reagents to 
remove the thioacetal group (HgClz, HgO-BF3, HzOz-HCl, t-
BuBr-Mezso, PbOz-BF3-etherate, MezSO-HCl-dioxane and 
(PhSeO)z0).70a Once the aldehyde is obtained, it can be 
reduced to the target compound. 
R'{)QJ [ s o /-CCI lewis Acid 
R' 
X = 0, S, N R': p R" 
CHO 
"' 
-...::: 
C02R 
I 
R 
100 
---
C02R 
R' 
R' 
s~ 
s 
s~ 
s 
~----@-co2R 
99 
.......... 
OH 
101 
~
103 
_..... 
-...::: ~ C02R 
C02R 
94 
95 
Another approach to reducing the toxicity of these 
compounds is to adopt a "pro drug" concept. This would 
entail purposefully leaving one or more sites of the 
retinoid vulnerable to metabolic degradation. The 
resulting compound(s) would have increased polarity 
(carbonyl or hydroxyl functionalities) increasing the 
hydrophilicity leading to presumably a more active 
retinoid. Two general retinoids of interest might be those 
shown below. 
8 
104 
-
3~R },SJQJ: v 
1 8 106 
....._ 
R 
0 
~R OJSJQJ ,-
Sulfur atoms are shown in these structures because of the 
preliminary evidence suggesting reduction in toxicity in 
compounds like 43.29 Obviousily, retinoid 104 is 
susceptible to oxidation at C(l) (also at the sulfur atom) 
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which could lead to thiolactone 105. Similarily, compound 
106 would expectedly give rise to 107. The synthesis for 
104 was briefly explored. The examined synthetic scheme is 
shown below. Alternative reactions conditions to give the 
"''©-_ a > 0 ··~ b "'"©t_ ) 0 s ............. C02 Et 
108 lQ2. Br l' .!l9. -
"''©() d "'"©t_.~H ( X 
112 111 ,.._ ,.._. 
a. NBS, CC1 4 , hv, 24 h 
b. CH 30Na, HSCH 2co 2Et 
c. 1.) 2 CH 3Mgi 2. ) H o+ 3 
d. H3Po4 , PzOs 
the isothiochroman 112 might include bioling Ill in 
aluminum chloride. Then the Grignard reagent of 112 with 
the appropreiate carbonyl compound (113 or 114) should give 
alcohols 115 (or 116) as precursors to the important 
phosphonium salts and finally the target compounds. 
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C©r~ ~[ C©;~··] -4 s 
C©('oHJc 1 
1 
a. Mg/THF 
b. 1.) CH 3C(O)CH=CH 2 (113) 2.) H3o+ 
c. 1.) CH 3CHO (114) 2.) H3o+ 
CHAPTER VI 
EXPERIMENTAL SECTION 
General Information 
All reactions were carried out in an inert nitrogen 
atmosphere using magnetic stirring except where otherwise 
specified. The NMR spectra were taken on a Varian XL-300 
NMR spectrometer operating at 299.9485 MHz for 1H, 75.429 
MHz for 13c, 121.421 MHz for 31p and at 282.203 MHz for 
1 9F. The 1H and 13c NMR signals are reported in 6 values 
or in ppm, respectively, downfield from tetramethylsilane 
with DCC1 3 as the solvent. The 31 P NMR signals are 
reported in ppm downfield from the external reference of 
98 
H3 Po 4 and with DCC1 3 as the solvent. However, CF 3 co 2 1l \vas 
used as the external standard for 1 9F which was in turn 
back referenced to FCC1 3 • The 19F NMR signals are reported 
in ppm upfield from FCC1 3 with DCC1 3 as the solvent. IR 
data was collected on a Perkin-Elmer 681 IR spectra-
photometer. Melting points were obtained using a Thomas 
Hoover melting point apparatus and are uncorrected. Chro-
matography was accomplished using a Chromatotron Model 7924 
(Harrison Research, 340 Moana Court, Palo Alto, California 
94306) as described in the Chromatotron Operation Manual 
with silica gel, unless otherwise specified. Starting 
materials were prepared by modified procedures from the 
literature (54,5 7 , 128 55,1 2 8 56,1 28 51a, 128 58, 70 69,21 
82,20,107 72,85 67,58 74,58 90,128 84,128). 
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Certain starting materials and other reagents were obtained 
form the sources listed below and were used without further 
purification except where cited: thiophenol (Aldrich, bp 
169°C), ethyl acrylate (Aldrich, bp 99°C), triethylamine 
(Fisher, distilled from KOH: bp 89-90°C), methyl iodide 
(Fisher, distilled from copper at 41-42°C), P 2o5 (Fisher, 
anhydrous white powder), H3 Po 4 (Fisher, 85%), acetyl 
chloride (Aldrich, bp 52°C), aluminium chloride (Fisher, 
anhydrous white powder), vinyl bromide (Aldrich, bp 
16°C/750 mm), triphenylphosphine (Alfa, rnp 79°C), HBr 
(Matheson, anhydrous, 99.8%), n-butyllithium/hexanes 
(Aldrich, 1.55 M), thionyl chloride (Eastman, bp 79°C), 
pyridine (Fisher, distilled from KOH: bp 114-115°C), N-2-
hydroxyethylphthalimide (Frinton, rnp 128°C), mesityl oxide 
(Eastman, bp 130°C), NaH (Aldrich, 60% dispersion in 
mineral oil), dimethyl sulfide (Aldrich, bp 38°C), ethyl 
bromoacetate (Alfa, bp 159°C), acrolein (Eastman, bp 53°C), 
sodium borohydride [Aldrich, mp 400°C (dec)]. Anhydrous 
solvents were obtained by known methods. Ether, THF and 
thiophene-free benzene were distilled from sodium prior to 
use. Carbon disulfide was distilled from P 2o5 before use. 
Acetone was stored over K2 co 3 for 24 hand filtered prior 
to use. All other solvents were obtained in anhydrous 
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condition and used without further purification. Brine was 
used as a saturated aqueous solution of NaCl. 
Ethyl 3-(Phenylthio)propionate 1i!l 
To a solution of 12.12 g (0.11 mol) of thiophenol (52), 
10.01 g (0.10 mol) ethyl acrylate (53), and 20 mL of dry 
HCC1 3 at 0°C in a 100-mL, one-necked, round-bottom flask 
was added 0.50 mL of triethylamine. The cold bath (ice) was 
removed after the addition of triethylamine, and the 
solution was allowed to stir at room temperature for 3 h. 
The resulting solution was diluted with 150 mL of ether and 
washed with 10% NaOH (2 x 50 mL), H20 (SO mL), and brine 
(50 mL). The mixture was dried (Na 2so 4 , overnight) and the 
solvents were removed (rotary evaporator). Vacuum distil-
lation gave 19.36 g (92.1%) of ethyl 3-(phenylthio)-
propionate (54) as a clear colorless liquid: bp 112-
1150C/0.15 mm (lit 57 117°C/2.5 mm, lit 128 115-118/0.2 mm); 
IR (neat) 1740 cm- 1 (C=O); 1 H NMR (DCC1 3 ) o 1.14 [t, 3 H, 
co 2 cH 2CJ!J], 2.54 [t, 2 H, C_!f2C0 2 CH 2 CH 3 ], 3.10 [t, 2 H, 
PhSC_!bCH 2 ], 4.06 [q, 2 H, C0 2 ClbCH 3 ], 7.13-7.32 [m, 5 H, 
Ph-H ] ; 13 C N M R ( DCC 1 3 ) p p m 1 3 . 6 [ C 0 2 C H 2f H 3 ], 2 8. 3 [ PhS C H 2 ], 
33.8 [CH 2co 2cH 2CH 3 ], 60.0 [C0 2CH 2CH 3 ], 125.8, 128.4, 129.3, 
134.8, 170.9 [f=O]. 
2-Methyl-4-(phenylthio)-2-butanol 1211 
To a freshly prepared solution [42.59 g, (0.30 mol) of 
methyl iodide, 7.41 g (0.305 g-at) of magnesium] of methyl-
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magnesium iodide in 75 mL of ether was added dropwise 21.03 
g (0.10 mol) of ethyl 3-(phenylthio)propionate (54) in 25 
mL of ether in a 500-mL, three-necked, round-bottom flask 
equipped with a condenser and a nitrogen inlet. The 
solution was boiled for 1 hand allowed to stir at room 
temperature for 10 h. The resulting solution was 
neutralized with 5% H2so 4 (pH approx. 6.5); the ether layer 
was separated and the aqueous layer was extracted with 
ether (3 x 75 mL). The ether layers were combined and 
dried (Na 2so 4 , overnight). Solvent was evaporated (rotary 
evaporator) and vacuum distillation of the residual oil 
gave 19.02 g (78.5%) 2-methyl-4-(phenylthio)-2-butanol (55) 
as a clear colorless liquid: bp 106-107.5°C/0.15 mm (Lit 128 
93-98°C/0.01 mm); IR (neat) 3400 cm- 1 (br, 0-H); 1 H NMR 
(DCC 1 3 ) 6 1. 18 [ s, 6 H, (C_!!J) 2 C ], 1. 7 6 [ m , 2 H, PhS C H 2 C .!!2 ], 
2.74 [br s, 1 H, OJ!], 2.95 [m, 2 H, PhSCJ! 2 ], 7.10-7.36 [m, 
5 H, Ph-J!]; 13c NMR (DCC1 3 ) ppm 28.6 [PhS_g_H 2 CH 2 ], 29.3 
[(_g_H 3 ) 2 C], 42.7 [PhSCH 2_g_H 2 ], 70.7 [(CH 3 ) 2_g_], 125.9, 128.9, 
136.5. 
4,4-Dimethylthiochroman ~ 
A mixture of 15.00 g (0.076 mol) of 2-methyl-4-(phenyl-
thio)-2-butanol (55), 12.75 g of H3 Po 4 , 27.0 g (0.190 mol) 
of P 2o 5 [this is added in three equal portions every 8 h] 
and 60 mL of anhydrous benzene was boiled for 24 h in a 
250-mL, three-necked, round-bottom flask equipped with a 
condenser and N2 inlet. The resulting, cooled (ice bath) 
heterogeneous mixture was separated and the lower oily 
layer was extracted with ether (2 x 50 mL). The combined 
organic layers were washed with H20 (50 mL) and brine (50 
mL) and then dried (Na 2so 4 , 4 h). Evaporation (rotary 
evaporator) of the solvent and vacuum distillation of the 
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oil gave 11.68 g (86.0%) of 4,4-dimethylthiochroman (56) as 
a clear colorless liquid: bp 75-82°C/0.1 mm (lit128 80-
850C/0.01 mm); 1H NMR (DCC1 3 ) o 1.29 [ s, 6 H, (CH 3 ) 2C] 1.92 
[ m , 2 H, P·h S C H 2 C H 2 ] 3. 0 0 [ m, 2 H, PhS C .!!.2 C H 2 ] , 6. 9 0- 7. 3 2 [ m, 
4 H, Ph-.!!.]; 13c NMR (DCC1 3 ) ppm 22.8 [PhS.Q.H 2CH 2 ], 29.9 
[ ( f H 3 ) 2 C ] , 3 2. 6 [ ( C H 3 ) C ] , 3 7. 4 [ PhS C H 2_g_ H 2 ] , 1 2 3. 7 , 1 2 5. 7 , 
126.1, 126.2, 131.5, 141.5. 
6-Acetyl-4,4-dimethylthiochroman (Sla) 
A solution of 10.0 g (0.056 mol) of 4,4-dimethylthio-
chroman (56) and 4.4 g (0.056 mol) of acetyl chloride in 
150 mL of dry carbon disulfide was added dropwise over a 45 
min period to a stirred suspension of A1Cl 3 (11.22 g, 0.084 
mol) in a 500-mL, three-necked, round-bottom flask equipped 
with a condenser and N2 inlet. The resulting yellowish-
orange mixture was allowed to stir for 10 hat room 
temperature; 80 mL of ice water was added and two layers 
separated. The aqueous layer was extracted with ether (3 x 
50 mL); the ether layers were combined and dried (Na 2so 4 , 6 
h). After evaporation (rotary evaporator), the resulting 
light yellow oil was vacuum distilled to give 10.83 g 
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(87.6%) of 6-acetyl-4,4-dimethylthiochroman (Sla) as a 
light yellow viscous oil: bp 168-173°C/2.0 mm (lit 128 126-
1300C/0.02 mm); IR (neat) 1680 cm- 1 ; 1H NMR (DCC1 3 ) o 1.31 
[s, 6 H, (CH 3 ) 2 C], 1.89 [m, 2 H, PhSCH 2 cH 2 ], 2.52 [s, 3 H, 
CH 3 C(O)] 3.01 [m, 2 H, PhSCH 2 cH 2 ], 7.11 [d, 1 H, J = 8.1 
Hz, H(8)], 7.57 [dd, 1 H, J = 1.7 Hz, J = 8.1 Hz, H(7)], 
8.00 [d, 1 H, J = 1.7 Hz, H(5)]; 13 c NMR ppm 23.1 
[PhSCH 2CH 2 ], 26.2 [CH 3C=O], 29.8 [(_g_H 3 ) 2C], 32.8 [(CH 3 ) 2C], 
36.8 [PhSCH 2_g_H 2 ], 125.8, 126.2, 132.9, 139.4, 141.7, 196.7 
[CH 3C(O)]. 
2-(4,4-Dimethyl-6-thiochromanyl)-
2-hydroxy-3-butene (6Ia) 
To a freshly prepared solution of vinylmagnesium 
bromide;102,103 [7.65 g (0.0715 mol) of vinyl bromide was 
added to 1.75 g (0.0720 gat) of magnesium, in 40 mL of dry 
THF; the preparation was by the usual procedure for 
Grignard reagents] was added dropwise 10.5 g (0.0477 mol) 
of 6-acetyl-4,4-dimethylthiochroman (Sla) in 25 mL of THF 
in a 200-mL, three-necked, round-bottom flask equipped with 
a condenser and N2 inlet with stirring. The solution was 
then boiled for 1 h and allowed to stir for 10 hat room 
temperature. Saturated NH 4 Cl solution was added in 1-mL 
portions until the solution was slightly acidic (pH approx. 
6.8), and the layers were separated. The aqueous layer was 
extracted with ether (4 x 100 mL) and the ether extracts 
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were combined with the organic layer. The organic solution 
was washed with 50 mL of H2 0 and 50 mL of brine and was 
then dried (Na 2so4 , 4 h). The resulting oil (assumed to be 
quantitative) was used without further purification; IR 
(neat) 3200-3600 cm- 1 (0-H); 1 H (DCC1 3 ) o 1.32 [s, 6 H, 
(CJfJ) 2 C], 1.95 [m, 2 H, PhSCH 2 C.!bL 2.11 [bs, 1 H, OJ:!.], 
3.00 [ m , 2 H, PhSCH 2 cH 2 ], 5.14 [dd, 1 H, J = 2.0 Hz, J = 
1 o. 5 Hz, CH=CH 2 (cis)], 5.30 [dd, 1 H, J 2.0 Hz, J 15 .o 
Hz, CH=CH 2 (trans)], 6.16 [dd, 1 H, J = 10.5 Hz, J = 15.0 
Hz, CH=CH 2 ], 7. 05 [ d, 1 H, J = 8 Hz, H(8)], 7.12 [dd, 1 H, 
J = 2 Hz, J = 8 Hz, H( 7)], 7. 52 [ d, 1 H, J = 2 Hz, H(5)]; 
13 c (DCC1 3 ) ppm 22.9 [PhS_g_H 2cH 2 ], 29.1 [CH 3COH], 30.2 
[(fH 3 ) 2C], 33.1 [(CH 3 ) 2C], 37.3 [PhSCH 2_g_H 2 ], 74.5 [CH 3_g_oi-I], 
112.1, 123.1, 123.2, 126.2, 130.2, 141.6, 142.1, 144.7. 
(E)-3-(1,2,3,4-Tetrahydro-4,4-dimethyl-
6-thiochromanyl)-2-butenyl-triphenyl-
phoshonium Bromide (63a) 
To a suspension of 15.6 g (45.4 mol) of triphenyl-
phosphine hydrobromide in methanol (100 mL) was added 
dropwise with stirring to a methanol solution (SO mL) of 
the previously prepared alcohol 61a (11.3 g, 45.4 mmol) in 
a 100-mL, one-necked, round-bottom flask at room 
temperature (N 2 ) for 9.5 h. Methanol was removed (rotary 
evaporator) from the clear solution, ether (approx. 400 mL) 
was added and crystrallization occurred within a short 
time. After standing overnight, 26.0 g of white crystals 
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of salt 63a formed which were collected, recrystallized 
(methanol/ether) and dried (24 h, 0.1 mm Hg). The yield of 
salt 63a was 25.7 g (98.8% from the allyl alcohol 61a): mp 
268.5-269.5 °C (dec); 1 H NMR (DCC1 3 ) o 1.26 [ s, 6 H, 
(CJ!J)2C], 1.63 [d, 3 H, J = 4.0 Hz, CH 3 C=CH (trans)], 1.93 
[m, 2 H, PhSCH 2 CH 2 ], 3.02 [m, 2 H, PhSCJ!2 CH 2 ], 4.89 [dd, 2 
H, J = 8.0 Hz, JpH = 15.1, C=CHCJ! 2 PPh 3 ], 5.60 [tq, 1 H, J = 
4.0 Hz, J = 8.0 Hz, CH 3 C=CJ!CH 2 PPh 3 ], 6.85 [dd, 1 H, J = 2.0 
Hz, J = 8.1 Hz, H(7)], 7.00 [d, 1 H, J = 8.1 Hz, H(8)], 
7.17 [d, 1 H, J = 1.7 Hz, H(S)], 7.66-8.00 [m, 15 H, P(Ph-
H)3]; 1 3 c NMR (DCC1 3 ) ppm 17.0 [CH 3 C=CH], 23.0 [PhSCH 2CH 2 ], 
25.4 [d, Jcp =49Hz, C=CHCH 2 ], 30.1 [(CH 3 ) 2 C], 33.0 
[(CH3) 2_g_J, 37.4 [PhSCH 2_g_H 2 ], 110.2, 110.3, 117.6, 118.8, 
123.4, 123.9, 126.4, 130.2, 130.4, 132.1, 133.9, 134.1, 
135.0, 138.0, 138.1, 141.9, 145.4, 145.6; 31p (DCC1 3 ) 
21.6' Anal. Calcd for C33H34SPBr: c, 69.10; H, 
5. 4 0. Found: c, 69.21; H, 6. 0 7; p, 5 .41. 
(2E,4E,6E)-3,7-dimethyl-7-(1,2,3,4,-tetrahydro-
4,4-dimethyl-6-thiochromanyl)-2,4,6-
heptatrienoic Acid (48b) 
5. 9 8; 
ppm 
P, 
To a stirred suspension of 3.56 g (0.00621 mol) of 
phosphonium salt 63a in 50 ml ether was added dropwise n-
butyllithium in hexane (4.01 mL, 1.55 M, 0.00621 mol) at 
room temperature in a 100-mL, three-necked, round-bottom 
flask equipped with a condenser and N2 inlet. The 
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resulting, dark orangish-red solution was cooled to -780C, 
and 0.90 g (0.00621 mol) of ethyl (E)-13-formylcrotonate 
(64) in 10 mL of ether was added dropwise in the dark 
(approx. 5-10 min). The dark red mixture was allowed to 
warm to room temperature for 10 h and was then diluted 
with 100 mL of hexane. The solution was filtered and 
evaporated (vacuum) to give a yellow oil. The resulting oil 
was added to a solution of 4.5 g (0.0802 mol) of KOH in 
aqueous ethanol (SO ml 4:1 ethanol/H 20) and the solution 
was boiled with stirring in the dark for 45 min. The 
reddish solution was cooled (RT), treated with 5.0 g of 
NaCl and extracted with 100 mL of ether. The ether layer 
was extracted with water (4 x 50 mL), and the combined 
aqueous layers were acidified slowly with dilute H2so 4 • At 
the neutralization point, solid began to form; the aqueous 
yellow suspension was extracted with ether (3 x 75 mL). 
The ether layer was dried (Na 2so 4 ) and evaporated (vacuum) 
to give a yellow solid. After fractional recrystallization 
(abs ethanol), 0.88 g (43.1% from the salt 63a) of yellow 
needles of acid 48b were obtained with amp of 204-204.5°C 
(dec); 1 H NMR (DCC1 3 ) o 1.37 [s, 6 H, (C_!i.J) 2 C], 1.98 [m, 2 
H, PhS C H 2 C H 2 ] , 2. 2 5 [ s, 3 H, C H 3 ] , 2. 4 2 [ s, 3 H, C .!!3 ] 3. 0 6 
[m, 2 H, PhSC_!!2 CH 2 ], 5.86 [br s, 1 H, CHC0 2 H], 6.44 [d, 1H, 
J =15Hz, CHC(CH 3 )CHC0 2 H], 6.59 [d, 1H, J = 12 Hz, 
PhC(CH 3 )CH], 7.09 [d, lH, J =7Hz, H(8)], 7.10 [dd, 1H, J 
=12Hz, J =15Hz, CH-C_!!=CH], 7.21 [dd, lH, J =2Hz, J 
7Hz, H(7)], 7.52 [d, 1H, J =2Hz, H(S)]; 13 c NMR (DCC1 3 ) 
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ppm 13.8 [CH 3 ], 16.1 [.Q,H 3 ], 23.0 [PhS.Q.H 2 CH 2 ], 30.1 
[(.Q,H 3 ) 2C], 33.0 [(CH 3 ) 2.Q,], 37.5 [PhSCH 2CH 2 ], 118.3 
[fHC0 2 H], 123.3 [C(7)], 123.6 [C(5)], 125.4 [PhC(CH 3 ).Q,H], 
126.4 [C(8)], 131.5, 131.7 [CH-fH=CH], 135.4 
[fHC(CH 3 )CHC0 2H], 138.1, 140.2 [PhC(CH 3 )CH], 141.7, 154.0 
[f(CH 3 )CHC0 2H], 170.8 [.Q,0 2H]. Anal. Calcd for c20 H24o2s: C, 
73.13; H, 7.36; S, 9.76. Found: C, 73.31; H, 7.37; S, 
10.01. 
Ethyl i1]h!!L_ 6E)-3, 7-Dimethyl-7-(1,2,3,4,-
tetrahydro-4,4-dimethyl-6-thiochromanyl)-
2,4,6,-heptatrienoate (48a) 
To a stirred suspension of 503 mg (1.53 mmol) of trans-
heteroarotinoic acid 48b in 8 mL of dry ether was added 
0.1420 g (0.00180 mol) of freshly distilled pyridine, and 
the mixture was cooled to -10°C in a 50 mL, round bottom, 
three-neck, flask equipped with a condenser and N2 inlet. 
A solution of 201 mg (1.69 mmol) of SOClz in ether (1 mL) 
was added and stirring was continued at room temperature 
for 1 h. The resulting dark red solution was filtered and 
cooled to -20°C (dry ice/CC1 4 ). Then 142 mg (1.80 mmol) 
of pyridine was added and 210 mg (4.59 mmol) of dry ethanol 
was introduced all at once and stirring was maintained at 
room temperature for 3 h. The yellow solution was diluted 
with 25 mL of ether, and the new solution was washed with 
water (4 x 30 mL); the ether layer was dried (Na 2 S04, 1 h). 
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The solvent was removed (rotor evaporator), and the 
resulting yellow oil was chromatographed on silica gel 
using hexane/ether (15:1) with the silica gel retaining the 
trans-heteroarotinoic acid 48b. The ethyl ester 48a 492 mg 
(88.1%) was obtained as a viscous yellow oil; 1H NMR 
(DCC1 3 ) o 1.30 [t, 3 H, co 2 cH 2 CH 3 ], 1.36 [s, 6 H, (CH 3 ) 2 C], 
1.96 [m, 2 H, PhSCH 2 CH 2 ], 2.22 [s, 3 H, CH 3 ] 2.38 [s, 3 H, 
CH 3 ], 3.14 [m, 2 H, PhSCH 2 CH 2 ], 4.19 [q, 2 H, C0 2 CH 2 CH 3 ], 
5.82 [s, 1 H, CHC0 2Et], 6.39 [d, 1 H, J = 15Hz, 
CHC(CH 3 )CHC0 2Et], 6.55 [d, 1 H, J = 12Hz, PhC(CH 3 )CH], 
7.03 [dd, 1 H, J = 12Hz, J =15Hz, CH-CH=CH], 7.07 [d, 1 
H, J = 8 Hz, H(8)], 7.18 [dd, 1 H, J = 2 Hz, J = 8 Hz, 
H(7)], 7.48 [d, 1 H, J =2Hz, H(5)]; 13c NMR (DCC1 3 ) ppm 
13.8 [C(.£H 3 )CHC0 2Et], 14.3 [CH 2CH 3 ], 16.2 [PhC(.£H 3 )CH], 
2 3.1 [ PhS C H 2 2 C I-I 2 ] , 3 0.1 [ ( C H 3 ) 2 C ] , 3 3 .1 [ ( C I-I 3 ) 2.£] , 3 7. 6 
[ PhSCH 2CH 2 ], 59.6 [£H 2cr-r 3 ], 118.7 [£HC0 2 Et], 123.4 [ C( 7)], 
123.6 [C(5)], 125.5 [.£I-I-CI-l=CH], 126.4 [C(8)], 131.1 [CI-I-
CI-l=CI-I], 135.5 [CH-CH=£H], 138.2, 139.9 [Ph£(CH 3 )CI-I], 141.7, 
152.3 [£(CI-I 3 )CI-IC0 2Et], 167.1 [C0 2Et]. Anal. Calcd for 
c22 r-r 28 so 2 : c, 74.12; H, 7.92. Found: c, 74.35; I-I, 8.06. 
2-Phthalimidoethyl (2E,4E,6E)-3,7-Dimethyl-
7-(1,2,3,4-tetrahydro-4,4-dimethyl-6-
thiochromanyl)-2,4,6-heptatrienoate 
(48d) 
To a suspension of 503 mg (1.53 mmol) of trans-
heteroarotinoic acid 48b in 8 mL of dry ether was added 142 
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mg (1.80 mmol) of freshly distilled pyridine in a 50-mL, 
three-necked, round-bottom flask equipped with a condenser 
and nitrogen inlet, and the suspension was cooled to -10°C 
(NaCl/ice slurry). A solution of 201 mg (1.69 mmol) of 
SOC1 2 in ether (1 mL) was added. The solution was stirred 
at room temperature for 1 h. The resulting ~ark red 
solution was filtered and cooled to -20°C (dry ice/CC1 4 ); 
142 mg (1.80 mmol) of additional pyridine was added. Then 
a bolus of 296 mg (1.55 mmol) of !-2-hydroxyethyl-
phthalimide in 8 mL of dry DMF was introduced and the 
solution was warmed to room temperature; the new solution 
was allowed to stir for 10 h. The resultant yellow 
solution was diluted with ether (25 mL) and washed with 
water (5 x 60 mL); the ether. layer was dried (Na 2S04, 
overnight). The solvent was removed (rotor evaporator) and 
the resulting yellow solid was chromatographed on silica 
gel (Chromatotran) using HCC1 3 • The phthalimido-
substituted heteroretinoid 48d [273 mg, (35.6 %)] was a 
yellow solid: mp 64-65°C; IR (KBr) l760-1710 (C=O) cm- 1 ; 1H 
NMR (DCC1 3 ) o 1.36 [s, 6 H, (CH 3 ) 2 C], 1.98 [ m, 2 H, 
PhSCH 2 CH 2 ], 2.24 [s, 3 H, CJ,b], 2.34 [s, 3 H, CH 3 ], 3.06 
[m, 2 H, PhSCH 2CJ:b]. 4.03 [t, 2 H, co 2 cH 2 CH 2 ], 4.40 [t, 2 
H, C0 2 CH 2 CH 2 ] 5.78 [s, 1 H, CHC0 2 CH 2 CH 2 ], 6.38 [d, 1 H, J = 
15Hz, CliC(CH 3 )CHCOzCH 2 ], 6.55 [d, 1 H, J =12Hz, 
PhC(CH 3 )CH], 7.03 [dd, 1 H, J =12Hz, J =15Hz, CH-
CH=CH], 7.08 [d, 1 H, J =8Hz, H(8)], 7.18 [dd, J =2Hz, 
J = 8 Hz, H(7)], 7.48 [d, 1 H, J = 2 Hz, H(S)], 7.75 [m, 
2 H], 7.80 [m, 2 H]; 1 3c NMR (DCC1 3 ) ppm 13.9 [C(CH 3 )CH], 
16.2 [PhC(CH 3 )], 23.1 [PhS.Q.H 2 CH 2 ], 30.2 [(CH 3 ) 2 C], 33.1 
[ ( C H 3 ) 2_g_], 3 7 • 1 [ C 0 2 C H 2_g_ H 2 ], 3 7 • 6 [ P h S C H 2_g_ H 2 ] , 6 0 • 8 
[C0 2.Q.H 2cH 2 ], 117.9 [CHC0 2cH 2 CH 2 ], 123.3, 123.4 [C(7)], 
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123.6 [C(S)], 125.5 [CH-CH=CH], 126.5 [C(8)], 131.4, 131.8, 
132.0 [CH-CH=CH], 134.0, 135.4 [CH-CH=.Q.H], 138.2, 140.1 
[ Phf( CH 3 )CH], 141.8, 153.5 [f(CH 3 )CHC0 2CH 2 ], 166.6 
[.Q.0 2CH 2CH 2 ], 168.0 [ CH 2 N(f=O) 2 ]; Anal. Calcd for 
c 30 H31 No 4 s: C, 71.83; H, 6.23; N, 2.79. Found: C, 71.47; H, 
6.31; N, 2.76. 
4-Methyl-4-thiaphenyl-2-pentanone ~ 
To a solution of 28.64 g (0.26 mol) of thiophenol (52), 
24.54 g (0.25 mol) of mesityl oxide (57) and 100 mL of 
HCC1 3 at 0°C (ice) in a 500 mL, three-necked, round-bottom 
flask was added 1.5 ml of triethylamine. The cold bath was 
removed (15 min) after the addition of triethylamine and 
the solution was stirred at room temperature for 1 h. The 
resulting clear, colorless solution was heated at reflux 
for an additional 24 h. The new solution was allowed to 
cool to room temperature and poured into a separatory 
funnel; the flask was rinsed with 25 mL of ether which was 
added to the separatory funnel. The mixture was washed 
with 10% NaOH (2 x 50 mL), and the combined aqueous layers 
were extracted with ether (3 x 50 mL). The organics were 
combined, washed with H20 (50 mL) and brine (50 ml) and 
then dried (Na 2S04, overnight). The dried solution was 
filtered and concentrated (rotary evaporator). Following 
vacuum distillation, 40.14 g (77.1%) of 4-methyl-4-
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thiaphenyl-2-pentanone (58) was obtained as a clear color-
less liquid: bp 85-87°C/0.01 mm (lit 70 94-95°C/0.01 mm); IR 
(neat) 1730 cm- 1 (C=O); 1 H NMR (DCC1 3 ) 6 1.41 [s, 6 H, 
C(CH 3 )], 2.15 [s, 3 H, 0=C-CH 3 ], 2.69 [s, 2 H, C.!:! 2 C(O)CH 3 ], 
7.34-7.42 [m, 3 H, Ph-H], 7.75 [dd, 2 H, J = 3.0 Hz, J:::: 
8.0 Hz, Ph-1!]; 13 c NMR (DCC1 3 ) ppm 28.1 [q, (CH 3 ) 2 C], 31.9 
[q, 0=C-CH 3 ], 46.9 [s, f(CH 3 ) 2 ], 54.2 [t, £H 2 C(O)CH 3 ], 
128.4 [d, C(2')], 128.8 [d, C(4')], 131.4 [s, C(l')], 137.4 
[d, C(3')], 205.5 [s, C=O]. 
2,4-Dimethyl-4-thiaphenyl-2-pentanol f12l 
To a freshly prepared solution [34.06 g, (0.24 mol) of 
methyl iodide, 5.83 g (0.24 g at) of magnesium in 100 mL of 
dry ether] of methylmagnesium iodide in 165 mL of ether was 
added dropwise 25.00 g (0.120 mol) of 2,4-dimethyl-4-
thiaphenyl-2-pentanone (58) in 50 mL of ether in a 500-ml, 
three-necked, round-bottom flask equipped with a condenser 
and N2 inlet. The solution was stirred at room temperature 
for 3 hand poured slowly into a 500-mL beaker half filled 
with ice. The resulting mixture was neutralized with 5% 
H2 S04 to a pH of approx. 6.5; the ether layer was 
separated, and the aqueous layer was extracted with ether 
(3 x 50 mL). The organic layers were combined and dried 
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(Na 2so4 , overnight). The solvent was removed (rotary 
evaporator) and the remaining oil was vacuum distilled to 
give 20.24 g (75.2 %) 2,4-dimethyl-4-thiaphenyl-2-pentanol 
(59) as a clear colorless liquid: bp 105-109°C/0.075 mm. 
The material was used without further purification. IR 
(neat) 3200-3600 cm- 1 (0-H); 1 H NMR (DCC1 3 ) 6 1.30 [s, 6 H, 
(CH 3 ) 2 C], 1.33 [s, 6 H, (C!!.J) 2 C], 1.79 [s, 2 H, 
PhSC(CH 3 ) 2 CH 2 ], 3.58 [br s, 1 H, 0!!,], 7.26-7.34 [m, 3 H, 
Ph- H ] , 7. 57 [ d d , 2 H , J ·:: 3. 0 Hz , J = 8. 0 Hz , Ph- H ] ; 1 3 C 
NMR (DCC1 3 ) ppm 30.8 [q, (CH 3 ) 2 C], 32.2 [q, (_g_H 3 ) 2 C], 49.1 
[s, PhSCC(CH 3 ) 2 ], 52.4 [t, PhSC(CH 3 ) 2CHz], 71.7 [s, 
PhS C ( C H 3 ) 2 C H 2_g_] , 1 2 8. 3 [ d, C ( 2') ] , 1 2 8. 6 [ d, C ( 4') ] , 13 1. 5 
[s, C(1')], 137.1 [d, C(3')]. 
2,2,4,4-Tetramethylthiochroman {2Ql 
To a 500-mL, three-necked, round-bottom flask equipped 
with a condenser, nitrogen inlet· and power stirrer was 
added 42.8 g (0.32 mol) of A1Cl 3 in 150 mL of dry cs 2 • To 
the stirred suspension of A1Cl 3 was added dropwise a 
solution of 18.0 g (80.2 mmol) 2,4-dimethyl-4-thiaphenyl-2-
pentanol (59) in 50 mL of CS2 at room temperature over 15 
min. The resulting suspension was heated at reflux for 10 
h with stirring. The suspension was allowed to cool to 
room temperature and poured into a 500-mL beaker half 
filled with ice, and the mixture was stirred for 5 min. 
The mixture was separated into two layers; the aqueous 
layer was extracted with ether (3 x 75 mL). The organic 
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extracts were combined, extracted with H20 (50 mL) and 
brine (50 mL) and then dried (Na2S04z overnight). The 
solvent was removed (rotary evaporator) and the resulting 
oil was flash chromatographed using hexane on silica gel. 
Removal of the solvent (rotary evaporator) gave 14.78g 
(89.3%) of 2,2,4,4-tetramethylthiochroman (60) as a clear, 
colorless oil. The bp was determined to be 66-680C/0.075 
mm. The oil was used without further purification. 1H NMR 
(DCCl3) o 1.38 [s, 6 H, C(CH3)2], 1.40 [s, 6 H, C(C_!!3)2], 
1.94 [s, 2 H, PhSC(CH 3 ) 2 cH 2 L 7.00-7.20 [m, 4 H, Ph-H]; 13c 
NMR (DCC1 3 ) ppm 30.4 [q, C(_g_H 3 ) 2 ], 31.3 [q, C(_g_H 3 )2], 34.2 
[s, Phf(CH 3 ) 2 ], 40.7 [s, PhSf(CH 3 ) 2 ], 53.2 [t, 
PhS C ( C H 3 ) 2f H 2 ] , 1 2 3. 6 [ d ] , 1 2 4. 5 [ d ] , 1 2 5. 3 [ d ] , 1 2 6. 6 [ d ] , 
131.3 [s], 141.2 [s]. 
2,2,4,4-Tetramethyl-6-acetylthiochroman (Slb) 
A solution of 5.0 g (0.024 mol) of 2,2,4,4-tetramethyl-
thiochroman (60) and 1.91 g (0.024 mol) of acetyl chloride 
in 30 mL of nitromethane was added drop~ise to a stirred 
solution of 6.46 g (0.048 mol) of A1Cl 3 in 30 mL of nitro-
methane at 0°C (ice bath) under nitrogen. The ice bath was 
maintained for 0.5 h, and the resulting yellow solution was 
then allowed to warm to room temperature with stirring (12 
h). The reaction mixture was slowly poured with stirring 
into a 250-mL beaker, half filled with ice. The new 
mixture was then transferred to a separatory funnel, and 
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the aqueous layer was separated and extracted with ether (3 
x SO mL). The combined organics were washed with SO mL of 
H20 and SO mL of brine. After drying overnight (Na2S04), 
the solvent was removed (rotary evaporator), and the 
resulting oil was divided into four equal portions and 
separated individually using chromatography (silica 
gel/hexane; Chromatotran). The four purified solutions 
were combined and concentrated (rotary evaporator) to give 
4.10 g ( 68.1%) of 2, 2, 4, 4-tetramethy 1-6-acet y 1 thiochroman 
(Sib) as a yellowish oil. The oil was used without further 
purifications. IR (neat) 1680 cm- 1 (C=O); 1H NMR (DCC1 3 ) o 
1.44 [s, 6 H, (CH 3 ) 2 C], 1.4S [s, 6 H, (CH 3 ) 2 C], 1.99 [s, 2 
H , PhS C ( C H 3) 2 C H 2 ] , 2. 59 [ s , 3 H, 0 = C- C _!!3 ] , 7. 18 [ d , 1 H, J 
= 8.0 Hz, H(8)], 7.63 [dd, 1 H, J = 2.0 Hz, J = 8.0 Hz, 
H(7)], 8.06 [d, 1 H, J = 2.0 Hz, H(5)]; 13c NMR (DCC1 3 ) ppm 
26.1 [q, 0=C-.Q.H 3 ], 31.5 [q, (.Q.H 3 ) 2C], 32.4 [q, (.Q.H 3 ) 2C], 
35.3 [s, PhC(CH 3 ) 2 ], 42.2 [s, PhSC(CH 3 ) 2 ], 53.7 [t, 
PhSC(CH 3 ) 2 CH 2 ], 125.7 [d], 126.2 [d], 127.4 [d], 133.6 [s], 
139.7 [s], 142.1 [s], 196~3 [s, £=0]. 
3-(1,2,3,4-Tetrahydro-2,2,4,4-tetramethyl-6-
thiochromanyl)-2-butenyltriphenyl-
phosphonium Bromide (63b) 
To a freshly prepared solution of vinylmagnesium bromide 
[2.58 g (0.024 mol) vinyl bromide and 0.59 g (0.024 gat) 
magnesium, in 50 mL of THF; the procedure was the same for 
as a normal Grignard reagents]103 was added dropwise 3.00 g 
115 
(0.012 mol) 2,2,4,4-tetramethyl-6-acetylthiochroman (Sib) 
in 30 mL of THF in a 200-mL, three-necked, round-bottom 
flask equipped with a condenser and N2 inlet (stirred). 
The solution was heated at reflux for 1 hand then allowed 
to cool to room temperature. The resulting metallic-
colored solution was poured into ice and neutralized 
carefully with 5% H2so4 to a pH of 6.5. The aqueous layer 
was separated and extracted with ether (3 x 50 mL), and the 
organics were combined. The organic layer was washed with 
H20 (50 mL) and brine (50 mL) and was then dried overnight 
(Na 2S04). Removal (rotary evaporator) of the solvent gave 
an o i 1 which was dis so 1 v e d in 2 0 m L of met han o 1; the n.e w 
solution was added dropwise to a cold (ice bath) suspension 
of 4.15 g (0.012 mol) of triphenylphosphine hydrobrornide 
(62)2 4 in 10 mL of methanol. The ice bath was removed 
after the addition and the resulting light purple 
suspension was allowed to warm to room temperature during 
4 h. The dark purple reaction mixture was evaporated under 
reduced pressure (rotary evaporator) and gave a thick 
purple oil which solidified upon trituration with 20 rnL of 
ether and scratching. A dark orange solid formed which was 
filtered and recrystallized (methanol and ether) to give 
4.70 g (65.1%) of 63b as a tan, powdery solid, suitable for 
further reactions: mp 224-225°C (dec.), an analytical 
sample was obtained by the technique of vapor diffusion 
recrystallization using methanol/ether; mp 227.0-227.5°C 
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(dec). 1 H NMR (DCC1 3 ) o 1.36 [s, 6 H, (CH 3 ) 2 C], 1.42 [s, 6 
H, (CH 3 ) 2 C], 1.67 [d, 3 H, J = 4.0 Hz, CH 3 C=CH (trans)], 
1.94 [s, 2 H, PhSC(CH 3 ) 2 CH 2 ], 4.85 [dd, 2 H, J = 8.0 Hz, 
JPH = 15.0 Hz, C=CHCH 2 PPh 3 ], 5.64 [tq, 1 H, J = 4.0 Hz, J = 
8.0 Hz, CH 3 C=CHCH 2 PPh 3 ], 6.89 [dd, 1 H, J = 2.0 Hz, J = 8.0 
Hz, H(7)], 7.02 [d, 1 H, J = 8.0 Hz, H(8)], 7.19 [d, 1 H, J 
= 2.0 Hz, H(5)], 7.70-7.99 [m, 15 H, P(Ph-H) 3 ] 13 c NMR 
(DCC1 3 ) ppm 16.9 [CH 3 C=CH], 25.4 [d, Jcp = 49.9 Hz, 
C=CHCH 2 ], 31.6 [(CH 3 ) 2C], 32.4 [(_g_H 3 )2C], 35.5 [PhC(CH3)2], 
42.1 [PhS_g_(cH 3 ) 2 ], 54.1 [PhSC(CH 3 ) 2CH 2 ], 110.1, 110.5, 
116.2, 119.6, 123.1, 123.9, 124.0, 127.6, 130.0, 130.4, 
132.8, 132.9, 133.5, 133.9, 134.9, 135.0, 138.5, 138.7, 
142.3, 144.9, 145.4. 
i11h_ 4E, 6E)-3, 7-Diemthyl-7-(1,2,3,4-tetra-
hydro-2,2,4,4-tetramethyl-6-thiochromanyl)-
2,4,6-heptatrieneoic Acid (48c) 
To a suspension of 1.50 g (2.5 mmol) of phosphonium salt 
(63b) in 10 mL of dry ether was added dropwise at room 
temperature .!!_-butyllithium (1.80 mL, 1.39 M, 2.5 mmol in 
hexane) and 5 mL of ether in a 50-mL, three-necked, round-
bottom flask equipped with a condenser and nitrogen inlet. 
The resulting, dark orangish-red solution was cooled to 
-78°C (dry ice and acetone), and 0.39 g ( 2.75 mmol) of 
ethyl trans-S-formylcrotonate (64) in 15 mL of ether was 
added dropwise (approx. 5 min) in the dark. The mixture 
was allowed to warm to room temperature with stirring over 
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10 h. The yellow suspension was diluted with 50 ml of 
hexane; the solution was filtered and passed through a plug 
of anhydrous Na 2so 4 (in a filter funnel) and evaporated 
(rotary evaporator) to give a organish-yellow thick oil. 
To this oil was added 20 mL ethanol, and the new solution 
was added all at once to a mixture of KOH (2.70 g, 0.048 
mol) in 4 mL of H2 0; the new mixture was heated to reflux 
for 45 min. The final dark red solution was cooled to room 
temperature and then diluted with SO mL of H2 0 and S.O g of 
NaCl; this new mixture was extracted with 100 mL of ether. 
The ether layer was extracted with H20 (3 x 2S mL), and the 
combined yellow aqueous layers were acidified (pH approx. 
3-4) slowly with S% H2so4 • However, at the neutralization 
point, the solution became cloudy; the aqueous solution was 
extracted with ether (2 x SO mL). The combined organics 
were extracted with H20 (25 mL) and brine (25 mL) and then 
dried (Na 2so 4 , overnight). After evaporation (rotor 
evaporator), the yellow solid was fractionally 
recrystallized (abs. ethanol) to give 0.267 g (30.0 % from 
the phosphonium salt 63b) of 48c as a grainy yellow solid: 
mp 224.5-225°C (dec). 1 H NMR (DCC1 3 ) o 1.42 [s, 12 H, 
( C H 3) 2 C ] , 1. 9 7 [ s, 2 H, PhS C ( C H 3) 2 C H 2 ] , 2. 2 5 [ s, 3 H, C .!!3 ] , 
2.41 [s, 3 H, CH 3 ], 5.86 [brs, 1 H, CHC0 2 H], 6.43 [d, 1 H, 
J = 1S.O Hz, CHC(CH 3 ), 6.58 [d, 1 H, J = 12.0 Hz, 
PhC(CH 3 )CH], 7.09 [d, 1 H, J = 8.0 Hz, H(8)], 7.10 [dd, 1 
H, J = 12.0 Hz, J = 15.0 Hz, CH-CH=CH], 7.21 [dd, 1 H, J = 
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2.0 Hz, J = 8.0 Hz, H(7)], 7.51 [d, 1 H, J = 2.0 Hz, H(5)]; 
13 c NMR (DCC1 3 ) ppm 14.1 [.Q.H 3 ], 16.3 [.Q.H 3 ], 31.7 [(CH 3 ) 2 C], 
32.6 [(.Q.H 3 ) 2 C], 35.7 [(CH 3 ) 2.£Ph], 42.2 [PhS.£(CH 3 ) 2 ], 54.4 
[ PhS C ( C H 3 ) 2.£ H 2 ] , 11 7. 8 [ .£ H C 0 2 H ] , 1 2 3. 5 , 1 2 4. 1 , 1 2 5. 7 1 2 7. 9 , 
132.0, 132.9, 135.4, 139.0, 140.7, 142.5, 155.1 
[.£(CH 3 )CHC0 2H], 170.8 [.Q.0 2H]. Anal. Calcd for c22 H28o2s: 
C, 74.12; H, 7.92; S, 8.99. Found: C, 74.09; H, 7.95; S, 
9.26. 
Methyl (E)-4-[2-(2,2,4,4-Tetramethyl-6-
thiochromanyl)-propenyl]-1-benzoate 
(49a) 
To a suspension of 10 mL of dry THF and NaH (19 mg, 60% 
as mineral dispersion, 4.9 mmol) in a 50-mL, three-necked, 
round-bottom flask with a N2 inlet was added dropwise at 
room temperature a solution of 2,2,4,4-tetramethyl-6-
acetylthiochroman [Slb, 1.10 g, 4.4 mol], dimethyl (4-
carbmethoxybenzyl)phosphonate [76, 1.25 g, 4.9 mmol), and 
15-crown-5 [77, 22 mg, 1.0 mmol] in 15 mL of THF. The 
suspension was stirred at room temperature for 24 hr to 
give a dark red suspension. This reaction mixture was 
treated with 1.0 mL of glacial acetic acid; the resulting 
light yellow solution was combined with 100 mL of brine and 
the two layers were separated. The aqueous layer was 
extracted with ether (2 x 50 mL). The organics were 
combined, washed with H20 (2 x 50 mL) and brine (50 mL) and 
finally dried (Na 2so 4 , overnight). The solution was 
concentrated and the yellow oil was separated (Chromato-
tron) using hexanes and silica gel which gave a slightly 
yellow oil. The oil was crystallized three times using 
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hexane giving 0.66 g (39.2 %) of (49a) as white flakes: mp 
88.5-89.0°C. IR (KBr) 1720 cm- 1 (C=O); 1 H NMR (DCC1 3 ) o 
1.43 [s, 12 H, (CH 3 ) 2 C], 1.97 [s, 2 H, PhSC(CH 3 ) 2 CH 2 ], 2.28 
[d, 3 H, J = 1.0 Hz, CH 3 C=CH (trans)], 3.93 [s, 3 H, 
C0 2 CH 3 ], 6.82 [d, 1 H, J = 1.0 Hz, CH 3 C=C1i (trans)], 7.13 
[d, 1 H, J = 8.0 Hz, H(8)], 7.23 [dd, 1 H, J = 2.0 Hz, J 
8.0 Hz, H(7)], 7.42 [d, 2 H, J = 8.0 Hz, H(l5,19)], 7.53 
[d, 1 H, J = 2.0 Hz, H(5)], 8.04 [d, 2 H, J = 8.0 Hz, 
H(16,18)]; 13c NMR (DCC1 3 ) ppm 17.6 [CH 3C=CH], 31.6 
[(_g_H 3 ) 2C], 32.6 [(_g_H 3 ) 2 C], 35.6 [(CH 3 ) 2fPh], 42.1 
[PhSf(CH 3 ) 2 ], 52.1 [Co 2cH 3 ], 54.4 [PhSC(CH 3 ) 2_g_H 2 ], 123.7 
[C(7)], 124.4 [C(5)], 125.9 [CH 3 C=~H], 127.8, 127.9 [C(8)], 
128.9 [C(l5, 19)], 129.1 [C(l6,18)], 132.4, 139.5, 139.5, 
140.1, 142.5, 143.2,167.0 [~o 2 cH 3 ]. Anal. Calcd for 
c 24 H28 so 2 : C, 75.75; H, 7.42. Found: C, 75.70; H, 7.ld. 
(E)-4-[2-(3,4-Dihydro-2,2,4,4-tetramethyl-
2H-1-benzopyran-6-yl)-1-propenyl]-
benzoic Acid (49b) 
Methyl (E)-4-[2-(2,2,4,4-tetramethyl-6-thiochromanyl)-
propenyl]benzoate [49a, 0.150 g, 0.394 mmol] was heated to 
reflux under nitrogen in an aqueous-ethanol (2.4 mL-10 mL) 
solution of KOH (0.105g, 1.9 mmol) for 1 h in a 25-mL, 
three-necked, round-bottom flask. After cooling to room 
temperature (30 min), the resulting solution was diluted 
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with ether (50 mL) and 50 mL_of brine. The two layers were 
separated and the organic layer was washed with H2 0 (2 x 25 
mL). The combined aqueous layers were acidified with 5% 
H2so4 to give a cloudy solution which was extracted with 
ether (3 x 50 mL). The extracts were washed with H20 (25 
mL) and brine (50 mL)and then dried (Na 2so 4 , overnight); 
concentration gave a white solid which, after recrystal-
lization (95% ethanol), gave 0.112 g (78.1%) of 49b as 
white needles: mp 147-148°C; 1H NMR (DCC1 3 ) o 1.46 [s, 12 
H, (CH 3 ) 2C], 1.99 [s, 2 H, PhSC(CH 3 ) 2 cB_2 ], 2.32 [d, 3 H, J 
= 1.0 Hz, CB_ 3 C=CH (trans)], 6.84 [d, 1 H, J = 1.0 Hz, 
CH 3 C=CH (trans)], 7.15 [d, 1 H, J = 8.0 Hz, H(8)], 7.25 
[dd, 1 H, J = 2.0 Hz, J = 8.0 Hz, H(7)], 7.48 [d, 2H, J = 
8.0 Hz H(l5,19)], 7.57 [d, 1 H, J = 2.0 Hz, H(5)], 8.14 [d, 
2 H, J = 8.0 Hz, H(l6, -18)]; 13 c NMR (DCC1 3 ) ppm 17.7 
[_g_H 3 C=CH], 31.7 [(_g_H 3 ) 2C], 32.7 [(.fH 3 ) 2 C], 35.7 
[(CH 3) 2CPh), 42.2 [PhS.Q.(CH 3 ) 2 ], 54.4 [PHSC(CH 3 ) 2 H2 ], 123.7 
[C(7)], 124.4 [C(5)], 125.8 [CH 3 C=CH], 126.9, 128.0 [C(S)], 
129.2 [C(15, 19)], 130.1 [C(16, 18)], 132.5, 139.9, 140.1, 
142.5, 144.1, 171.7 [_g_o 2 H]. Anal. Calcd for c23 H26 so 2 : C, 
75.37; H, 7.21. Found: C, 75.06; H, 7.21. 
Trifluoroacetyl chloride ~ 
To 10.00 g (0.074 mol) of anhydrous sodium trifluoro-
acetate in a three-neck, round-bottom flask equipped with a 
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condenser and nitrogen inlet was added dropwise 12.3 mL of 
POC1 3 (20.29 g, 0.132 mol) over 10 min (caution foaming). 
A slow stream of nitrogen was passed over the solid through 
the condenser into a dry ice/acetone trap which condensed 
the volatile trifluoroacetyl chloride at -78°C (dry-
ice/acetone) in a 10-mL, round-bottom flask equipped with a 
drying tube (CaS0 4). After the initial reaction had sub-
sided (approx. 20 min), the reaction mixture was heated 
under gentle reflux for 1 h to give about 5.0 ml of 
trifluoroacetyl chloride (83) which distilled over as a 
clear colorless liquid. This liquid was used directly 
without further purification (lit 20 , 107 mp -146°C, 
bp -27°C, amide mp 74-75°C). 
4,4-Dimethyl-6-thiochromanyl Trifluoromethyl 
Ketone or 1-(3,4-Dihydro-4,4-dimethyl-2H-
1-benzothiopyran-6-yl)-2,2,2-trifluoro-
ethanone ..{lli 
To a suspension of 4,4-dimethylthiochroman [56, 3.57 g, 
0.020 mol), A1Cl 3 (5.33 g, 0.040 mol) and cs 2 (35 mL) in a 
50-mL, three-necked, round-bottom flask equipped with a 
dry-ice condenser was added (stream of N2 ) 1.5 mL of 
trifluoroacetyl chloride (82) over 30 min. After 1 h from 
the start of the reaction, an additional 1.5 mL of 
trifluoroacetyl chloride (82) was added to the dark, 
orangish suspension over 30 min. The resulting mixture was 
stirred for an addidtional 30 min and was poured into ice; 
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two layers separated. The aqueous layer was extracted with 
ether (3 x 50 ml); the ether layers were combined, washed 
with brine and dried (Na 2so4 , 6 h). After evaporation 
(rotor evaporator), the resulting yellow oil was separated 
(Chromatotron) using hexanes on silica gel to give 1.73 g 
(31.5%) of 83 as a viscous yellow oil which was used 
without further purification. IR (neat) 1720 cm- 1 (C=O); 
1 H NMR (DCC1 3 ) o 1.33 [s, 6 H, (CJ:i)) 2 C], 1.83 [m, 2 H, 
PhSCH 2 cH 2 ], 3.07 [m, 2 H, PhSCH 2 CH 2 ], 7.20 [d, 1 H, J = 8.0 
Hz, H(8)], 7.68 [dd, 1 H, J = 8.0 Hz, J = 1.0 Hz, H(7)], 
8.14 [d, 1 H, J = 1.0 Hz, H(S)]; 13 c NMR (DCC1 3 ) ppm 23.2 
[ PhS .Q. H 2 C H 2 ], 2 9. 3 [ (f H 3 ) 2 C ], 3 2. 8 [ ( C H 3) 2 C ], 3 6. 2 
[PhSCH 2 cH 2 ], 116.7 [q, 1 JcF = 291.6 Hz, .Q.F 3 ], 125.2, 126.5, 
126.7, 127.5, 142.2, 143.8, 178.8 [q, 2 JCF = 34.5 Hz, .Q.=O]; 
1 9 F N M R (DCC 1 3 ) ppm - 71. 7 2 [ C £.3 ] • 
Methyl (E)-4-[2-trifluoromethyl-2-(4,4-dimethyl-
6-thiochromanyl)ethenyl]benzoate (50a) 
To a suspension of 10 ml of THF and NaH (0.080 g, 60% as 
·mineral dispersion, 2.01 mmol) in a 50-mL, three-necked, 
round-bottom flask equipped with a condenser and N2 inlet 
was added dropwise at room temperature a solution of 4,4-
dimethyl-6-thiochromanyl trifluoromethyl ketone [(83), 0.50 
g, 1.82 mmol], dimethyl (4-carbmethoxybenzyl)phosphonate 
[(76), 0.52 g, 2.01 mmol], and 15-crown-5 [(77), 0.11g, 
0.50 mmol] in 15 mL of THF. The suspension was stirred 
(room temperature) for 24 h to give a dark red suspension. 
The reaction mixture was treated with 1.0 mL of glacial 
acetic acid, and the resulting light yellow solution was 
combined with 100 mL of brine; two layers separated. The 
aqueous layer was extracted with ether (2 x 50 mL) and 
dried (Na 2S04, overnight). The solution was concentrated 
(rotor evaporator) and the yellow oil was separated 
(Chromatotron) using hexanes and silica gel which gave a 
123 
slightly yellow oil. The oil was crystallized three times 
using hexanes giving 0.45 g (61.2%) of 50a as a white 
powder: mp 83.5-84.5°C. 1 H NMR (DCC1 3 ) 6 1.15 [s, 6 H, 
(CH 3 ) 2 C], 1.92 [m, 2 H, PhSCH 2 CH 2 ], 3.02 [m, 2 H, 
PhSCH 2 cH 2 ], 3.89 [s, 3 H, co 2q!)J, 6.96-7.30 [m, 6 H], 7.86 
[d, 2 H, J = 8.0 Hz]; 13 c NMR ppm 23.1 [PhS.Q.H 2 CH 2 ], 30.1 
[(£H3 ) 2C], 32.9 [(CH 3 ) 2_g_], 37.4 [PhSCH 2.Q.H 2 ], 52.2 [Co 2_g_H 3 ], 
118.4, 126.7, 127.1, 127.4, 128.4, 129.4, 129.8, 131.9, 
1 3 3. 5, 1 3 8. 4, 1 4 2. 6, 1 6 6. 4; 1 9 F N M R ppm -6 6. 6 0 [ C £.3 ] . 
Anal. Calcd for c 22 H21 o 2 sF 3 : C, 65.01; H, 5.21; F, 14.02. 
Found: C, 65.24; H, 5.49; F, 14.02. 
(E)-4-[2-(Trifluoromethyl)-2-(4,4-dimethyl-
6-thiochromanyl)ethenyl]benzoic acid (SOb) 
Methyl (E)-4-[2-(trifluoromethyl)-2-(4,4-dimethyl-6-
thiochromanyl)ethenyl]benzoate [50a, 0.2074 g, 0.510 mmol) 
was heated to reflux under nitrogen in an aqueous-ethanol 
(3 mL-12 mL) solution of KOH (0.844 g, 15.0 mmol) for 1 h 
in a 15-mL, three-necked, round-bottom, flask (stirring). 
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After cooling to room temperature, the resulting solution 
was diluted with ether (50 mL) and brine (50 mL). Two 
layers separated and the organic layer was washed with H2o 
(2 x 25 mL). The combined aqueous layers were acidified 
with 5% H2S04 to give a cloudy solution which was extracted 
with ether (3 x 50 mL). The extracts were washed with H20 
(25 mL) and brine (SO mL) and then dried (Na2S04, 
overnight). Concentration (rotor evaporator) gave a white 
solid, which, after recrystallization (95% ethanol), gave 
0.162 g (81.0%) of SOb as a white powder: mp 223.5-224.0°C. 
IR (KBr) 1700 cm-1 (C=O); 1H NMR (DCCl3) o 1.16 [s, 6 H, 
(CH 3 ) 2 C], 2.94 [m, 2 H, PhSCH 2 C.!!_ 2 ], 3.03 [m, 2 H, PhSCH 2 ], 
6.95-7.30 [m, 6 H], 7.95 [d, 2 H, J = 8.0 Hz]; 13 c NMR 
(DCC 1 3 ) ppm 2 3 .1 [ PhS C H 2 C H 2 ], 3 0 .1 [ {f H 3 ) 2 C ] , 3 2. 9 
[(CH 3 ) 2 C], 37.3 [PhSCH 2 CH 2 ], 126.6, 127.1, 128.3, 128.9, 
129.9, 130.0, 131.6, 133.6, 139.3, 142.6, 170.7 [C0 2 H]; 19 F 
N M R ( DCC 1 3 ) p p m - 6 6 . 6 1 [ CI_3 ] • An a 1. C a 1 c d f o r C 21 H 1 9 0 2 S F 3 : 
C, 64.27; H, 4.88; F, 14.52. Found: C, 64.08; H, 5.04; F, 
14.25. 
6-Trifluoroacetyl-4,4-dimethyl-
chroman l...ffi 
To a suspension of 4,4-dimethylchroman [84, 5.00 g, 0.02 
mol), A1Cl 3 (10.66 g, 0.04 mol) and cs 2 (60 mL) in a 100-
mL, three-necked, round-bottom flask equipped with a dry-
ice condenser was added with stirring (stream of nitrogen) 
2.5 mL of trifluoroacetyl chloride (82) over 30 min. After 
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1.5 h from the start of the reaction, an additional 2.5 mL 
of trifluoroacetyl chloride (82) was added to the 
yellowish-orange suspension over 30 min. The resulting 
mixture was stirred for an additional 1 hand poured into 
ice, two layers separated. The aqueous layer was extracted 
with ether (3 x 75 mL); the ether extracts were combined, 
washed with brine, and dried (Na 2so4 , overnight). After 
evaporation (rotor evaporator), the resulting orangish oil 
was separated (Chromatotron) using hexanes on silica gel to 
give 2.74 g (53.1%) of 86 as a light orange solid: mp 41.5-
42.5°C. The Ketone was used without further purification. 
IR (KBR) 1720 cm-1; 1H NMR (DCC1 3 ) o 1.33 [s, 6 H, 
(CH 3 ) 2 C], 1.82 [m, 2 H, PhOCH 2 CH 2 ], 4.26 [m, 2 H, 
PhOCH 2 CH 2 ], 6.83 [d, 1 H, J = 8.0, H(8)], 7.77 [dd, 1 H, J 
= 8.0 Hz, J = 1.0 Hz, H(7)], 8.06 [d, 1 H, J = 1.0, H(5)]; 
13 c NMR (DCC1 3 ) ppm 30.7 [(CH 3 ) 2C], 30.9 [(CH 3 ) 2.Q.], 36.9 
[PhOCH 2cH 2 ], 64.3 [PhOfH 2CH 2 ], 118.0 [q, 1JcF = 291.3 Hz, 
_g_F 3 ], 123.4, 130.8, 131.2, 133.5, 161.5 [C(8a)], 180.2 [q, 
2JcF = 34.0 Hz, C(O)CF 3 ]; 19 F NMR (DCC1 3 ) ppm -71.53 [Cf3 ]. 
Methyl (E)-4-[2-(trifluoromethyl)-(4,4-dimethyl-
6-chromanyl)ethenyl]benzoate (50e) 
To a suspension of 10 ml of dry THF and NaH (0.16 g 60% 
as mineral dispersion, 3.9 mmol) in a 50-mL, three-necked, 
round-bottom flask was added dropwise (room temperature) a 
solution of 4,4-dimethyl-6-chromanyl trifluoromethyl ketone 
[86, 1.00 g, 3.87 mmol], dimethyl (4-carbomethoxybenzyl)-
phosphonate [ 76, 1.01 g, 3.9 mmol], and 1S-crown-S [ 77, 
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0.22 g, 1.0 mmol) in 1S mL of dry THF. The new suspension 
was stirred at room temperature for 16 h to give a red 
suspension. This reaction mixture was treated with 1.0 mL 
of glacial acetic acid, and the resulting light yellow 
solution was combined with 100 mL of brine and the two 
layers separated. The aqueous layer was extracted with 
ether (2 x SO mL) and the organics were combined and washed 
with H2o (2 x SO mL) and brine (SO mL). After drying 
(Na 2so4, overnight), the solution was concentrated to a 
yellow oil which was separated (Chromatotron) using hexanes 
and silica gel and gave a slightly yellow oil. After 
treatment with decolorizing carbon for 20 min in boiling 
ether, the resulting mixture was filtered, condensed (rotor 
evaporator) and, after crystallization from gave hexane, 
gave 0.52 g (34.4%) as a white crystalline solid: mp 94.5-
95.00C. IR (KBr) 1720 (C=O) cm- 1 ; 1 H NHR (DCC1 3 ) o 1.18 
[s, 6 H, (CJ!J) 2 C], 1.81 [m, 2 H, Ph.OCH 2 C.!.! 2 ], 3.88 [s, 3 H, 
C 0 2 C .!.!3 ] , 4. 2 1 [ m , 2 H, Ph 0 _g_ H 2 C H 2 ] , 6. 81 [ d , 1 H , J = 8. 0 
Hz, H(8)], 7.00 [dd, 1 H, J = 8.0 Hz, J = 1.0 Hz, H(7)], 
7.11 [s, 1 H, PhC(CF 3 )CH], 7.12 [d, 1 H, J = 8.0 Hz, 
H(16,18)], 7.20 [d, 1 H, J = 1.0 Hz, H(5)], 7.86 [d, 2 H, J 
= 8. 0 Hz , H ( 15 , 1 9) ] ; 1 3 C N M R (DCC 1 3 ) 3 0. 5 [ ( C H 3 ) 2_g_] , 3 0. 8 
[ (f H 3 ) 2 C ], 3 7 • 3 [ PH 0 C H 2 C H 2 ] , 6 3 • 2 [ C 0 2_g_ H 3 ], S 2 • 2 
[PhO_g_H 2 cH 2 ], 117.6 [C(8)], 123.6, 128.1 [C(7)], 128.9 
[PhC(CF 3 )CH], 129.4 [C(16,18)], 129.8 [C(15,19)], 131.5 
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[C(5)], 134.3, 138.6, 154.3, 166.5; 1 9F NMR (DCC1 3 ) ppm 
-6 6. 8 0 [ C [ 3 ] An a 1. C a 1 c d for C 2 2 H 2 1 0 3 F 3 : C, 6 7. 6 9; H, 5. 4 2 ; 
F, 14.60. Found: C, 67.94; H, 5.42; F, 14.90. 
(E)-p-[2-(Trifluoromethyl)-2-(4,4-dimethyl-
6-chromanyl)ethenyl]benzoic acid (SOf) 
Methyl (E)-p-[2-(trifluoromethyl)-2-(4,4-dimethyl-6-
chroman)ethenyl]benzoate [SOe, 0.1645 g, 0.421 mmol) was 
heated to relux under nitrogen in an aqueous-ethanol (1.0 
mL-3.0 mL) solution of KOH (0.48 g, 8.5 mmol) for 1 h. 
After cooling to room temperature, the resulting solution 
was diluted with ether (50 mL) and brine (50 mL). Two 
layers were separated, and the organic layer was washed 
with H20 (2 x 25 mL). The combined aqueous layers were 
acidified with 5% H2so4 to give a cloudy solution which was 
extracted with ether (3 x 50 mL). The extracts were washed 
with H2o (25 mL) and brine (50 mL) and then dried (Na 2so 4 , 
overnight); concentration (rotor evaporator) gave a white 
solid, which, after recrystallization (95% ethanol), gave 
0.1276 g (80.5%) of 50£ as a white crystalline solid: mp 
207.5-208.0°C; 1 H NMR (DCC1 3 ) o 1.18 [s, 6 H, (CH 3 ) 2 C], 
1.82 [m, 2 H, PhOCH 2 CH 2 ], 4.22 [m, 2 H, PhOCH 2 CH 2 ], 6.81 
[d, 1 H], 7.01 [dd, 1 H], 7.09 [d, 1 H], 7.15 [d, 2 H], 
7.22 [d, 1 H], 7.92 [d, 2 H]; 1 3c NMR (DCC1 3 ) ppm 30.5 
[(CH 3 ) 2f], 30.8 [(.Q.H 3 ) 2C], 37.2 [PhOCH 2.Q.H 2 ], 63.2 
[PhO.Q.H 2 CH 2 ], 117.6, 123.5, 128.1, 128.8, 128.9, 129.9, 
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130.0, 131.4, 131.5, 132.4, 139.6, 154.3, 170.8 [_g_0 2 H]; 19 F 
N H R (DCC 1 3 ) ppm - 6 6. 8 2 [ C I 3 ] • An a 1. C a 1 c d for C 21 H 1 9 0 3 F 3 : 
C, 6 7. 0 2 ; H, 5. 0 9 ; F, 15 .14. Found : ·c, 6 6. 7 5 ; H, 5. 1 4; F, 
14.95. 
Trifluoroacetyl-2,2,4,4-tetramethyl-
6-thiochromanyl ~ 
To a suspension of 2,2,4,4-tetramethylthiochroman [(60), 
2.50 g, 0.012 mol), AlC1 3 (3.23 g, 0.024 mol) and 30 mL of 
cs 2 in a 100-mL, three-necked, round-bottom flask equipped 
with a dry ice condenser was added (stream of nitrogen) 1.5 
mL of trifluoroacetyl chloride (82) over 30 min (stirred). 
After 1 h from the start of the reaction, an additional 1.5 
mL of trifluoroacetyl chloride (82) was added to the dark 
orange suspension over 30 min. The resulting mixture was 
stirred for an additional 1 h and poured into ice; two 
layers separated. The aqueous layer was extracted with 
ether (3 x 50 mL): the ether layers were combined, washed 
with brine and dried (Na 2 so 4 , 6 h). After evaporation 
(rotary evaporator), the resulting yellow oil was separated 
(Chromatotron) using hexanes on silica gel to give 0.75 g 
(20.3%) of 85 as a viscous yellow oil which was used 
without further purification. Ketone was used without 
further purification. IR (neat) 1715 cm- 1 (C=O); 1H NHR 
(DCC1 3 ) o 1.21 [brs, 12 H, (CH 3 ) 2 C], 1.98 [s, 2 H, 
PhSC(CH 3 ) 2 CH 2 ], 7.21 [d, 1 h, J = 8.0 Hz, H(S)], 7.69 [dd, 
1 H, J = 8.0 Hz, J = 1.0 Hz, H(7)], 8.15 [d, 1 H, J = 1.0 
Hz, H(S)]; 13 c NMR (DCC1 3 ) ppm 31.6 [(.Q.H 3 ) 2C], 32.4 
[(CH 3 ) 2C], 35.4 [Ph.Q.(CH 3 ) 2 ], 42.9 [PhSC(CH 3 ) 2 ], 53.3 
[ Ph C ( C H 3 ) 2_g_ H 2 ] , 11 6. 9 [ q , 1 J c F = 2 9 1. 2 Hz , C F 3 ] , 1 2 6. 2 , 
126.9, 127.9, 128.5, 143.0, 144.4, 179.0 [q, 2JcF = 34.o 
Hz, C(O)CF 3 ]; 19F NMR (DCC1 3 ) ppm -71.74 [CF 3 ]. 
Methyl (E)-4-[2-(trifluoromethyl)-2-(2,2,4,4-
tetramethyl-6-thiochromanyl)-ethenyl]-
benzoate (SOc) 
To a suspension of 10 mL of dry THF and NaH (0.0723 g, 
60% dispersion in mineral oil, 1.81 mmol) in a three-
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necked, round-bottom flask equipped with a condenser and N2 
inlet was added dropwise at room temperature a solution of 
trifluoroacetyl-2,2,4,4-tetramethyl-6-thiochromanyl [85, 
0.50 g, 1.64 mmol], dimethyl (4-carbmethoxybenzyl)-
phosphonate [76, 0.465 g, 1.81 mmol] and 15-crown-5 [77, 
0.11 g, 0.5 mmol] in 15 mL of dry THF. This suspension was 
stirred at room temperature for 16 h to give a dark red 
suspension. The mixture was treated with 1.0 mL glacial 
acetic acid, and the resulting light yellow solution was 
combined with 100 mL of brine; two layers separated. The 
aqueous layer was extracted with ether (2 x 50 mL) and 
dried (Na 2so 4 , overnight). Concentration (rotor 
evaporator) of the solution gave a yellow oil was separated 
(Chromatotron) using hexanes and silica gel; a slightly 
yellow oil resulted. The oil was crystallized with hexanes 
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and the recrystallized twice using hexanes to give 0.339 g 
(47.7%) of SOc as clear colorless prisms: mp 87.0-87.soc. 
IR (KBr) 1740 (C=O) cm- 1 ; 1 H NMR (DCC1 3 ) c5 1.21 [s, 6 H, 
(CH) 3 ) 2C], 1.42 [s, 6 H, (CH 3 ) 2C], 1.94 [s, 2 H, 
PhSC(CH 3 )CH 2 ], 3.89 [s, 3 H, C0 2 CH 3 ], 6.98-7.30 [m, 6 H], 
7.86 [d, 2 H]; 13c NMR (DCC1 3 ) ppm 31.4, 32.6, 3S.3, 42.2, 
52.2, S4.1, 126.7, 128.S, 128.9, 129.4, 129.9, 131.9, 
132.0, 134.3, 138.4, 143.2, 166.4; 1 9F NMR (DCC1 3 ) ppm 
-66.S9 [CF 3 ]. Anal. Calcd for c 24 H2 ss0 2 F 3 : C, 66.34; H, 
5.86; F, 13.12. Found: C, 66.28; H, S.86; F, 12.77. 
(E)-4-[2-(Trifluoromethyl)-2-(2,2,4,4-tetra-
methylthio-6-chromanyl)ethenyl]-
benzoic acid (SOd) 
Methyl (E)-4-[2-(trifluoromethyl)-2-(2,2,4,4-tetra-
methyl-6-thiochromanyl)ethenyl] benzoate [SOc, 0.150g, 0.345 
mmol) was heated to reflux with stirring under nitrogen in 
an aqueous-ethanol (2 mL-10mL) solution of KOH (0.40, 7.13 
mmol) for 1 h in a 25-mL, three-necked, round-bottom flask 
equipped with a condenser and N2• After cooling to room 
temperature (30 min), the resulting solution was diluted 
with ether (SO mL) and brine (50 mL). Two layers were 
separated and the organic layer was washed with H2 0 (2 x 25 
mL). The combined aqueous layers were acidified with 5% 
H2S04 to give a cloudy solution which was extracted with 
ether (3 x SO mL). The extracts were washed with H20 (25 
mL) and brine (SO mL) and then dried (Na 2S04, 6 h); 
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concentration gave a white solid which, after recrystal-
lization (95% ethanol), gave 0.1135 g (78.2%) of SOd: mp 
169.0-170.0°C. 1 H NMR (DCC1 3 ) 8 1.21 [ s, 6 H, (CH 3 ) 2 C], 
1.42 [s, 6 H, (CH 3 ) 2 C], 1.93 [s, 2 H, PhSC(CH 3 ) 2 CH 2 ], 6.97-
7.30 [m, 6 H], 7.92 [d, 2 H]; 13c NMR (DCC1 3 ) ppm 31.7, 
32.7, 35.7, 42.1, 54.5, 123.8, 124.5, 125.9, 127.0, 128.0, 
129.2, 130.2, 132.6, 140.0, 140.1, 142.6, 144.1, 171.7; 1 9F 
NMR (DCC1 3 ) ppm -66.61 [ C£.3 ]. Anal. Calcd for c 23 H23 so 2F 3 : 
C, 65.70; H, 5.51; F, 13.56. Found: C, 65.86; H, 5.53; F, 
13.47. 
ill.z.±§..z_ 6E)-3, 7-Dimethyl-7-(1,2,3,4-tetra-
hydro-4,4-dimethyl-6-thiochromanyl)-
2,4,6-heptatrienoic Acid (48f) 
To a stirring suspension of KH (0.214 g, 24% mineral oil 
dispersion, 5.35 mmol) in 6.0 mL of dry THF was added salt 
63a (1.54 g, 2.68 mmol) at room temperature in a 50-mL, 
three-necked, round-bottom flask equipped with a condenser 
and nitrogen inlet. After 20 min, the resulting dark red 
mixture was cooled in an ice bath for 10 min and 4-hydroxy-
3-methylbut-2-enolide21 [69, 0.45 g, 2.68 mmol] was added 
in 8.0 mL of dry THF dropwise (5 min). The reaction 
mixture was allowed to warm to room temperature overnight 
with stirring. The dark reaction mixture was poured into 
50 mL. of ice water and the resulting solution was extracted 
with (2 x 25 mL). The combined organics was extracted with 
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H2 0 (2 x 25 mL) while the aqueous layers were combined and 
acidified with 5% H2so4 to approximately pH 4.0. The 
cloudy yellow solution was extracted with ether (3 x 50 
mL); the ether solutions were combined and washed with H20 
(2 x 25 mL). This new solution was treated with a small 
crystal of I 2 for 2 min followed by immediate quenching 
with 5% sodium thiosulfate (2 x 25 mL). The resulting 
solution was washed with H2o (25 mL), brine (25 mL) and 
dried Na 2so4 (4 h). The mixture was concentracted and the 
yellow oil was crystallized twice (abs ethanol) to gave 
0.31 g (35.2 %) of acid 48f as a yellow solid: mp 172.5-
173.00C (dec). IR (KBr) 1675 (C=O) cm- 1 ; 1 H NMR (DCC1 3 ) o 
1.36 [s, 6 H, (CH 3 ) 2 C], 1.96 [m, 2 H, PhSCH 2 CH 2 ], 2.14 [s, 
3 H, CH 3 ], 2,23 [s, 3 H, CH 3 ], 3.03 [m, 2 H, PhSCH 2 C.!! 2 ], 
5.71 [brs, 1 H, Cfl.C02H], 6.69 [d, 1 H, J = 9Hz, 
PhC(CH 3 )Cfl.-CH=CH], 7.07 [d, 1 H, J =7Hz, H(8)], 7.08 [dd, 
1 H, J = 9.0 Hz, J = 15.0 Hz, CH-CH=CH], 7.21 [dd, l H, J = 
7.0 Hz, J = 2.0 Hz, H(7)], 7.51 [d, 1 H, J = 2.0 Hz, H(S)], 
&.86 [ d, 1 H, J =15Hz, Cfl.C(CH 3 )CHC0 2 H]; 16.2 [PhC(fH 3 )], 
21.3 [C(fH 3 )CHC0 2H], 23.1 [PhSCH 2 CH 2 ], 30.2 [(CH 3 )2C], 33.1 
[ ( C H 3 ) 2_g_], 3 7 • 6 [ PhS C H 2_g_ H 2 ], 115. 9 [ C H C 0 2 H ], 1 2 3 • 5 [ C ( 7 ) ], 
123.6 [C(5)], 126.0 [PhC(CH 3 )fH], 126.4 [C(8)], 129.2 
[fHC(CH 3 )CHC0 2H], 131.9 [ C(8a)], 133.4 [fH=CHC(CH 3 )CHC0 2 ], 
138.0 [C(6)], 140.9, 141.7, 153.7 [C(CH 3 )CHC0 2 H], 172.1 
[f0 2 H]. Anal. Calcd for c20 H24 o2 s: C, 73.13; H, 7.36; S, 
9.76. Found: C, 73.32; H, 7.32; S, 9.93. 
Dimethyl (Carboethoxymethyl)sulfonium 
Bromide iffi 
A solution of 57.00 g (0.92 mol) of dimethyl sulfide 
132.50 g (0.795 mol) ethyl bromoacetate and 250 mL of dry 
acetone was stirred at room temperature in a 1000-mL, 
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round-bottom, three-neck flask under a nitrogen atmosphere 
for 24 h. The resulting white precipitate was filtered, 
washed with ether (100 mL), and dried under high vacuum 
(0.1 mm, RT) for 24 h in a desicator (CaS0 4 ) to give 146.80 
g (80.6%) of 72: mp 82.0-82.5°C (lit 85 mp 78-80°C). 1 H 
NMR (DCC1 3 ) o 1.35 [t, 3 H, OCH 2 C_!!.J], 3.52 [s, 6 H, 
(CH 3 ) 2S], 4.53 [q, 2 H, OCHCH 3 ], 5.52 [s, 2 H, CHC0 2 Et]; 
13 ( C NMR DCC1 3 ) ppm 13.2, 23.3, 43.7, 62.4, 163.3. 
Ethyl (Dimethylsulfuranylidene)-
acetate - (EDSA) iZ1l 
To a solution of 140.0 g (0.611 mol) of dimethyl 
(carboethoxymethyl)sulfonium bromide (72) in 486 mL of 
HCC1 3 , which was stirred at 0°C (ice bath) was added all at 
once a mixture of 365 ml of saturated K2 co 3 and 48.9 mL of 
12.5 N NaOH (0.611 mol). The ice bath was removed after 10 
min, and the biphase reaction mixture was stirred for 30 
min. The mixture was transferred to a separatory funnel, 
and the lower aqueous layer was removed and the chloroform 
layer was then dried (K 2co 3 , 2 h). Evaporation (rotor 
evaporator) of the solvent at 25°C gave an oil but residual 
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solvent was removed under high vacuum (0.10 mm, RT, 30 min) 
to give 88.80 g (98.0%) of ylide 73 (lit 85 1 H NMR (DCC1 3 ) 
o 1.2 [t, 3 H], 3.9 [q, 2 H], 2.7-2.8 [s with shoulder, 7 
H]) as an almost colorless liquid. The ylide must be used 
directly or stored under nitrogen at 0°C; 13C NMR (DCC1 3 ) 
ppm 14.1, 29.5, 31.4, 56.5, 168.8. 
Ethyl cis/trans-2-Formylcyclopropan-
carboxylate i&.ll 
To a solution of 44.40 g (0,30 mol) of EDSA 73 in 250 mL 
of dry boiling acetone was added dropwise acrolein (16.80 
g, 0.30 mol) over 15 min in a 500 mL, three-necked, round-
bottom, flask. The ~esulting light orange solution was 
heated for an additional 15 min, the solvent was removed 
and the residual oil was vacuum distilled to give 14.99 g 
(35.2%) of an isomeric mixture [84:16 trans-cis, via 13c 
NMR (no NOE) of the aldehyde carbon at 198.0 and 199.5 ppm 
respectively] of 67 as a clear colorless liquid: bp 57-
620C/1.0 mm. 
Ethyl trans-2-Hydroxymethylenecyclo-
propancarboxylate iZ!l 
To a stirred solution of 12.00 g (0.084mol) of the 
mixture of isomers of ethyl 2-formylcyclopropancarboxylate 
(67) in 65 mL of 95% ethanol was added in four equal por-
tions 6.39 g (0.168 mol) of NaBH 4 over 30 min in a 200-mL, 
three-necked, round-bottom, flask. The resulting 
suspension was stirred for an additional 2 h; the mixture 
was filtered and the filtrate was evaporated (rotor 
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evaporator) to give a colorless liquid. The crude alcohol 
was distilled to give 5.05 g (41.5%) of ethyl trans-2-
hydroxymethylenecyclopropancarboxylate (74) as a clear 
colorless liquid: bp 127-131°C/20 mm (lit 58 121-123°C/20 
mm); 1 H NMR (DCC1 3 ) o 0.86 [m, 1 H], 1.20 [m, 1 H], 1.25 
[ t' 3 H, co 2 cH 2 CJ!3 ], 1.56 [ m' 1 H], 1.91 [ m' 
1 H], 3.46 [ m' 1 H], 3. 6 2 [ m' 1 H], 4.13 [ q' 
co 2 cH 2 CH 3 ]; 13 c NMR (DCC1 3 ) ppm 12.6, 14.1' 
60.6' 6 4. 3' 174.0. 
Ethyl trans-2-Formylcyclopropan-
carboxylate (67) 
1 H], 2. 31 [ m' 
2 H, 
18.3' 2 4. 2' 
To a 200-mL, three-necked flask equipped with a 
condenser, nitrogen inlet and power stirrer was added 4.00 
g (27.7 mmol) of ethyl trans-2-hydroxymethylenecyclopropan-
carboxylate (74), 8.97 g (41.6 mmol) of pyridinium 
chlorochromnate (75) and 80 mL of CH 2c1 2• The mixture 
immediately became black with insoluble reduced reagent 
which caused stirring to become difficult. After 2 h, the 
mixture was diluted with 50 mL of ether, and the flask was 
rinsed with an additional 50 mL of ether. The resulting 
solution was evaporated (rotor evaporator), depositing more 
reduced reagent. The residue was taken up in 25 mL of 
ether and filtered through a 20 mm column of florasil with 
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ether (approx. 250 mL) as the eluent. After concentration 
(rotor evaporator), an oil was obtained which, upon distil-
lation, gave 2.55 g ( 64. 7%) of ethyl trans -2-f or mylcyclo-
propancarboxylate (67) as a clear, colorless liquid: bp 
134-136°C/20 mm (lit 58 100-102°C/20 mm). IR (neat) 2740 
cm- 1 [CHO, C-H strech], 1703 cm- 1 [C=O]; lH NMR (DCC1 3 ) 8 
1.28 [t, 3 H, C0 2CH 2CH 3 ], 1.52 [m, 1 H, H(3)], 1.60 [m, 1 
H, H(3)], 2.28 [m, 1 H, H(l)], 2.43 [m, 1 H, H(2)], 4.19 
[q, 2 H, C0 2 CJ!2CH 3 ], 9.31 [d, 1 H, CJ!O]; 13 c NMR (DCC1 3 ) 
ppm 14.2 [q, CH 3 ], 14.8 [t, C(2)], 22.2 [d, C(l)], 30.7 
[ d d , C ( 2) ] , 6 1. 3 [ t , C 0 2_g_ H 2 ] , 1 7 1. 1 [ s , _g_ 0 2 C H 2 ] , 1 9 8. 3 [ d , 
_g_Ho J • 
(2E,4E,6E)-3,7-methyl-(1,2,3,4,-tetrahydro-4,4-
dimethyl-6-thiochromanyl)-2,4,6-hepta-
triene-2,3-dihydro-3-desmethyl-2,3-
methylene-carboxylic Acid (48e) 
To a stirred suspension of 6.05 (10.6 mmol) of 
ph o s p h o n i u m sa 1 t 6 3 a in ,6 0 m L o f d r y e t her w a s ad de d 
dropwise n-butyllithium (6.81 mL, 1.55 M, 10.6 mmol) in 
hexane at room temperature in a 200-mL, three-necked, 
round-bottom flask equipped with a condenser and N2 inlet. 
The resulting, dark orangish-red solution was cooled to -
78°C (dry-ice, acetone), and 1.50 g (10.6 mmol) of ethyl 
trans-2-formylcyclopropancarboxylate (67) in 20 mL of ether 
was added dropwise in the dark. The mixture was allowed to 
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warm to room temperature with stirring over 12 h. The 
almost colorless suspension was diluted with 50 mL of 
hexanes, filtered, and concentrated. The resulting oil was 
passed through a 15 em column containing a slurry of silica 
gel using 1:1 ether:hexanes. Removal (rotor evaporator) of 
the solvents gave 3.06 g of the crude esters 68 as a thick 
oil. To 0.50 g (1.40 mmol) of this oil was added 10 mL of 
methanol, and this new solution was added to a mixture of 
KOH (0.28 g, 4.21 mmol) in 2 mL of H2 0. Heating this 
mixture to a gentle reflux followed for 30 min. The clear 
resultant solution was allowed to cool (30 min) to room 
temperature, was diluted with 50 mL of H2 0 and 5.0 g of 
NaCl, and was finally extracted with 100 mL of ether. The 
ether layer was extracted with H20 (3 x 25 mL), and the 
combined aqueous layers were acidified slowly with 5% H2S04 
(approx. pH 3). At the neutralization point, the solution 
became cloudy. The aqueous solution was extracted with 
ether (2 x 50 mL); the organics were combined, extracted 
with H20 (25 mL) and brine (50 mL). After drying (Na 2so4, 
overnight), evaporation (rotor evaporator) of the ether 
gave a slightly colored oil which was crystallized 
(ethanol:H20) to give 0.98 g (28.2%) of acid 48e 
(recrystallized from ethanol:H 20) as a tan solid: mp 149.5-
152.00C; 1 H NMR (DCC1 3 ) o 1.12 [ m, 1 H], 1.33 [ s, 6 H, 
(CH 3 ) 2 C], 1.51 [m, 1 H], 1.69 [m, 1 H], 1.95 [m, 2 H,--
PhSCH2CH2], 2.20 [m, 1 H], 2.12 [s, 3 H, PhC(CH 3 )], 3.02 
[m, 2 H, PhSCH 2 CH 2 ], 5.34 [dd, 1 H, J = 9.0 Hz, J = 15.0 
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Hz, PhC(CH 3 )CHCH=CH], 6.34 [d, 1 H, J = 12.0 Hz, 
PhC(CH 3 )CH], 6.61 [dd, 1 H, J = 12.0 Hz, J = 15.0 Hz, CH-
CH=CH], 7.04 [d, 1 H, J =; 8.0 Hz, H(8)], 7.12 [dd, 1 H, J = 
8.0 Hz, J = 2.0 Hz, H(7)], 7.43 [d, 1 H, J = 2.0 Hz, H(5)]; 
13c NMR (DCC1 3 ) ppm 15.9, 16.9, 22.4, 23.1, 26.8, 30.2, 
33.1, 37.7, 123.3, 123.6, 125.0, 126.4, 128.1, 130.7, 
133.1, 135.2, 138.8, 141.6, 179.5. Anal. Calcd for 
c20 H24 so 2 : C, 73.13; H, 7.37. Found: C, 73.09; H, 7.52. 
Ethyl 3-Phenoxypropionate i2Ql 
The procedure used was similiar to that described by 
Hall and Stern. 50 To a solution of 47.D g (0.50 mol) of 
phenol (89) and 50.0 g (0.50 mol) of ethyl acrylate (53) 
was added 0.60 g (0.02 gat) of metallic sodium at RT in a 
200-mL, three-necked, round-bottom flask equipped with a 
condenser and N2 inlet. Heating was started after the 
sodium had dissolved and the solution temperature was 
brought to approximately 95°C (slightly lower than the bp 
of 53). After 36 h, the resulting solution was cooled and 
0.5 mL of acetic acid in 100· mL of H20 was added. The new 
mixture was extracted with ether (3 x 100 mL), the organic 
layers were combined and dried (Na 2so4 , 12 h). Ether was 
removed (rotary evaporator) and the resulting oil was 
vacuum distilled to give 36.32 g (37.4 %) ethyl of 3-
phenoxypropionate (90) as a clear co~orless liquid: bp 139-
1420C/11 mm (lit50 142°C/11 mm); IR (neat) 1740 cm- 1 (C=O); 
1 H NMR (DCC1 3 ) o 1.15 [t, 3 H, C0 2 CH 2 CH 3 ], 2.65 [t, 2 H, 
CH 2 co 2 cH 2 CH 3 ], 4.10 [m, 4 H], 6.75-7.25 [m, 5 H, Ph-H]. 
2-Methyl-4-Phenoxy-2-butanol i2!l 
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To a freshly prepared solution [ 70.14 g, (0.494 mol) of 
methyl iodide, 12.01 g (0.494 g ·at) of magnesium] of 
methylmagnesium iodide in 300 mL of dry ether was added 
dropwise 32.00 g (0.165 mol) of ethyl 3-phenoxypropionate 
(90) in 150 mL of ether in a 1000-mL, three-necked, round-
bottom flask equipped with a condenser and N2 inlet. The 
solution was boiled for 1 hand allowed to stirrat room 
temperature for 10h. The resulting solution was 
neutralized with 5% H2so 4 (pH approx. 6.5); the ether layer 
was separated, and the aqueous layer was extracted with 
ether (3 x 100 mL). The ether layers were combined and 
dried (Na 2so 4 , overnight). Solvent was evaporated (rotary 
evaporator), and vacuum distillation of the residual oil 
gave 24.06 g (80.9%) of 2-methyl-4-phenoxy-2-butanol (91) 
as a clear, colorless liquid; bp 85-86.5°C/0.2 mm (lit 128 
81-84°C/0.07 mm); IR (neat) 3130-3610 cm-1 (0-H); 1H NMR 
(DCC1 3 ) o 1.26 [s, 6 H, (CH 3 ) 2 ], 1.95 [t, 2 H, PhOCH 2 CJ! 2 ], 
2.90 [brs, 1 H, Ol!.], 4.12 [t, 2 H, Ph0Cl!. 2 ], 6.80-7.40 [m, 5 
H, Ph-H]; 13c NMR (DCC1 3 ) ppm 29.6, 41.6, 65.0, 70.3, 
114.4, 120.9, 129.4, 158.3. 
4,4-Dimethylchroman ~ 
To a 500-mL, three-necked, round-bottom flask equipped 
with a condenser, N2 inlet and power stirrer was added 
23.01 g (0.173 mol) of AlC1 3 in 100 mL of freshly 
distilled, dry nitromethane. To the stirred solution of 
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AlC1 3 was added dropwise a solution of 23.00 g (0.128 mol) 
of 2-methyl-4-phenoxy-2-butanol (91) in 125 mL of dry 
nitromethane at RT over 30 min and the mixture was stirred 
for 24 h. To the new solution was added 200 mL 6 N HCl. 
The resulting mixture was separated and the aqueous layer 
extracted with ether (3 x 75 mL). The organics were 
combined, extracted with H20 (SO mL) and brine (50 mL) and 
then dried (Na 2so4 , overnight). The solvent was removed 
(rotorary evaporator) and the resulting brown oil was 
vacuum distilled to give 13.40 g (64.5%) of 4,4-
dimethylchroman (84) as a clear colorless liquid: 54-
550C/0.2 mm (lit 128 74-80°C/0.7 mm); 1H NMR (DCC1 3 ) 6 1.30 
[ s, 6 H, ( C .!!3 ) 2 ] , 1. 8 2 [ m, 2 H, Ph 0 C H 2 C H 2 ] , 4. 18 [ m , 2 H, 
PhOCH 2CH 2 ], 6.70-7.30 [m, 4 H, Ph-H]; 13c NMR (DCC1 3 ) ppm 
30.4, 31.0, 37.6, 63.1, 117.0, 120.3, 126.8, 127.0, 131.7, 
153.5. 
Dimethyl (4-Carbmethyoxybenzyl)-
phosphonate il§l 
The procedure used was similiar to that described by 
Dawson for diethyl (3-carbethoxybenzyl)phosphonate.29 To a 
250-mL, three-necked, round-bottom flask equipped with a 
condenser was added 15.8 g (0.13 mol) trimethyl phosphite 
and 25.7 g (0.11 mol) methyl bromomethylbenzoate (80). A 
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stream of N2 was swept over the mixture and the flask was 
slowly heated to 150°C with an oil bath over 1 h (caution: 
MeBr is evolved during the reation causing the mixture to 
bubble violently if heated to fast). The resulting mixutre 
was then heated to 190°C for 30 min and then allowed to 
cool to RT while maintaining the N2 atmosphere (about 30 
min). After vacuum distillation (138-147°C/0.075 mm) 17.7 
g (61.0%) of dimethyl (4-carbomethoxybenzyl)phosphonate 
(76) was obtained as a thick, viscous, clear, colorless 
oil: IR (neat) 1740 cm-l (C=O); 1 H NMR (DCCl3) o 3.24 [d, 
2 JPH =21Hz, 2 H, P(O)CH 2 ], 3.67 [d, 3 JPH =11Hz, 6 H, 
3 4 P 0 2 C .!!3 ], 3. 8 8 [ s, 3 H, C 0 2 C J:!_J ], 7. 3 7 [ d d , J H H = 8 Hz , J pH 
=3Hz, 2 H, Ph-.!! (ortho)], 7.97 [d, 3 JHH =8Hz, 2 H, Ph-H 
( m e d a ) ] ; 1 3 C N t1 R ( DC C 1 3 ) p p m 3 2 • 3 [ d , 1 J p C = 1 3 6 • 9 H z , 
P(O)fH 2 ], 51.8 [d, 2 Jpc = 26.4 Hz, P0 2_g_H 3 ], 52.1 [C0 2.Q.H 3 ], 
128.1, 128.2, 128.9, 129.1, 136.0, 136.4, 165.8; 3 1 p 
(DCC1 3 ) ppm 25.38. 
ppm 1eo IGO 140 
I 
50 0 0 
' 250 0 
10 0 0 
50 0 
PLATE I 
120 100 80 60 40 20 o 13c 
I - -----,-------.----., 
i:§L S -""/C02Et 
' J, /~\ A-)\...__ _ 
ppm 9 
B 7 6 5 4 2 o lH 
ln NHR Spectrum of 54 
PFT X CH : Solvent: DCCl3 ; SF: 299.948 MHz; we: 2999.4 Hz; T: RT OC; NT: 8 
Size: 12 K; -pl~/RF: 25.0 ]Js/dB; SO: 0 Hz; FB: - Hz; Lock: DCCl3 ; Delay: 0 s • 
DC: N : Gated Off: ; Offset: Hz: RF: - H/dB; NBW: 0 Hz; LB: - . 
........ 
-1>-
N 
PLATE II 
ppm 180 160 1 40 120 100 eo 60 40 20 
I 
5 00 
I 
)00 
' 000 
;o o 
r§ls~co2Et 
B 6 5 4 3 2 
13c NMR Spectrum of 54 
PFT X CW Solvent: DCC1 3 SF: 75.429 MHz; WC: 15085.9 Hz; T: RT °C; NT: 12 
Size: 20 K; Pt\1/RF: ]2.0 )Js/dB; TO: 1000 Hz; FB: Hz;· Lock: DCC13 ; Dl,D5: 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 10 W/dB; NBW: 200 Hz; LB: 3.0 
o 13c 
4.0 s. 
Hz. 
...... 
.j::--
w 
H 
H 
H 
~ j 
p., 
0 
0 
.. 
~ 
=-== 
==:-:: 
~-=================-
.. 
w 
0' 
u 
< (/) 
© 
\ 
0 0 0 
::1 
"' 
... 
144 
0 
0 
'<I' 
0 
0 
tD 
0 
0 
= 
0 
0 
0 
0 
0 
N 
...:t 
Ll"\ 
4-1 
0 
... E 
;::l 
~ 
~ .IJ 
u 
Q) 
0.. 
Cf) 
~ 
H 
0 
0 
0 
0 ... 
N 
PLATE IV 
ppm 180 160 140 120 100 80 60 lfO 20 o 13c 
I I I 
00 
I 
2 ,oo 
000 
©Ls~" iO 0 I 
I 
I 
' 
'L- .........__ l ..) l -. ~ 
-
-~ 
o ln 1 3 2 
I .__ _____ I -
.. 
I__ 
_L_ ---
-
5 
L _ ___. ___ 
-
5 
J. -
8 7 
J _j_ ...1 
9 
_l ppm 
...1 _l 
lH NMR Spectrum of 55 
PFT X CW : Solvent; DCC1 3 . SF: 2999.948 mlz; we: 2999.4 Hz; T: RT OC; NT: 8 , 
8 5 0 2 0 Size: K; PH/Rfct ~s/dB; ro: Hz; FB: - Hz; Lock; H i Dl,DS: s . 
0 -
1-' 
DC: Y, N ; Gated Otf:A or D ; ou: !iz; HF(Power): \J I dB; NIM: 0 tl<!; LB: - Hz. ~ V1 
PLATE V 
rrrn 
r 
13 lBO 160 140 120 100 60 60 40 20 0 C 
50 0 0 
I 
2 50 0 
I 
I o o o 
I 
so 0 
ppm 
PFT X CW 
Size: 8 
9 
DC: Y, N : 
. 
• 
K; 
J II I 
6 7 
Solvent: DCC13 ; 
PH/RF: 9 lJS/dB; 
Gated Off:A or D ; DO: 
©ls~OH 
_, j t )II ) 
6 5 4 3 2 1 ~ IH 
13c NMR Spectrum of 55 
SF: 75.429 MHz; we: 15085.9Hz; T• RT oc; NT: 300 . 
2 
TO: 10000 Hz; FB: - Hz; Lock: H ;Dl,DS: 4.0 
s . 
Hz; RF(Power): 10 \.J/ dB; NBW: 200 Hz; LB: 1.0 Hz. 
._. 
.p-
()\ 
~----~ 
0 
0 
0 0 
<D 
0 
"' 
' 0 
N 
147 
PLATE VII 
13 
180 160 litO 120 100 80 60 ItO 20 0 C 
50 0 0 
2500 
0 
I o 0 0 
50 0 ro 
J I 
ppm '1 8 7 G 5 It 3 
2 1 0 111 
1n NMR Spectrum of 56 
PFT X CW . Solvent: DCC13 . SF: 299.9485 ffilz; WC:2999.4 Hz; T• RT OC; NT: 8 . • . 
Size: 8 K; PV/RF: 9 IJS/dB; TO: 0 Hz; FB: - Hz; Lock: 2H ; Dl,DS: 0 s • 
0 0 
1-' 
DC: Y, N ; Gated Off:A or D ; DO: Hz; RF(Power): - H/dB; NBW: liz; LB: - Hz. .j::--CX> 
50 0 0 
' 2500 
1000 
50 0 
PLATE VIII 
180 160 140 12n 100 80 60 40 20 o 13c 
©0 
I 
tL - ~ 
ppm 9 8 7 s 5 4 3 2 1 
L---~-----L----~----L---~-----L----~--L---~----~----~----~--~-----L----~----L---~-----L----~----L---~ 
13c NMR Spectrum of 56 
PFT X CW : Solvent: DCC1 3 ; SF: 75.429 MHz; WC: 15085. 9Hz; T: RT oc; NT: 300 
so: 1000 
2 4.0 ]Js/dB; Hz; FB: - Hz; Lock: H ; Delay: s . Size: 20 K; -Plv/RF: 12 
DC: Y Gated Off: Offset: Hz; RF: 10 W/dB; NBW: 200 Hz; LB: 1.0 
f-' 
.j::--
\0 
~ 
H 
l'il 
H 
~ 
,...:~ 
l=l-< 
l ____ g 
'<t 
0 
0 
<D 
.c: 
~= 
~ 
0 
J 0 :1) 
0... ( 0 0 0 N 
I 
l 
1--
-....._ , 
0 0 0 0 0 
0 :1) <Q ., N 
150 
s 
::l 
!-1 
+.J 
u 
ClJ 
0. 
U) 
~ 
f-1 
PLATE X 
ppm 
r 
lJ 
180 )60 1 ~0 120 100 60 60 40 20 0 c 
so o o 
I 
2 s 0 0 
I 
10 0 0 
I 
~0 0 
0 
-
r-
I 
/
----- -
---------------
------------ -~: I. 
~ 
If · 
=1 ' I; I 
--_ __t_JL_ --------·------__________ jL __ jl ____ )L_Jl ____________ j 
ppm 9 0 7 6 5 2 o I H 
PFT X CW Solvent: DCCl 3 
lH NMR Spectrum of Sla 
SF: 299.948 Z.fllz; WC: 2999.4 Hz; T: RT 
Size: 12 K; PH/RF: 8 • 0 lJS/dB; TO: 0 Hz; FB: 
2 
Hz; Lock: H 
°C; NT: 16 
; Dl,DS: 0.5 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 10 W/dB; NBW: 200 Hz; LB: 
s • 
Hz, 
1-' 
lJ1 
1-' 
PLATE XI 
180 160 1 4 0 120 100 60 60 40 20 0 13c 
50 0 0 
2500 
1000 I ~0 50 0 
I 
I 
I I 
I 
I 
II UL I i I ! I 
ppm 9 8 7 6 
___!__ 
5 4 3 2 I o lH 
13 c Ni'·1R Spectrum of Sla 
PFT X CW : Solvent: DCC1 3 ; SF: 75.429 :t-'ffiz; we: 15085. <Ez; T: RT OC; NT: 300 
2 4.0 Size: 20 K· -PH/RF: 12 fJS/dB; so: 1000 Hz; FB: - Hz; Lock: H ; Delay: s. 
' 
DC: y : Gated Off: ; Offset: Hz: RF: 10 W/dB; NBH: 200 Hz; 
...... 
LB: 1.0 \.J1 
N 
H 
H 
::< 
!'a 
E-1 
<t: 
...:! 
P-< 
o:r 
r-_____ g 
0 
0 
.. 
0 
a) 
0 
CD 
0 
"' 
0 
-==-
-=-..,..-=--
0 
N 
0 
0 
CD 
0 
0 
a) 
0 
0 
CD 
... 
0 
0 
a) 
0 
0 
0 
N 
0 
0 
0 
., 
153 
ttl 
~ 
Ll"l 
4-l 
0 
s 
;::! 
~ 
.w 
u 
(lJ 
0.. 
(/) 
;::.~ 
f-i 
PLATE XIII 
1so J6o 140 120 100 eo so 
5000 
I 
2500 
1000 
50 0 
ppm 
PFT X CW 
Size: 12 
9 
DC: Y, N ; 
: 
K; 
8 7 
Solvent: DCC1 3 ; 
PH/RF: 8.0 JJs/dB; 
Gated Off:A or D ; DO: 
6 5 4 3 
lH Spectrum of 61a 
SF: 299.948 MHz; WC: 2999.4 Hz; 
TO: 0 Hz; FB: - Hz; 
0 Hz; RF(Pm-1er): 10 H/dB; 
ItO 20 o 13c 
2 1 o lH 
T: RT oc; NT: 16 
Lock: 2H ; D1 ,D5: 0.5 s. 
I-' 
lJl 
NBH: 200 Hz; LB: - Hz. ~ 
ppm 180 160 140 
5 00 
I 
; 0 0 
) 0 0 
5 00 
ppm 9 8 7 
PFT X CH . Solvent: DCC13 ; . 
Size: 20 K; Ptv/RF: 12 lJs/dB; 
DC: Y, N ; Gated Off:A or D ; DO: 
PLATE XIV 
120 100 80 60 
6 5 4 3 
13c Spectrum of 61a 
SF: 75.429 MHz; WC: 15085.9Hz; 
TO: 1000 Hz; FB: - Hz; 
0 Hz; RF(Power): 10 H/dB; 
40 20 
2 1 
T: RT oc; NT: 
2 Lock: H ;D1,D5: 
NBW: 200 Hz; LB: 
o 13c 
o lH 
400 
4.0 
1.5 
s . 
...... 
Vl 
Hz. Vl 
PLATE XV 
180 160 140 120 100 80 60 
so 0 0 
I 
2500 
0 
1000 
so 0 
ppm 9 8 7 
PFT X CW . Solvent: DCC13 ; . 
Size: 8 K; Ptv/RF: 5 )Js/dB; 
DC: Y, N ; Gated Off:A or D ; DO: 
6 5 
lH Spectrum of 
.. 
63a 
+ 
PPh3Br 
3 
SF:299.9485 MHz; wc:2999.4 Hz; 
TO: 1000 Hz; FB: - Hz; 
0 Hz; RF(Power): - \v/ dB; 
.. 0 20 o IJc 
2 I 0 lll 
T: RT OC; NT: 8 
Lock: 2H ;Dl,D5: 0 s • 
1-' 
0 0 Hz, VI NBW: liz; LB: 0\ 
PLATE XVI 
180 160 140 120 100 80 60 
so 0 0 
I 
250 0 
1000 
50 0 
ppm I 
PFT X C\.J' 
Size: 20 
9 
I 
DC: Y, N ; 
: 
K; 
8 7 6 5 .. 3 
I I I 
13c NMR Spectrum of 63a 
Solvent: DCC13 ; SF: 75.429 MHz; WC: ] 5085. 9Hz. 
' 
PH/RF: 12 ~s/dB; TO: 1000 Hz; FB: - Hz; 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 10 \J I dB; 
40 20 o 13c 
+ 
P Ph3Br 
2 1 ? lH 
T: RT oc; NT: 400 
Lock: 2H ; Dl ,D5: 5.0 s • 
...... 
VI 
NBW: 200 Hz; LB: 2.0 Hz. --..1 
ppm 160 160 
I 
50 0 0 
I 
25 0 0 
]000 
50 0 
ppm 45 40 
I 4 0 
35 
PLATE XVII 
12 0 100 60 60 
+ 
P Ph3 Br 
30 . 25 20 15 
31 P NMR Spectrum of 63a 
PFT X CW : Solvent: DCC1 3 ; SF: 121.421 MHz; WC: 6071.0 Hz; 
Size: 9998 K; Pl.f/RF: 16.0 )Js/dB; TO: 0 Hz; FB: - Hz; 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 \J I dB; 
'10 20 o 13c 
j 
10 5 0 31p 
T: RT DC; NT: 16 
Lock: ; D1,D5: 6.0 s • 
...... 
NBW: Hz; LB: 1. 061 Hz, Vl <Xl 
0 
0 
-
... 
Cll 
.c 
n. 
+U. 
---==--
- ............ ~ 
---~~ 
~ 
----::;._. 
...,;._ 
---s.. 
= 
0 
<D 
0 
159 
PLATE XIX 
13 
lBO 160 140 120 100 80 GO l!O 20 0 C 
500 0 
I 
250 0 
' 
I 0 0 0 
50 0 ~~C02H 
ppm 9 8 7 6 5 .. 3 2 1 o lH 
IH Spectrum of 48b 
PFT X CW : Solvent: DCC1 3 ; SF:299.9485 :t-lllz; WC: 2999.4 Hz; T: RT oc; NT: 100 
Size: 18 K; PH/RF: 20 jJS/dB; TO: 0 Hz; FB: 2 0 -- Hz; Lock: H ; D1,D5: s . 
._... 
20 DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): U/dB; NBW: 0 Hz; LB: - Hz. 0\ 0 
PLATE XX 
180 160 140 120 100 80 60 
so 0 0 
I 
25 0 0 
1000 
50 0 
ppm 
PFT X CW 
9 
. 
. 
Size: 16 K; 
DC: Y, N ; 
8 7 
Solvent: DCC1 3 ; 
Pt~/RF: 12 lJS/dB; 
Gated Off:A or D ; DO: 
~~ 
6 5 4 3 
13c Spectrum of 48b 
SF: 75.429 M"tlz; we: 15085 Hz; 
TO: 1000 Hz; FB: - Hz; 
0 Hz; RF(Power): 20 \J/ dB; 
40 20 o 13c 
C02H 
2 1 o lH 
T: RT oc; NT: 100 
Lock: 
2H 
; D1,D5: 4.0 s . 
I-' 
NBW: 200 Hz; LB: 4. 0 Hz, Q\ I-' 
0 
0 
... 
J: 
C'l 
0 
u 
'I 
'I 
0 
a) 
0 
<0 
~--~--:::?E=--
-
/ 
~ 
J 
~ 
~ 
:::F 
1 
0 
"' 
162 
0 
0 
"' 
0 
0 
<0 
0 
0 
a) 
0 
0 
0 
0 
0 
N 
0 
0 .c 
.., 
co 
..:t 
0 4-l 0 
<0 0 
~ 
8 
;:l 
0 1-1 
0 
.j..J 
a) 
~ u 
(j) 
P.. 
0 (/) 
0 
0 
N ~ 
f-' 
0 
0 
It) 
N 
0 
0 
0 
(") 
0 
0 
It) 
(") 
0 
0 
I 0 
0 ~ 
N 
PLATE XXII 
ppm 180 160 140 120 100 eo 60 
~~ 
50 0 0 
I 
2 50 0 
1000 
50 0 
ppm 
PFT X CW 
Size: 12 
9 
DC: Y, N ; 
. 
. 
K; 
8 7 
lH 
Solvent: DCCl ; 
3 
Pt.J/RF: 5.0 JJs/dB; 
Gated Off:A or D ; DO: 
~~C02Et 
6 5 lj 3 
Spectrum of 48a 
SF:299.9429 MHz; WC: 2999.4 Hzj 
TO: 0 Hz; FB: - Hz; 
0 Hz; RF (Power): 20 \~/dB; 
lfO 20 0 13c 
I 
r 
I 
I 
I 
I 
i 
I 
I 
I 
2 1 ~ Ill 
T: RT oc; NT: 40 
2 
Lock: H ;Dl,D5: 0 s • 
Hz. 1-' NBW: 0 Hz; LB: - 0\ w 
PLATE XXIII 
ppm 1eo 160 1 ~o 120 100 80 60 
r 
500 0 
I 
25 0 0 
1000 
50 0 
ppm I 
PFT X CW 
Size: 20 
9 
I 
. 
. 
K; 
DC: Y, N ; 
~~C02Et 
8 7 6 5 . ~ 3 
I I I I 
13c NMR Spectrum of 48a 
Solvent: DCC13 . SF: 75.429 MHz; WC: 15085.9Hz; 
' 
PV/RF: 35 }Js/dB; TO: 1000Hz; FB: - Hz; 
Gated Off:A or D ; DO: 0 Hz; RF (Power) : 20 lJ/dB; 
~0 20 o 13c 
2 1 o 1 II 
T• . RT oc; NT: 1120 
Lock: 
2H 
;Dl,D5: 4.0 s. 
NBW: 200 Hz; LB: 2.5 Hz. 
._.. 
(J'\ 
+:--
::> 
H 
>:: 
>:: 
l:t:l 
H 
<:t: 
.--< 
~ 
... 
w 
N 
0 
(..) 
'I 
'I 
0 
0 
~ 
0 
0 
(Q 
0 
0 
= 
0 
0 
0 
0 
0 
N 
0 
C) 
~ 
0 
0 
<D 
0 
0 
= 
0 
0 
0 
N 
0 
0 
Ill 
N 
0 
0 
0 
M 
0 
0 
..., 
M 
0 
~----------~---------.----------~--------~--------~g 0 
0 
0 
= 
0 
<D 
0 
N 
~ 
165 
(1j 
00 
..:!' 
~ 
0 
s 
::::: 
l-< 
.jJ 
u 
(J) 
0.. 
(/) 
X 
•-; 
PLATE XXV 
180 )60 140 120 100 60 60 ~0 20 o I3c 
50 0 0 
I 
25 0 0 
I 
1000 
so 0 co2~N~ ~"-:::: 
0 
ppm I 9 
6 7 6 5 .. 3 2 1 o 111 
I I I I I 
lH NMR Spectrum of 48d 
PFT X CW . Solvent: DCC1 3 . SF:299.9485 MHz; we: 2999.4 Hz; T• RT oc; NT: 8 . • . 
Size: 8 K; Pt.J'/RF: 6.0 ps/dB; TO: 0 Hz; FB: - Hz; Lock: 2H ; Dl,D5: 0 s • 
t-' 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 15 H/dB; NBW: O Hz; LB: - Hz. 0"1 0"1 
~ 
500 0 
I 
2 50 0 
I 
I o o 0 
I 
50 0 
PLATE XXVI 
160 160 !~tO 120 100 80 60 ItO 20 o 13c 
~-...;::: co2~N~ 
0 
~ ~--_J,~~··.~ ..... ~tJ1.~1l~.~~.·~~·~~.l LA.J~~VA __ JJ1.tJL~.) 
prm I - 8 7 6 
5 .. 3 2 I o 1 H 
I I I I I 
13 c NMR Spectrum of 48d 
PFT X CH . Solvent: DCC13 . SF: 75.429 :t-rnz; WC: 15085. 9 Hz; T: RT oc; NT: 
1000 
. 
' 
S 1.z e : 16 K; PH/RF: 12 )Js/dB; TO: 1000 Hz; FB: - Hz; Lock: 2H ;Dl,DS: 4.0 s • 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 H/dB; NBW: 200 Hz; Hz. LB: 2.0 
f-' 
a-, 
-....J 
100-
80-
60-
20-
4000 3500 3000 
PLATE XXVII 
0 
~~co2~.~ /,y \ Nyg 
,4,1 0 
2500 2000 1800 1600 1400 
IR Spectrum of 48d 
1200 1000 BOO 600 400 
1-' 
(J'\ 
(X) 
PLATE XXVIII 
ppm lao 160 1 ~o 120 100 eo so 
I 
so 0 0 
I 
2 50 0 
I 
)000 
I 
50 0 
ppm 
PFT X C\1 
Size: 12 
DC: Y, N ; 
©LsxJl 
_J 
--------·· I 
----~! l 
9 6 7 6 5 .. 
lH NMR Spectrum of 58 
: Solvent: DCC13 . SF:299.9485 Nllz; HC: 2999.4 Hz; T• , . 
K; Pt.J/RF: 5 · 0 ~s/dB; TO: 0 Hz; FB: - Hz; Lock: 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 lJ/dB; NB\.J: 
~0 20 0 lJC 
2 o IH 
RT oc; NT: 8 
2H 
iDl,D5: 0 s • 
I-' 
0 liz; Hz, 0' LB: - \.0 
ppm 180 ]60 1 4 0 
0 0 
I 
so 0 
000 
,Q 0 
L 
. 
ppm 9 a 7 
PFT X CH Solvent: DCC1 3 
Size: 8 K; PH/RF: 12 ps/dB; 
DC: Y, N; Gated Off:A or D; DO: 
PLATE XXIX 
120 100 60 60 .. 0 20 
©ls~ 
6 5 .. 3 1 
13c NMR Spectrum of 58 
SF: 75.429 t-mz; HC:15085.9 Hz; T: RT °C; NT: 
TO: 1000 liz; FB: Hz; 
2 
Lock: H ; Dl,DS: 
0 Hz; RF (Pm..rer) : 10 H/dB; NBH: 200 liz; LB: 
1500 
10 
' 13 
0 c 
0 111 
s • 
Hz. 
1-' 
--..1 
0 
'<!' r-----------------g 
---------~ 
( 
0 0 0 
0 <.0 <.0 
.. 
. 
0 0 
., N 
0 
0 
CJ:) 
0 
0 
<.0 
0 
171 
4-1 
0 
PLATE XXXI 
ppm lao 160 1 ~o 120 100 eo so 
so o o 
I 
2 s 0 0 
I 
1000 
I 
~0 0 ©tsX-kOH 
1,0 20 0 
I I -T 
_____ J_.~-~ Ul ) 
ppm 
PFT XcH 
9 
_l 
. 
. 
Size: 12 K; 
I 
B 
I 
Solvent: 
PH/RF: 
DCCl 
7 
I 
3 
. 
t 
5
·
0 ~s/dB; 
DC: Y, N i Gated Off:A or D ; DO: 
6 
I 
5 
I 
lH NMR Spectrum of 
.. 
I 
59 
SF: 29.9.9485 Hllz; HC: 299.4 
TO: 0 liz; FD: -
0 Hz; RF(POt.;er): 20 
3 
I 
Hz; 
liz; 
11/dB; 
T· . ·RT 
2 
I 
2 
Lock: H 
N ill~: 0 
oc; 
l 
I 
NT: 
; Dl,DS: 
llz; LD: 
4 
0 
o I H 
I 
IJC 
s • 
liz. 
t-' 
~ 
N 
ppm 
0 0 
I 
.._ ..J 0 0 
I o o 0 
~0 0 
-
ppm 
PFT XCH 
Size:8 
DC: Y, N 
180 160 
9 8 
.l _l 
Solvent: 
K; PIJ/RF: 12 
I~ 0 
u 
7 
_l 
DCC1 3 
ps/dB; 
Gated Off:A or D ; DO: 
PLATE XXXII 
12 0 100 eo 60 .. 0 20 
©lsxXOH 
_ill 
..l. 
6 5 .. 3 2 I 
.l I I l .l ..1 
l3c NMR Spectrum of 59 
SF: 75.429 HHz; t-IC: 15085.9Hz; T: RT °C; NT: 
TO: 1000 liz; Fll: Hz; Lock: 
2H 
; Dl,D5: 
0 Hz; RF(Power): lO H/dB; NBI.f: 200 liz; LB: 
. 13 
0 c 
o Ill 
.l -
752 
4.0 s • 
Hz. 
1-' 
...... 
lJJ 
174 
0 
0 
'<t 
0 
0 
(Q 
0 
0 
<D 
0 
0 
0 
0 
0 
N 
0 
0 
~ 
0\ 
\/") 
0 ~ H 0 0 H c.o 
H 
::< s 
::< :1 
::< I-< 
rzl 0 .w 0 u ~ :X: <D Q) 
....:l ~ 0.. p... r:Jj 0 0:::: 0 1-' 0 N (/) (Q) 0 0 
...., 
N 
0 
0 
0 
C') 
0 
0 
lt'l 
C') 
0 
0 
0 
0 0 0 0 0 
.., 
0 <D c.o '<t N 
-
so 0 0 
250 0 
1000 
50 0 
PLATE XXXIV 
180 ]60 140 120 100 80 60 ItO 
oct 
I 
! 
.I 
! 
'! ~ 
~ 
ij 
ij 
:; 
'I 
~! 
i! 
;; 
20 . o 13c 
• i .I 
+-- " ft._)/L_ ;;__) \4, # 
ppm 9 8 7 6 It 2 0 111 
lH NMR Spectrum of 60 
PFT X CH : Solvent: DCC1 3 ; SF: 299.9485 NHz; HC: 15085.9 liz; T: RT oc; NT: 4 
Size: 12 K; Pt-l/RF: 5.0 jJs/dB; TO: 0 Hz; FB: - Hz; Lock: 2H ; Dl,D5: 0 s • 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Poto~er): 20 H/dB; NB\.,: 200 liz; LI3: Hz. 1-' 
-....j 
V1 
PLATE XXXV 
ppm 190 )60 1 ~ 0 120 100 80 60 .. 0 20 o 13c 
00 
I 
50 0 
' 
000 ©Q ~0 0 
... .l J 
"'· 
..... 
""" 
l~ ..... 1¥ \M.... 
~ ..• .... .. ...... ~w . . ·-
ppm 9 8 7 6 5 .. 3 2 1 0 111 
13c NMR Spectrum of 60 
PFT Xct.J . Solvent: DCC1 3 i SF: 75.429 ~mz; He: 15085.9 Hz; T: RT OC; NT: 
1200 
. 
Size: 8 K; PH/RF: 12 )Js/dB; TO: 1000 Hz: FB: - liz; Lock: 
2H 
i Dl,D5: 4.0 s • f-' 
-...! 
DC: Y, N ; Gated Off:A or D ; DO: 
0 RF(Power): 10 NB\-1: 200 - Hz, 
0\ 
Hz; \I I dB; liz; LB: 
PLATE XXXVI 
100-
80· .,.,~v'l' 
~,.,~~·viM·wjft~ 
60 
40-
oct I~ 
ij 
20-
4000 3500 3000 2500 2000 1800 1600 
IR Spectrum of 60 
NY 
1400 1200 1000 800 600 400 
....... 
-..J 
-..J 
So 0 D 
I 
2 50 0 
I 
)000 
I 
500 
PLATE XXXVII 
l60 I ~0 120 100 60 60 
'0 
1<0 20 
l 
I 
I 
I 'L-~L--.-----
' i :: 
________ iil iL__jl l 
ppm 9 a 7 6 It 2 
1H NMR Spectrum of Slb 
PFT X CI.J : Solvent: DCC1 3 SF: 299.9485 NHz; HC: 2999.4 Hz; T• 
RT oc; NT: 4 . 
Size: 12 K; PIJ/RF: 5 · 0 JJs/dB; 0 Hz; Fn: - Hz; 
2H 0 TO: Lock: ;Dl,DS: 
DC: Y, N ; Gated Off!A or D ; DO: 0 Hz; RF(Power): 20 H/dB; Nll\.J: 0 liz; Lll: -
o 13c 
o 1 H 
s . 
...... 
-.J 
Hz. ():) 
PLATE XXXVIII 
13 
ppm 1ao 160 1a.o 120 100 eo 60 a.o 20 o C 
r 
so 0 0 
2500 
1000 
50 0 
'0 
ppm 9 8 7 6 5 
.. 3 2 1 0 lll 
13c NMR Spectrum of Slb 
PFT X CH . Solvent: DCC1 3 . SF: 75.429 J-fllz; HC: 15085.911z; T: RT OC; NT: 500 . I 
2 4.0 Size: 8 K ; PI.J/RF: 12 )Js/dB; TO: 1000Hz; FB: - liz; Lock: H ; Dl,DS: s . ...... 
" 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz· RF(Pm..rer): 10 H/dB; 200 liz; - Hz. 
\0 
• 
NB\\f: LB: 
~ ~----g
0 
0 
0 0 
"' 
0 
~ 
0 
N 
180 
PLATE XXXX 
ppm ISO 160 140 120 100 80 60 
·r I I I I I I I 40 20 soo 0 
I 
2500 
I 
1000 
I 
500 
ppm. 
PFT X CH 
Size: 12 
DC: Y, N ; 
9 
. 
: 
K; 
+ 
P Ph3 Br 
I 
I 
ll 
'· •!
!' d It 
II ji 
,I 
il 
11 
.I 
II 
ll 
i . H 
'I ,, i ll 1 
WAi\ i l t. ~~;: ; 
__ . 'LJJLL __ _r. ___ __,... ,._1 jUU»L. ___ _) 
B 7 6 5 4 3 2 I 
1H NMR Spectrum of 63b 
Solvent: DCC1 3 j SF:299.9429 ~mz; HC: 2999.4 Hz; T: RT oc; NT: 4 
PH/RF: 5.0 )Js/dB; TO: 0 liz; FB: - Hz; Lock: 2H iDl,D5: 0 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 ll/dB; NBI-1: 0 Hz; LB: -
o 13c 
o IH 
s • 
...... 
CXl 
liz. ...... 
50 0 0 
' 2500 
I a o 0 
so 0 
ppm 
PFT X C\.J 
Size: 8 
DC: Y, N ; 
PLATE XXXXI 
180 160 I ~0 120 100 80 60 
+ 
P Ph3 Br 
9 8 7 6 5 . 
" 
3 
13c NMR Spectrum of 63b 
. Solvent: DCC1 3 . SF:75.429 ~Diz; WC:l5085.9 Hz; . 
' 
K; Pl.J/RF: 12 IJS/dB; TO: 1000 liz; FB: - liz; 
Gated Off:A or D ; DO: 0 Hz; RF(Potver): 10 H/dB; 
l!O 20 o 13c 
2 I ? 111 
T: RT OC; NT: 1600 
Lock: 2H ;Dl,D5: 4.0 s . 
...... 
(X) 
NBI.J: 200 - Hz, N liz; LB: 
PLATE XXXXII 
ppm 100 160 1~0 12b 100 eo 6o ~o 20 o 
I 
so 0 0 
I 
2500 
I 
1000 
I 
~0 0 
ppm I 
27 
I 
24 
I 
18.90 
21 18 15 12 
3lp NMR Spectrum of 63b 
PfT X C\J . Solvent: DCC1 3 ; SF:121.421 ~nlz; HC: 3642.6 . 
Size: 12 K; PH/RF: 14 JJs/dB; TO: 1000 liz; FD: -
DC: Y, l1 ; Gated Off:A or D ; DO: 0 Hz; RF(Po\..rcr): 20 
+ 
P Ph3 Br 
__) 
---------
9 6 3 o 111 
liz; T· RT OCj NT: 200 . 
liz; Lock: i Dl,D5: 2.0 
H/JU; l/131/: liz; LD: 
lJC 
I 
s • 
to-' 
liz. OJ 
w 
0 
0 
... 
.... 
II] 
.1:: 
a. 
+a. 
0 
CCI 
0 
cQ 
0 
~ 
0 
N 
184 
0 
0 
"1 
0 
0 
tO 
0 
0 
CCI 
0 
::; 
0 
0 
0 
N 
0 ,.CI 
0 C"1 
"1 
"' 
4-1 
0 0 0 
IQ s .. 
::l 
""' 0 -1-l 
0 u 
CCI Cl) .. 
0. 
C/) 
0 
0 ~ 
0 1-' N 
0 
0 
Ill 
N 
0 
0 
0 
M 
0 
0 
., 
M 
0 
0 
0 
.. 
PLATE XXXXIV 
ppm 
r 
Jeo 160 140 120 100 eo 60 
so 0 0 
I 
2SOO 
I 
1000 
I 
~0 0 
ppm 
PFT X C\J 
9 
Size: 12 K; 
DC: Y, N ; 
r-------.-------,--------r-------~ 
R 
~~C02H 
R 
_jJL_AL_j ___ _ 
8 7 6 .. 
1H NMR Spectrum of 48c 
Solvent: DCC1 3 
PIJ/RF: 5 )JS I dB; 
Gated Off:A or D ; DO: 
SF:299.9485 ~nlz; HC: 2999.4 liz; 
TO: 0 
0 Hz; 
liz; FB: 
RF(Pm.,rer): 
- liz; 
\-1/ dB; 
40 
I 
!ULJ 
2 
T; RT 
2 
Lock: H 
NillJ: 
I• !I 
!I 
'I 
20 
°C; NT: 
;Dl,DS: 
0 liz; Lll: 
0 
o 13c 
o 1 H 
4 
s. 
liz. 
1--' 
()} 
Vl 
PLATE XXXXV 
ppm ISO 160 I ItO 120 100 eo 60 
so 0 0 
I 
2 50 0 
I 
I o o 0 
I 
50 0 
~ ~ C02H 
~ :r 
,.:· 
~\ 
:,i 
:\; 
;;t 
;~ 
1;, 
~ 
!~ 
1:1 
~ 
~i 
~~ ~ 
jf 
~ 
~~' 
~ 
' ! ,.,* t 
. ~ . . I l l ~!I ! ,j : ':: . ·, }. t ' I ' ) , I. 
. ; ~-·---------'"' ___ ,___..ttL .. tt ...... ~X-·-·-1...- .. ·----·---·-~ ... -~' ~__ ·- • 
ppm 9 a 7 6 5 It 3 
13c NMR Spectrum of 48c 
PFT XCll . Solvent: DCC1 3 ; SF: 75.429 ~nlz; tlC: 15085.Mz; . 
Size: 8 1<; PtJ/RF: 12 JJS/dB; TO: 1000 liz; FD: - liz; 
DC: Y, N i Gated Off:A or D ; DO: 0 Hz; RF(Power): 10 II/ dB; 
ItO 20 o 13c 
2 I o I H 
T• RT OCj NT: 1600 . 
2 4.0 Lock: H i Dl,DS: s • 
~ 
liz. (X) NDll: 200 liz; LD: - 0\ 
l _ ____:_ _ g 
-: 
0 
0 
<l) 
J: 
N 
0 
u 
-=-
0 
0 
CD 
0 
0 
IQ 
0 
0 
Cl) 
~0~----------~----------::----------i;--~-------,----------_l ~ 0  ~ 0 • g ~ 0 0 N " 
187 
4-l 
0 
s 
:::l 
s... 
.i-J 
u 
(!) 
0.. 
C/) 
~ 
H 
500 0 
I 
250 0 
I 
1000 
I 
500 
PLATE XXXXVII 
180 )60 140 120 100 80 60 
.. 0 20 
I i 
I . ! 
___ ____.A__Vw~L.t~-~-~-------·-----"···- .~lL,L .. J 
o 1 3c 
ppm 9 8 7 6 5 .. 3 2 I ~ IH I I I I I I 
lH NMR Spectrum of 49a 
PFT X CI.J . Solvent: DCC1 3 ; SF:29?.9284 z.m z ; HC: 2 9 9 9 • 4 liz; T· RT oc; NT: 16 . . 
Size: 16 I<; PIJ/RF: 5 •0 J.Js/dB; TO: 0 liz; FD: - liz; Lock: 2H ;Dl,D5: 0 s. 
nc: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 ll/dB; NBI.J: 0 liz; LD: - liz. 
I-' 
(X) 
(X) 
PLATE XXXXVIII 
1eo 1so 140 120 1oo eo 60 
so 0 0 
2 50 0 
1000 
50 0 
ppm 
PFT X CW 
Size: 20 
9 
; 
-
K; 
DC: Y, N ; 
a 7 6 5 . lj 3 
13c NMR Spectrum of 49a 
Solvent: DCC1 3 ; SF: 75.429 NHz; 1-JC: 15085.9Hz; 
PI.J/RF: 12 lJs/dBj TO: 1000 Hz; FB:- Hz; 
Gated Off:A or D ; DO: 0 Hz; RF (Pmver): 20 \~/dB; 
l!O 20 o 13c 
2 I ? 111 
T: RT oc; NT: 200 
Lock: 2H ; Dl,DS: 5.0 s • 
~ 
200 2.0 Hz. (XJ NB\.J: liz; LB: \,() 
190 
0 
0 
~ 
0 
0 
10 
0 
0 
CD 
0 
0 
0 
0 
0 
N 
0 
0 
~ ~ 
0\ 
-4' 
0 ~ 
0 0 
CD 
.. E! 
....J ;::l 
H 1-< 
w 0 .w 
~ 0 u CD (!) 
....J a. 
Po< [./) 
0 0<: 
0 H 
0 
N 
M 
:I: 
0 
N 
0 0 
0 0 It) 
N 
0 
0 
..., 
c-, 
0 
0 
• 
0 
0 0 0 0 0 ... 
0 CD <D ... N 
... 
PLATE L 
ppm 
r 
1 J 
lBO )60 I ~0 120 100 eo ~0 40 20 0 C 
soo 0 
I 
2 50 0 
I 
I o o o 
I 
50 0 
C02H 
l'i 
:I 
i 
I /_./" _________ ./ 
I l-- _)~ 
------~--- ------:----- jr! , 
-- I I 
------,/ )J I~ I 
------- 1 JL _ Uv UL"-
I I i I 
! I 1: I 
r 1' : 
I' I ll i ~---....._.______Jt_j~-~ -~--~~ 
ppm 9 0 7 6 .. 2 o 'u 
lH NMR Spectrum of 49b 
I'FT X CH ; Solvent: DCCl3 . SF: 299.9485 Hllz; IJC: 2999.4 liz; T: RT 
oc; llT: 8 
, 
-
Size: 16 K; P!J/RF: 5.0 ~s/dn; TO: 0 Hz; Fn: - liz; Lock: 
2H ;Dl,DS: 0 
DC : Y, !l ; GJtcd Off:A or D ; DO: 0 liz; RF(PDI.Jcr): 11/JB; llU 11: 0 liz; LU: 0 
s. 
liz. 
f-' 
1.0 
....... 
PLATE LI 
ppm 1eo 160 140. 120 100 eo so 
so 0 0 l --- ~ ~----+----~---..!! 40 20 
I 
2 50 0 
I 
I o o o 
I 
~0 0 
II l I j' I, I 
ll II 
I! 
l\111' 1\ i I I! I 
:1 I ! I ! I J l llil,!t '1 I i ll 1 L_ \ ~.···j··· 't u L'·' I ' ·li!· ·' ~t. : . i ~~ f! 
_____ • . _ LJ'L_i : n~t~~L--.r---~- _... J t __..; L-J l...., • )1_.. • j 
o 1 3c 
ppm 9 a 7 6 5 " 
2 o 1 H 
13c NMR Spectrum of 49b 
PFT XC\~ . Solvent: DCC1 3 . SF: 299.9485 H1Iz; HC: 2999.4 liz; T: RT oc; NT: 8 • ' 
2 0 Size: 12 K; PI~/RF: 5 · 0 ~s/dB; TO: 0 liz; FD: - liz; Lock: H ; Dl,DS: s • 
DC: Y, H ; Gated Off:A or D ; DO: 0 Hz; RF(PoHer): 10 ll/dl3 i tllll~: 200 liz; LD: 3.0 liz. 
I 
....... 
'.0 
N 
193 
0 
0 
"" 
0 
0 
tO 
0 
0 
= 
0 
0 
0 
0 
0 
N 
0 
0 
..,. 
.c 
"' :I: ...::1'N 
0 0 4-1 u 0 
<D 0 
H a H 
::l H 
1-< 0 
.w ..:l 0 ~ = u Q) H 0.. ~ 
r:J) 
0 ~ 0 
0 H 
N 
0 
0 
It) 
N 
0 
0 
0 
M 
0 
0 
It) 
M 
0 
0 
0 
0 0 0 0 0 ~ 0 
= <D 
..,. N 
PLATE LIII 
ppm 180 160 140 120 100 eo 
5 00 
I 
2 50 0 
000 ~~ ,o 0 
'--- ...____.. 
ppm g 8 7 6 5 . 4 
lH NMR Spectrum of 83 
PFT X CW Solvent: DCC1 3 SF:299.9485 ffilz; WC:2999.4 
Size: 12 K; Ptv/RF: 5.0 !Js/dB; TO: 0 Hz; FB:-
DC: Y, N Gated Off:A or D ; DO: 0 Hz; RF(Power): 12 
60 40 20 
L.....A.,.) 
3 2 l 
Hz; T: RT °C; NT: 
Hz; Lock: 2H ;Dl,D5: 
tJ/dB; NBW: 0 Hz; LB: 
12 
0 
o 13c 
t 
o lH 
s . 
Hz. 
I-' 
\0 
+:--
PLATE LIV 
1eo 160 140 120 100 ea 60 ItO 20 o 13c 
so 0 0 
I 
250 0 
' I o D 0 
so 0 
JL 
ppm g 
PFT X CW 
Size: 12 K; 
·-........--~-_...,. J.. 
B 
Solvent: 
Pt.J/RF: 12 
7 
DCC1 3 
lJS/dB; 
DC: Y, N ; Gated Off:A or D ; DO: 
~CF3 0 
5 
~~~~~~----~~--------~~vu~ 
6 5 .. 3 2 0 111 
13 c NMR Spectrum of 83 
SF: 75.429 MHz; WC: 15085.9Hz; T: RT °C; NT: 600 
TO: 1000 Hz; FB: - Hz; Lock: 2H iD1,D5: 4.0 
0 Hz; RF(Power): 10 tJ/dB; NBW: 200 Hz; LB: 2.0 
s. 
Hz. 
...... 
\.0 
\Jl 
PLATE LV 
lBO 160 1~0 120 100 80 60 ~0 20 0 
so 0 0 
I 
2 50 0 
I 
1000 
I 
50 0 
__ ...... ,_..,._.~----·--···--------...._----.. --.-·-···~--·· 
ppm 18 16 14 
PFT XC11 . Solvent: DCC1 3 . . t 
Size: 2 K; PIJ/RF: 7 )Js/dB; 
DC: Y, N ; Gated Off:A or D ; DO: 
6.78 
~3 
lsJSJ o 
·····------· --··--·-----) '-------------------' 
12 10 8 6 4 2 o 1 H 
19F Nt1I\ Spectrum of 83 
SF:282.203 ~nlz; HC: 5644.1 liz; T: RT oc; NT: 8 
TO: liz; FD: - liz; Lock: ;D1,DS: 2.0 
0 Hz; RF(P01.:er): 20 11/JB; t/IJ\1: liz; LD: 2.0 
IJC 
s • 1-' 
~ 
liz. "" 
~--=== 
-
==-
-=== ·- ...:...::==.,..._ 
--- ~
-'----=-
U.M Q 
C,) 
-=~~-----~--
0 
0 
"'=' 
0 
0 
<0 
0 
0 
Q) 
0 
0 
0 
0 
0 
N 
0 
0 
"!!' 
0 
0 
<Q 
0 
0 
Q) 
0 
0 
0 
N 
0 
0 
Ill 
N 
0 
~----------~--------~----------~----------.----------~g 0 
0 
-
0 
Q) 
0 
<Q 
0 
"' 
0 ... 
N 
197 
("") 
co 
4-4 
0 
s 
::l 
... 
oiJ 
u 
(1) 
0.. 
cr:: 
0::: 
H 
ppm 
r 
so 0 0 
I 
2 50 0 
I 
1000 
I 
500 
PLATE LVII 
1eo 160 1 ~o 120 100 eo 60 t.O 20 ~--------. - . I - -- - ~I 
C02CH3 
I 
I I l 
-----'l _ _j:'A ... \. ________ ·-·--. I ~ A I !: I -.....J~ JL--~ Lj__jl J 
o 13c 
ppm 9 8 7 6 5 I, 2 o I H 
lH NMR Spectrum SOa 
PFT X CH Solvent: DCC1 3 i SF: 299.9485 .NJ!z; HC: 2999.4 liz; T: RT °C; NT: 8 
Size: 16 K; PH/RF: 6 l-JS/dB; TO: 0 Hz; Fn: Hz; 2 - Lock: H i Dl,DS: 0 s . 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Pover): - II I dB; Nlllh 0 liz; Lll: liz. 
t-' 
\0 
Q:l 
ppm 
r 
so 0 0 
I 
2 50 0 
I 
1000 
I 
~ 0 0 
ppm 
PFT X CH 
Size: 8 
DC: Y, N 
PLATE LVIII 
1eo 160 140 120 100 eo Go 40 r ------- ,- - ---.----~----.-----~ 
I ~ . 
C02CH3 
9 B 7 6 5 4 2 
13c NMR Spectrum of 50a 
Solvent: DCC13 SF: 75.429 1-n!z; HC: 15085.9 Hz; T: RT 
K; PIJ/RF: 12 }Js/dB; TO: 1000 liz; FB: 
2 
Hz; Lock: H 
20 o I3c 
o 1 H 
°Cj NT: 1000 
iDl,DS: 4.0 s • 
Gated Off: A or D ; DO: 0 liz; RF(Potver): 10 ll/JB; NU\J: 200 liz; LB: 2.0 Hz. 
....... 
\0 
\0 
-
so 0 0 
I 
250 0 
I 
)000 
I 
so 0 
PLATE LIX 
Jeo l60 l40 120 100 eo 60 40 
11.9 i 
C02CH3 
' __ '"",,____ ............ -~-------------~----·------··---- .. -·.-··-x--- '~~. ~---·--........,....·· 
----
18 16 14 12 10 8 6 4 ppm 
19F NMR Spectrumof SOa 
PFTX cu . Solvent: DCC13 . SF: 282.203 Nllz; HC: 5644.1 liz; T: RT . • 
Size: 2 K; PI.J/RF: 7.0 )Js/dB; TO: Hz; FB: - liz; Lock: 
DC: Y, N : Gated Off:A or D ; DO: 0 Hz; RF(Pm.;er): 20 ll/dil; NBH: 
----- -------------
20 o 1 3c 
j 
~__) 
2 
OC; NT: 8 
;Dl,DS:2.0 
liz; LB: 
o 1 H 
2.0 
s • 
liz. 
N 
0 
0 
100-
80 
C02CH3 
60 
40 
20-
4000 3500 3000 2500 
PLATE LX 
2000 1800 1600 1400 
IR Spectrum of 50a 
1200 1000 800 600 400 
N 
0 
~ 
PLATE LXI 
ppm lBO 160 I ~o 120 100 80 60 loO 20 o 13c I - I I 
50 0 0 
I 
2500 
I 
1000 
I 
so 0 
C02H 
_ _____.· j _ L_ __ 
_A A ~u 
ppm 9 8 7 6 5 ~ 3 2 o 1 H 
lH NMR Spectrum of SOb 
PFT Xcll . Solvent: DCC1 3 . SF: 299.9485 ~nlz; HC: 2999.4 liz; T: RT oc; NT: 8 . 
' 
Size: 161<; PIJ/RF: 6 ).ls/dB; TO: 0 liz; 
2 0 FB: - Hz; Lock:' H iDl,D5: s. 
N 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): - 11/dil; Nilll: 0 - lfz, 0 liz; LB: .N 
PLATE LXII 
ppm 1eo 160 140 120 100 eo 60 
f 
so 0 0 
I 
250 0 
1000 
50 0 
C02H 
ItO 20 13 0 c 
'-<---~~-~-~~~ _J ~~--_, __ jj-1_~--
ppm 9 8 7 6 5 .. 3 2 0 lH 
13c NMR Spectrum of SOb 
PFT X CH . Solvent: DCC1 3 . SF: 75.429 ~mz; HC: 15085. 9 Hz; T: RT oc; NT: 1000 
-
~ 
' 
8 12 IJS/dB; 1000 -
2H 4.0 Size: K; PH/RF: TO: Hz: FB: Hz; Lock: iDl,D5: s. 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Pmver): 10 ll/dB; NBH: 200 Hz; LB: 2.0 Hz. 
N 
0 
L/.) 
PLATE LXIII 
ppm 
·r 
1eo IGO 1~0 120 Joo eo so 
so 0 0 
I 
2 50 0 
I 
I o o 0 
I 
so 0 
ppm 
PFT X Cll 
Size: 2 K; 
DC: Y, N ; 
---- I . - ~----.,...-----..-----,. 
C02H 
__________ __,· '···-··-----------·---
7 6 5 ~ 
l9F NMR Spectrum of 50b 
Solvent: ncc13 SF: 282.203 Nllzj llC: 5644.1 liz; T: RT 
P!J/RF: 7.0 ~s/dn; TO: liz; Fn: Hz; Lock: 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 11/dll; WJll: 
ItO 
2 
20 o 1 3c 
l 
__J 
o I H 
°C; NT: 8 
;01,05: 2.0 s. 
liz; Lll: 2.0 lfz. 
N 
0 
~ 
::> 
1-1 
:X: 
H 
>:<:! 
E-< 
<t: 
H 
P-< 
~----g ~ 
0 
0 
<0 
:I: 
8 
0 
0 
0 
= 
0 0 
cQ 
... 
0 0 
= ... 
:~j:-----------;~;-____ _l _____ ~g----------~0~------------,-----------_l g 
.., 0 0 
N "" 
205 
4-l 
0 
s 
;:l 
!-! 
.j...l 
(.) 
Q) 
0.. 
Cf) 
::.:: 
H 
so 0 0 
250 0 
10 0 0 
50 0 
PLATE LXV 
180 160 140 120 100 80 60 
O©t; 
ljO 20 o 13c 
I 
l 
, ____ _ L __ A _ _)ll---- ~-L.__ ____ _ 
ppm 9 a 7 6 5 . 4 3 2 1 0 lll 
lu NMR Spectrum of 86 
PFT X CH . Solvent: DCC13 ; SF:299.9284 HHz; Hct999. 4 Hz; T: RT oc; NT: 8 . 
Size: 8 K; Pt-J/RF: 6.0 l-Js/dB; TO: 0 Hz; FB: - Hz; Lock: 
2H 
; Dl,DS: 0.5 s • 
DC: y I N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 13 H/dB; NBW: 0 Hz; LB: - Hz, 
N 
0 
0\ 
PLATE LXVI 
ppm teo 160 1"0 120 too eo 60 
I 
so 0 0 
I 
250 0 
1000 
so 0 
ppm. 
PFT J>_ CH 
Size: 8 
9 
. 
• 
-
K; 
nc: Y, N ; 
& CF3 0 
0 
j 
_JJUJ_L ___ ~---L_Jl 
8 7 6 5 .. 3 
I 
13c NMR Spectrum of 86 
Sal vent: DCC13 . SF: 75.429 t-mz; WC: 15085.9Hz; , 
PV/RF: 12 ~s/dB; TO: 1000 Hz; FB: - Hz; 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 10 U/dB; 
40 20 o IJc 
I T I 
)L_jL__j 
2 I 0 111 
I I I I I I 
T• RT oc; NT: 500 . 
Lock: 2H ; Dl,DS: 4.0 s • 
N 
200Hz. 1.0 
0 
NBH: LB: Hz. -..J 
' 
so 0 0 
I 
2 50 0 
I 
)000 
I 
~0 0 
PLATE LXVII 
Jeo 160 140 120 100 eo so 
6.97 
' l 
OlfCF3 0 
0 
·--------~----- ,_ ___ ., __________ _. _______ _ 
ppm 9 7 6 5 " 
19F NMR Spectrum of 86 
PFT X CH . Solvent: DCC13 . SF: 282.203 NJ!z; llC: 2822.0 Hz; . t 
Size: l. 6K; PtJ/RF: 5.0 )Js/dB; TO: 0 liz; FD: liz; 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 IJ/ dB; 
40 
2 
T: RT 
2 
Lock: H 
NBI-1: 
20 
oc; NT: 
i 
f 
___ _..,.._; 
l 
iDl,DS: 2.0 
llz; LB: 2.0 
o 13c 
o I H 
s 0 
N 
0 
liz. ():) 
100-
80 
60 
4000 3500 3000 2500 
PLATE LXVII I 
OifCF3 0 
0 
2000 1800 1600 1400 
IR Spectrum of 86 
1200 1000 800 600 400 
N 
0 
1.0 
so 0 0 
I 
2 50 0 
I 
1000 
I 
50 0 
PLATE LXIX 
160 160 I ~0 120 100 80 60 i,O 20 0 13c 
C02CH3 
.-__..JLJ"-L-----~__l___L 
I I ~LJ t.L__j ' 
-------
ppm 9 8 7 6 5 ~ 2 o I H 
lH NMR Spectrum of 50e 
PFT X Cll . Solvent: DCC1 3 ; . SF:299.9485 Nllz; HC: 2999.4 Hz; T: RT oc; NT: 4 
Size: 8 K; PIJ/RF: S.O ~s/dB; TO: 0 Hz; FB: - liz; Lock: 2H ; Dl,D5: 0 s • 
DC: Y, N : Gated Off:A or D ; DO: 0 Hz; RF(Pm .. er): 20 H/dB; ND\1: 0 liz; LB: liz. 
N 
....... 
0 
ppm 
I 
so o o 
I 
2 50 0 
I 
1000 
I 
~0 0 
PLATE LXX 
leo l6o 1 ~o 120 100 eo 60 
-r --- -----,-----,.-----.-----~ 
l 
,, 
~ 
I 
~ ~ ,,
~! 
.i.l 
C02CH3 
40 20 o 13c 
. I Ill 
___,__l _,) - uv .. ~~" il ~ _.JLJL ... . I 
ppm 9 8 7 6 5 It 2 
13c NMR Spectrum of 50e 
PFT X. CH _ ; Solvent: DCC1 3 SF:75.429 N1lz; HC: 15085. 9llz i T: RT 
Size: 20 . K; P!l/RF: 12 Jjs/dB; TO: 1000 liz; FD: 2 liz; Lock: H 
DC: Y, N Gated Off:A or D ; DO: 0 liz; RF(Pot.,er); 20 11/dB; Nil!J:200 
o I H 
°Cj NT: 6064 
; Dl,DS: 4.0 s. 
liz; LB: 2.0 liz. 
N 
1-' 
...... 
PLATE LXXI 
ppm lao 160 1 ~o 120 1oo eo 6o 
so 0 0 
I 
2 50 0 
I 
1 0 0 0 
I 
50 0 
ppm 
PFT X CH 
18 16 14 
. Solvent: DCC1 3 . 
11.70 
I t. 
" ; ; 
-·-· ,____,. ;,.._ 
12 
C02CH3 
10 8 6 
19F NMR Spectrum of 50e 
. SF: 282.203 ~niz; HC: 5644.1 liz; 
' 
Size: 2 · 5 K; PIJ/RF: 7 · 0 JJs/dB; TO: liz; FD: - liz; 
DC: Y, N i Gated Off:A or D j DO: 0 Hz; RF(Pm.;er): 11 I d n; 
~0 20 o 13c 
4 2 
o I H 
T: RT oc; NT: 8 
Lock: iDl,DS: 2.0 s. 
N 
I-' 
N ill/: liz; LD: 2.0 liz. N 
• 
100-
80-
60-
40-
20-
4000 3500 3000 2500 
PLATE LXXII 
C02CH3 
2000 1800 1600 1400 
IR Spectrum of SOe 
1200 
I 
1000 800 600 400 
N 
....... 
w 
so 0 0 
I 
2 50 0 
I 
1000 
I 
so 0 
ppm 
PFT X CH 
Size: 12 
DC: Y, N ; 
PLATE LXXIII 
Jeo 160 1 t.o 120 100 eo Go "0 20 o 13c 
C02H 
__ _Llk_t __ 
__L ----'L---..J'----
8 7 6 5 .. 2 o I H 
lH NMR Spectrum of 50£ 
: Solvent: DCC1 3 . SF: 299.9485 ~fllz; HC:2999.4 Hz; T: RT 
' 
°C; NT: 16 
PH/RF: JJs/dB; 0 
2 
K; 5.0 TO: liz; Fn: - liz; Lock: H ;Dl,DS: 0 s • 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 ll/dB; NDI~: 0 liz; LB: Ilz. 
w 
...... 
~ 
so 0 0 
I 
2 50 0 
I 
1000 
I 
~0 0 
PLATE LXXIV 
. 13 1eo JGo 140 120 1oo eo so ~oo 20 o C 
C02H 
!J! 
:·1 
· I i I j! I' 
' i I I :I 
l I i 
I , II 
II ': 
I i I 
I i. I I l',LL 1, . _______..~Jv11 . ~~~ ~ 
ppm 9 e 7 6 5 " 
2 o I H 
13c NMR Spectrum of SOf 
PFT X CH . Solvent: DCC1 3 . SF: 75.429 Hllz; HC: 15085.911z; T• RT oc; NT: 6064 . I . 
Size: 20 K; PH/RF: 12.0 JJS/dB; TO: 1000 liz; FD: - liz; Lock: 2H ;Dl,DS: 9.0 s • 
DC: Y, N ; Gated Off:A or D ; DO: 0 liz; RF(Pot.,rer): 10 11/dll; Nnl~: 200 liz; LD: 2.0 liz. 
N 
~ 
l.T1 
500 0 
I 
2 50 0 
I 
1000 
I 
~0 0 
PLATE LXXV 
160 160 I ~0 120 100 BO SO ~0 20 o 13c 
11.68 CF3 
C02H 
--·~-·-·------------·····--·-·-) \··---·---~------·------~---------·-__) 
18 16 14 12 10 8 6 4 2 ? I H ppm 
19F NMR Spectrum of 50f 
PFT X CH . Solvent: DCCl . SF: 282.203 ~!liz; HC: 5644.o liz; T· RT oc; NT: 8 . 3 . . 
Size: 2560K; PH/RF: 7.0 ~s/dB; TO: liz; FD: - Hz; Lock: ;Dl,DS: 2.0 s . 
DC: Y, N ; Gated Off;A or D ; DO: 0 Hz; RF(Pot.Jer): 11/dD; NDI~: liz; LD: 2.0 liz. 
N 
1-' 
0\ 
100-
CF3 
80 
C02H 
60 
40~ 
20~ 
4000 3500 3000 2500 
PLATE LXXVI 
2000 1800 1600 1400 
IR Spectrum of SOf 
1200 1000 800 600 400 N 
1-' 
-..j 
so 0 0 
I 
250 0 
I 
I o o 0 
I 
50 0 
PLATE LXXVII 
1eo JGO 1~0 120 1oo eo 6o ItO. 
0 
' 
J, ~ ~ --------~·IL_j L-/ L~ --.--~-----··--·-····- ··---·--· 
ppm 9 8 7 6 5 ~ 2 
lH NMR Spectrum of 85 
PFT X Ch' Solvent: DCC1 3 SF:299.9485 ~nlz; HC: 2999.4 liz; T: RT 
0 
2 
liz; Lock: H liz; FD: Size: 8 K; PlJ/RF: 5.0 ).ls/dB; TO: 
DC: Y, N Gated Off:A or D ; DO: 0 Hz; RF(PoHer): 20 IJ/dB; NB\.J: 0 
20 
~ i 
°Cj NT: 8 
i Dl,DS: 0 
liz; LB: 
o 13c 
o I H 
s • 
liz. 
N 
f-' 
co 
PLATE LXXVII I 
rrm leo 160 140 120 Joo eo 60 ~0 20 0 IJC 
r 1~--- I - - --~1 1 
so 0 0 
I 
.. 
2 50 0 
I 
1000 
I 0 
~0 0 
-----~L_ ___ _ ~ ~-'l ~~ - ~J J~ ~_l_ _______ ~________).J~'---------1~- ~--__l 
ppm 9 a 7 6 s ~ 2 o I H 
13c NMR Spectrum of 85 
PFT ~ CW . Solvent: DCC1 3 ; SF: 75.429 -~ 1-ffiz; 'WC:l5085.9 Hz; T: 
RT oc; NT: 300 
Pl.J/RF: 8.0 
2 
; Dl,D5: 4.0 Size: 20 K; lJS/dB; TO: 1000 Hz; FB: - Hz; Lock: · H s. N 1--' 
\0 
20 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): H/dB; NBW: 200 Hz; LB: 2. 0 Hz. 
ppm 
I 
so 0 0 
I 
2 50 0 
I 
1000 
I 
~0 0 
PLATE LXXIX 
lBO 160 I ~0 12'0 100 80 60 
.;..:_ __ .- ~-- -. 6. 7 6 
0 
j: 
'i 
I; 
'\ 
~0 
_______ ;\__ __ . -·-·-·-· 
ppm 1.8 
PFT K Cl-l 
Size• 2.5K· 
. ' 
DC: Y, N ; 
.16 
Solvent: 
PtJ/RF: 7.0 
14 
DCC1 3 ; 
~s I dB; 
Gated Off:A or D ; DO: 
12 10 8 f> 4 
19F NMR Spectrum of 85 
SF: 282.203 I·niz; l·lC: 5644.1 liz; T: RT 
TO: Hz; FD: - liz; Lock: 
0 Hz; RF(Pol.'er): ll/dB; Nl.ll-1: 
20 
2 
oc; NT: 
;Dl,DS: 
liz; LB: 
o 13c 
__.1 
o I H 
8.0 
2.0 s. 
2.0 Hz. 
N 
N 
0 
221 
'<:!' ~----g
0 4-1 
0 0 co 
~ s ;::l 
...:I ~ 
!:il 
H 
< 
...:I 
0 -I.J 
0 l) 
Cl) 
... ClJ 
0. 
Po< 0 en 
p;::: 
1--i 
0 
0 
' 
0 
0 0 0 0 0 .. 
0 a:! <D ., N 
-
PLATE LXXXI 
ppm lBO 160 140 120 100 eo 60 
so 0 0 
I 
2 50 0 
I 
)000 
I 
50 0 
C02CH3 
40 20 o 1 3c 
I 
! I -
i I 
-
1 
I : 
~ ! : 
______ L_yt 
---------~---- ~-·-~-·----~. 
I • ~ -
___ J _fL-JlJU ___ __j 
ppm 9 B 7 6 5 4 2 o 1 H 
lH NMR Spectrum of SOc 
PFT X CH . Solvent: DCC13 . SF:299. 9485 ~mz; HC: 2999.4 liz; T: RT . , °Cj NT: 8 
Size: 12 K; PH/RF: 5.0 l-JS/dB; TO: 0 liz; FB: - liz; Lock: 2H ; Dl,D5: 0 s • 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Pot.Jer): 20 lJ/dB; NI31h 0 liz; LB: liz. 
N 
N 
N 
PLATE LXXXII 
180 160 140 120 100 80 60 40 20 0 
50 0 0 
2 50 0 
1000 
so 0 
~~--L~-~JJJ 
ppm 9 8 7 
PFT X CW : Solvent: DCC13 ; 
srze: 20 K; Ph'/RF: 12 ~s/dB; 
DC: Y, N ; Gated Off:A or D ; DO: 
C02CH3 
_,)'""Y-~~··----,.,.~---------...-...-""'-..... '-."'-.._~ ...... -.....~. -~,"~--Ll ·~~~ ........ '1.\1-'" 
6 5 . 4 2 0 111 
13c NMR Spectrum of SOc 
SF: 75.429 t-mz; Hc:15085.9uz; T: RT oc; NT: 6064 
2 9.0 TO: 1000 Hz; FB: - Hz; Lock: H ; Dl,D5: 
0 10 200 liz. 2.0 Hz; RF(Power): tl/dB; NBH: LB: , 
13c 
s • 
N 
N Hz, (....) 
PLATE LXXXIII 
lBO 160 140 120 100 80 60 .. 0 20 
suo o 
I 
250 0 
I 
IOOO 
I 
~0 0 
11.91 
C02CH3 
_____ J______ ---
18 16 14 12 10 8 6 ppm 
19F NMR Spectrum of SOc 
PFT X C\-1 . Solvent: DCC13 . SF: 282.203 l-nlz; HC: 5644.1 liz; T• . 
' 
. 
Size: 2. 5 K; Pl·.T/RF: 7.0 l-Js/dB; TO: liz; Fn: - liz; Lock: 
nc: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF (Pot.,rer): ll/dB; Nlll~: 
4 2 
RT oc; NT: 
iDl,DS: 
liz; LB: 
' 
o 13c 
J 
? IH 
12 
2.0 s • N 
N 
2.0 liz, .p.. 
100-
80-
20-
-4000 3500 3000 2500 
PLATE LXXXIV 
C02CH3 
2000 1800 1600 1400 
IR Spectrum of SOc 
1200 1000 800 600 400 
N 
N 
ln 
so 0 0 
I 
2 50 0 
I 
1000 
I 
so 0 
PLATE LXXXV 
1eo 160 140 120 100 eo 60 
C02H 
. .I ·--Lll--.--~------·--·-· 
ppm 9 8 7 6 5 4 3 
lu NMR Spectrum of SOd 
PFT X CIJ . Solvent: DCC13 . SF: 299.9485 ~nlz; HC: 2999.4 liz; . I 
Size: 16 K; PIJ/RF: 6.0 ~s/dB; TO: 0 liz; FD: - liz; 
0 DC: Y, N ; Gated Off:A or D ; DO: Hz; RF (Pot.,er) : - ll/dB; 
40 20 o 13c 
I I 
I 
Ll 1 l 
. Jut _ J 
2 o I H 
T: RT oc; NT: 8 
Lock: 2H iDl,DS: 0 5 • 
N 
N 
NDIJ: 0 liz; LD: - liz. 0\ 
PLATE LXXXVI 
ppm leo 160 1~0 120 100 eo 60 ~0 20 r 
so 0 0 
I 
250 0 
' 1000 
so 0 
ppm . 
PFT X CW 
Size: 20 
DC: Y, N ; 
9 
I 
. 
. 
K; 
e 7 
I I 
Solvent: DCC1 3 . , 
PH/RF: 12 l-JS/dB; 
Gated Off:A or D ; DO: 
C02H 
~~~ ........ L·~"" 
6 5 ~ 3 2 I 
13c NMR Spectrum of SOd 
SF: 75.429 .t-mz; we: 15085. 9Hz; T· RT OC; NT: 6064 . 
2 9.0 TO: 1000 Hz; FB: - Hz; Lock: H ; Dl,D5: 
0 RF(Power): 20 200 2.0 Hz; lJ/ dB; NBlJ: liz; LB: 
o 13c 
0 111 
s • 
N 
N Hz. ----.) 
PLATE LXXXVII 
lBO 160 I ~0 120 100 80 60 
so 0 0 
I 
2 50 0 
I 
1000 
I 
~0 0 
---------· 
18 16 
ppm 
I f I I I I 
PFT X CH 0 Solvent: _, 
Size: 2.5 K; PIJ/RF: 7.0 
11.89 
C02H 
~· ........ -·- ..... -----·/ \ .. ~·-~-·---
__ .... __ 
14 12 10 8 6 
I I 
19F NMR Spectrum of SOd 
DCC1 3 0 SF:282.203 NHz; HC: 5644ol liz; . 
IJs/dB; TO: Hz; FB: - Hz; 
nc: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF (Pm..re r) : 11/dB; 
40 20 o 13c 
- ___ ) 
-~--' 
4 2 ~ 1 H 
To RT oc; NT: 8 0 
Lock: i Dl,D5: 2.0 s • 
N 
N 
NIJIJ: liz; LB: 2.0 liz. 
(P 
100-
80 
60 C02H 
40 
20-
4000 3500 3000 2500 
PLATE LXXXVIII 
2000 1800 1600 1400 
IR Spectrum of SOd 
1200 1000 800 600 400 
N 
N 
\0 
PLATE LXXXIX 
rrm . lJC 100 160 l~O 120 100 BO 60 ~0 20 0 
I 
so 0 0 
I 
2 50 0 
I 
I o o 0 
I 
~0 0 
ppm 
PFT XCH 
9 
. 
~ 
Size· 32 K· . , 
a 7 
Solvent• DCCl • 3 
PIll R F: 5 · 0 ~ s I d n; 
DC: Y, H ; Gated Off:A or D ; DO: 
~~ 
6 s .. 
1H NMR Spectrum of 48f 
SF: 299.9485 tnlz; HC: 2999.4 
TO: 0 liz; FD: -
I 
C02H 
~ li 
__, l 
liz; 
liz; 
1 I I 
I r- 1\ I 
\..JU JlL.__!'"' .. • J 
2 
T: RT 
2 
Lock: H 
o 'u 
oC; liT: 8 
iDl,D5: 0 
0 liz; HF(PolJcr): - 11/dU; liU\1: 0 liz; LD: 
1 
s • 
liz. 
N 
VJ 
0 
50 0 0 
I 
250 0 
1000 
50 0 
ppm 
PFT X CW 
Size: 20 
DC: Y, N ; 
PLATE LXXXX 
lBO 160 140 120 100 80 60 
9 a 
. Solvent: . 
K; PI-1/RF: 14 
l 
I I 
I 
I 
l 
'L..i 
7 6 
' 
5 It 
~~ 
I 
C02H 
3 
13c NMR Spectrum of 48f 
DCC13 . SF: 75.429 ~filz; WC: 15085.9Hz; T• , . 
~s/dB; TO: 1000 Hz; FB: - Hz; Lock: 
1!0 
2 
RT 
2H 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 H/dB; NBW: 200 
20 o 13c 
I ? 111 
oc; NT: 5600 
;Dl,D5: 4.0 s • 
N 
Hz. w Hz; LB: - ...... 
100-
80-
-4000 3500 3000 2500 
PLATE LXXXXI 
~"' I 
C02H 
2000 1800 1600 1400 1200 
IR Spectrum of 48f 
1000 800 600 400 N 
UJ 
N 
rrrn 
r 
so 0 0 
I 
2 50 0 
I 
)000 
I 
~0 0 
100 )60 
I 
PLATE LXXXXII 
I ~0 120 100 80 GO 
I 1 
\+ 
Br- 5\ 
I C02Et 
I 
I 
•· I 
~o 20 o 13c 
--~-~ I 
• !, . 1 1-----~--------' LJL. ___ .~, I I 
ppm' 9 
0 7 6 5 .. ) 2 I o I H 
r I 
lH NMR Spectrum of 72 
PFT X Cll . Solvent: DCC13 . SF: 29?. 9485 ~mz; HC: 2999.4 liz; T: RT oc; liT: 8 
- J 
, 
Size;l6 K; PIJ/RF: 6. o ~s/dn; TO: 0 liz; Fll: - liz; 
2 Lock: H iDl,D5: 0 s . 
DC: Y, ll ; Gated Off:A or D ; DO: 0 liz; RF (Pol.Jcr): - I/ I J B j lll.Jl/: 0 liz; LU: 0 liz. 
N 
w 
w 
PLATE LXXXXIII 
ppm Ieo 160 litO 120 100 80 60 ItO 
I 
50 0 D 
I 
25 0 0 
' 
10 0 0 
50 0 
ppm 
PFT X CW 
Size: 8 
DC: Y, N ; 
g 8 7 
: Solvent: DCC1 3 
. , 
K; Pt.J/RF: 12 lJS/dB; 
Gated Off:A or D ; DO: 
- \s+ 
Br \ 
I C02Et 
6 5 It 3 2 
13c NMR Spectrum of 72 
SF: 75.429 MHz; WC: 15085.9 Hz; T• . RT 
1000 2 TO: Hz; FB: - Hz; , Lock: H 
0 Hz; RF(Power):20 \J/dB; NBW: 200 
20 o 13c 
1 0 111 
oc; NT: 100 
; Dl,D5: 4.0 s. 
4.0 Hz. N Hz; LB: w +--
PLATE LXXXXIV 
ppm 1ao J6o 1'+0 120 1oo 80 60 
'+0 
I 
500 0 
I 
250 0 
I 
10 0 0 
50 0 
ppm. 
PFT X CW 
Size: 12 
DC: Y, N ; 
9 
I 
. 
. 
K; 
8 7 
I I . I . 
Solvent: DCC13 . 
' 
PV/RF: 8.0 IJS/dB; 
Gated Off:A or D ; DO: 
I 
\ 
s \ 
I C02Et 
_tJ~ 
6 5 
" 
3 2 
. I 
lH NHR Spectrum of 73 
SF: 299.9485MHz; wc:2999.4 Hz; T• . RT 
TO: 0 Hz; FB: - Hz; Lock: 2H 
0 RF(Power): - lJ/dB; 0 Hz; NBW: 
20 . o I3c 
I I 
) 
1 o Ill 
. I . I 
oc; NT: 8 
;Dl,D5: 0 s • 
-
Hz, N Hz; LB: VJ 
U1 
PLATE LXXXXV 
180 160 I ~0 120 100 80 60 
500 0 
I 
250 0 
1 0 0 0 
so 0 
ppm I 
PFT Xcw 
9 
I 
. 
. 
Size: 12 K; 
DC: Y, N ; 
8 7 
I I I I I 
Solvent: DCC13 . , 
Plv/RF: 5 · 0 j.Js/dB; 
Gated Off:A or D ; DO: 
A,,,, HO~ 'co2e:t 
6 5 ~ 
lH NMR Spectrrum of 
3 
74 
SF: 299.9485 MHz; WC: 2999.4 Hz; 
TO: 0 Hz; FB: - Hz; 
0 Hz; RF(Power): 15 \J/ dB; 
40 20 o 13c 
2 1 0 111 
T• RT oc; NT: 12 . 
Lock: 2H ;Dl,DS: 0 s . 
N 
NBW:· 0 0.5 Hz. 
l;..l 
Hz; LB: 0\ 
5 
2 
ppm lBO 160 
00 
I 
50 0 
' 
000 
iO 0 
ppm 9 a 
'---------•--- l ___ L __ I-- I 
PFT X CW Solvent: DCC1 3 
Size: 20 K; PI.J/RF: 12 
1~0 
7 
I I 
lJS/dB; 
DC: Y, N Gated Off:A or D ; DO: 
PLATE LXXXXVI 
120 100 80 60 lfO 20 
p,, 
HO '''co2et 
J 
-
6 5 It 3 2 ] 
__ j 
-- ---•-- -_I_ I I I I I I I 
13c NMR Spectrum of 74 
SF: 75.429 MHz; WC: 15085.9Hz; T: RT °C; NT: 
TO: 0 Hz; FB: - Hz; Lock: 2H ;Dl,D5: 
0 Hz; RF(Power): 20 W/dB; NBW: 200 Hz; LB: 
o 13c 
o 111 
I I 
1000 
0 s. 
1.0 Hz. 
N 
w 
-....J 
100-
80 
60 
40 
20-
4000 3500 3000 
PLATE LXXXXVII 
/\,, HO~ '''co2et 
2500 2000 1800 1600 1400 
IR Spectrum of 74 
1200 1000 800 600 400 N 
(..,.) 
CXl 
PLATE LXXXXVIII 
ppm 180 )60 11!0 120 100 eo 60 a.o 20 o 13c 
00 
I 
00 
0 
000 
)00 
OHC? "''co," 
r 
ppm 9 B 1 6 5 .. 3 2 1 o 111 I • I I I I I 
1H NMR Spectrum of 67 
PFT X CW . Solvent: DCC1 3 . SF: 299.9485 MHz; wc:2999.4 Hz; T• RT oc; NT: 12 . , . 
Size: 12 K; PI.J/RF: 5.0 ~s/dB; TO: 0 Hz; FB: - Hz; Lock: 2H ;Dl,D5: 0 s • 
N 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Power): l5 ll/dB; NBW: O Hz; LB: 0.5 Hz. l.V \.0 
500 0 
I 
250 0 
1000 
50 0 
ppm. 
PFT X CW 
Size: 16 
DC: Y, N ; 
PLATE IC 
1eo J6o lifO 120 1oo eo 60 110 
I 
OHC?'"•· co," 
1 ~ Ln._ __ J 
9 e 7 6 5 . If 3 2 
I I I I I . 
13c NMR Spectrum of 67 
. Solvent: DCC13 ; SF: 75.429 MHz; WC: 15085.9 Hz; T• RT . . 
Pt-1/RF: 12 IJS/dB; 1000 Lock: 
2 
K; TO: Hz; FB: - Hz; H 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 lJ/dB; NBW: 200 
20 o 13c 
I I 
11.....-JL-J 
1 o 111 
. I 
oc; NT: 600 
;Dl,D5: 4.0 s • 
N 
Hz; LB: 1.5 Hz. ~ 0 
u 
l'il 
~ 
....4 p.... 
~----~ 
0 
0 
(D 
0 
0 
10 
.. 
0 
0 
10 
... 
iii 
.. 
0 
u 
<l 
u 
I 
0 
~2;:------------~j:------------~gl"----------~o~------------""______ ______ j_ g 
't 0 0 N ... 
241 
" \0 
4-< 
0 
s 
!:j 
1-< 
.w 
u 
(]) 
0.. 
C/) 
~ 
f-1 
PLATE CI 
ppm IBO 160 lifO 120 100 so so 
I -
500 0 
I 
2500 
1000 
50 0 
ppm I 
PFT X CW 
Size: 16 
9 
I 
: 
K; 
nc: Y, N ; 
9 7 
I I I I I 
Solvent: DCC1 3 . t 
Pl.J/RF: 5.0 lJS/dB; 
Gated Off:A or D ; DO: 
6 5 . It 
,, 
,,, 
lH NMR Spectrum of 48e 
SF: 299.9485 MHz; we: 2999.4 
TO: 0 Hz; FB:-
0 Hz; RF(Power): -
C02H 
3 
Hz; 
Hz; 
lUdB; 
ItO 20 o 13c 
2 I o 111 
T: RT oc; NT: 32 
Lock: 2H ; Dl,D5: 0 s • 
0 Hz, N NBW: Hz; LB: - .p-
N 
PLATE CII 
ppm 1eo 160 1 lfO 120 100 eo 60 r -
500 0 
I 
250 0 
0 
I 0 0 0 
so 0 
ppm I 
PFT X CW 
Size:16 
DC: Y, N ; 
9 
I 
. 
. 
K; 
.,, 
,,, co2H 
8 7 6 5 . .. 3 
I I I I I 
13c NMR Spectrum of 48e 
Solvent: DCC1 3 . SF: 75.429 MHz; WC: 15085. '1Iz; • 
Pt-1/RF: 12 ~s/dB; TO: 0 Hz; FB: - Hz; 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 U/dB; 
ljQ 20 o 13c 
2 I 0 111 
T• RT oc; NT: 1000 . 
Lock: 2H ;Dl,D5: 4.0 s. 
200 Hz; 2.0 Hz, 
N 
NBW: LB: .p.. (.;.) 
1-1 
1-1 
1-1 
u 
~ 
E--< 
~ 
....:! p... 
r--------------------------------------------------P~ 
:I:"' 
0 
u 
,, 
,,' 
0 
0 
10 
0 
0 
CD 
~--------~--------~--------r-----_j~~-------Lg g 0 0 0 ~ 
... Cl) (Q 'It 
244 
Q) 
00 
..::1' 
4-l 
0 
8 
;::J 
~ 
.j...l 
u 
Q) 
0. 
r:/j 
0::: 
H 
.,. 
PLATE CIV 
ppm lBO 160 140 120 100 80 60 
r 
so 0 0 
I 
2 50 0 
I 
)000 
I 
~0 0 
ppm 
PFT XC\~ 
9 
: 
Size: 8 K; 
DC: Y, N : 
8 7 
lH 
Solvent: DCC1 3 . SF: , 
PH/RF: 5.0 )Js/dB; TO: 
Gated Off:A or D ; DO: 
~ o-"./CO,Et 
6 5 
" 
3 
NMR Spectrum of 90 
299.9485 ~mz; HC: 2999.4 Hz; 
0 liz; FB: - liz; 
0 Hz; RF(Pot.;er): 20 H/dB; 
~0 20 o 13c 
2 
T: RT oc; NT: 8 
Lock: 2H ; Dl,DS: 0 s • 
N 
.p-. 
NBH: 0 - Hz. liz; LB: 
Vl 
PLATE CV 
ppm 
I 
. JJC 1ao l60 140 120 Joo eo 60 ~o 20 o 
So o o 
I 
2 50 0 
I 
1000 
I 
50 0 
-- --· -- ------ --J ---- L -
ppm 9 8 7 
PFT X CH . Solvent: DCC13 ; . 
Size: 20 K; PV/RF: 8.0 J.ls/dB; 
DC: Y, N ; Gated Off:A or D ; DO: 
.J 
~O~C<J,EI 
) .., ) 
6 5 ~ 2 o 1 H 
13C NMR Spectrum of 90 
SF: 75.429 ~mz; HC: 15085. 9Hz; T: RT oc; NT: 300 
1000 
2 
; Dl,DS: 4.0 TO: liz; Fll: - Hz; Lock: H s • 
0 Hz; RF(Potver): 20 H/dB; Nll\.f: 200 Hz; Lll: 2.0 Hz, 
N 
.p-. 
0\ 
247 
0 
0 l; 
,.-----------
2: 
~ =- 0 0 «l 
'-,. 
i :: 
0 
0 
0 
N 
0 
iiJ ~ 
0 0 ..,. 
cf 0"1 
u ( ~ 4-l 0 0 0 H cQ 
> s u 0 ::I 
~ @ ... ~ 0 0 +J ,..:J «l u P-< (J) 
0.. 
0 en 
0 
0 0<:: 
N H 
0 
0 
Ill 
N 
0 
0 
0 
~ 
0 
0 
., 
~ 
0 
0 
0 
0 0 0 0 0 • 
0 = 
cQ • N 
PLATE CVII 
ppm lBO 160 140 120 100 eo 
5 00 
I 
2 50 0 
000 ©La~OH ;o o 
J j 
4 7 6 5 9 a 
I I I ppm I l _j_ 
lH NMR Spectrum of 91 
PFT X CW DCC1 3 SF: 299.9485 2999.4 : Solvent: ; MHz; WC: 
12 PH/RF: 12 lJS/dB; 0 Hz; FB: -Size: K; TO: 
DC: Y, N; Gated Off:A or D ; DO: 0 Hz; RF(Power): 
60 lfO 
1 
-
3 2 
I I 
Hz; T: RT 
Hz; Lock: 
2H 
\J I dB; NBW: 
20 
1 
r 
OC; NT: 8 
; Dl,D5: 
0 
Hz; LB: 
0 
o 13c 
o lH 
I 
s . 
Hz. 
N 
~ 
(X) 
PLATE CVIII 
ppm lBO 160 140 12 0 100 80 60 .. 0 20 o 13c 
00 
r 
2 50 0 
I 00 0 ©la~OH so 0 
1 
--
ppm 9 B 7 6 5 4 3 2 
1 0 111 
I I I I I I I I I I 
13c NMR Spectrum of 91 
PFT X C\-1 . Solvent: DCC1 3 . SF: 75.429 ~mz; we: 15085.9Hz; T: RT oc; NT: 600 . 
' 
Size: 20 12 1000 
2 4.0 K; PH/RF: )Js/dB; TO: Hz~ FB: - Hz; Lock: H ; Dl,DS: s • N 
~ 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF (Power) : 20 H/dB; NBW: 200 Hz; LB: 2.0 Hz. 
\.0 
::< 
H 
u 
I'L4 
~ 
,...:l p.., 
~ 
..:r 
~ 
~ 
~ 
~ 
~~=--~ 
I 
~ 
0 
© 
0 
0 
a) 
c 
0 
0 
N 
0 
0 
a) 
0 
0 
0 
N 
0 
0 ------------~)___________"ior-----------~~~----------"1~:---------- ~ 
0 <Q ~ 
0 
0 
250 
~ 
0'1 
4-l 
0 
E 
;:::! 
l-; 
-1-l 
t) 
aJ 
a. 
Cfl 
~ 
H 
PLATE CX 
ppm Jeo 160 1 ~o 120 100 eo 60 ~0 20 0 
I 
so 0 0 
I 
I ~----~------,~-----,------r-----r ,------.------' 
2 50 0 
I 
1000 
I 
~0 0 00 
I ___ • W)l 1--------
ppm 9 0 7 6 s ~ 2 
lH NMR Spectrum of 84 
PFT X CH _ : Solvent: DCC13 SF: 29?.9485 Hllz; l1C: 2999.4 liz; T: RT 
Size: 12 K; PH/RF: 12 ~s/dB; TO: 0 liz; FD: -
0Hz; RF(Pot.,rcr): -
2 
liz; Lock: H 
DC: Y, H; Gated Off:A or D i DO: 11/Jll; lllliJ: 
IJl~ 
o I H 
°Cj ur: 8 
;Dl,DS: 0 
0 liz; LD: 
JJC 
s. 
liz. 
N 
\.J1 
..... 
PLATE CXI 
ppm 
I 
160 JGO 140 120 100 eo 60 ~0 20 o IJC 
so 0 0 
I 
2500 
I 
IOOO 
I 
so 0 
ppm. 
PFT X Cl~ 
9 
. 
~ 
Size: 16 K; 
DC: Y, N ; 
00 
L L)~__ll__________J _ __jl_____ji_J~ 
8 7 6 5 .. 3 2 
I I I 
l3c NMR Spectrum of 84 
Solvent: DCC1 3 . SF: 75.429 z.mz; we: 15085. 9Hz; T· RT 
' 
. 
Pl-1/RF: 12 IJS/dB; 1000 Hz; FB: 
- Hz; Lock: 2 TO: H 
Gated Off:A or D ; DO: 0 Hz; RF(Power): 20 H/dB; NBW: 200 
_j 
o J H I 
I I I I 
oc; NT: 600 
;Dl,D5: 4.0 s . 
Hz; LB: Hz. 1.5 
N 
Vt 
N 
0 
0 
0 0 
10 
0 
oq' 
0 
N 
253 
4-1 
0 
PLATE CXIII 
ppm 13 lBO ]60 l ~0 120 100 eo 60 loO 20 0 C 
I 
so 0 0 
I 
2500 
I 
1000 
I 
~0 0 
C02 Me 
~P\OMel2 
II 
0 
11 
II 
II 
I I! 
I I 
. 'i i ;; 
~ '· I 
. I ;: t j ! j l !! 1,. I :LJI ,[ '!l ~" i 
------"' ....__ __ ______..__~JU~ ..... -~.-'.•I _______________________ ~~L.___ _ __, 
ppm 9 8 7 6 s 1o 3 2 1 o I H 
I I I 
lH NMR Spectrum of 76 
PFT X Cl/ _; Solvent: DCC13 ; SF: 2_99.94851-nlz; HC: 2999.4 liz; T: RT °Ci llT: 8 
I 
Size: 16 'K.; PIJ/RF: 6.0 )Js/dD; TO: 0 liz; FD: - liz; Lock: 2H i Dl,D5: 0 s • 
N 
DC: Y, H j Gated Off:A or D ; DO: 0 Hz; RF(Pm..rcr): - ll/JU; lll.ll/: 0 liz; Lil: - liz, ~ 
PLATE CXIV 
ppm ISO ]60 I 4 0 120 100 eo 60 40 20 o 1 3c 
0 0 
I 
2 50 0 
C02 Me 
~PIOMel2 
I 
DOO 
I 
00 
II 
0 
I 
. 
ppm 9 8 7 6 
13c NMR Spectrum of 76 
PFT X Ch' . Solvent: DCC1 3 j SF: 75.429 l·nl z; HC :J.5085. 9 Hz; T: RT oc; NT: 300 . 
20 K; 8 • 0 ~s/dB; 1000 2 4.0 Size: Pl~/RF: TO: liz; FD: - liz; Lock: H i Dl,DS: s. 
N 
DC: Y, N ; Gated Off:A or D ; DO: 0 Hz; RF(Pot.;er): 20 ll/ dB; Nlll': 200 liz; Lil: 2.0 
V1 
llz. V1 
PLATE CXV 
100 160 140 120 100 BO 60 40 20 0 lJC 
I 
so 0 0 
I 
2 50 0 
I 
1000 
I 
~·0 0 
ppm. 
25.4 
27 24 
I__ __ -~• --- I -
21 
I I 
PFT X CH . 
·' 
Solvent:: DCC13 
Size: 12 K; PlJ/RF: 14 ~s/dB; 
I 
DC: Y, H ; Gated Off:A or D ; DO: 
C02 Me 
~PIC Mel, 
18 
II 
0 
15 
I - _ _j _ __l 
12 
3lp NMR Spectrum of 76 
---------------
9 
I I 
SF: 121.421 ~lllz; HC: 3642.6 liz; T· . 
TO: liz; FD: - liz; Lock: 
0 Hz; RF(Pot.Jer): 11/dilj lll.liJ: 
I 
) 
6 3 
o 111 
j_____t __ l_ •-~- I 
RT oc; NT: 16 
iDl,DS: 2.0 s • 
liz; LD: 2.0 liz. 
N 
U1 
Q'\ 
100-
80 
60-
40-
20-
4000 3500 3000 2500 
PLATE CXVI 
C02 Me 
~PIOMol, 
II 
0 
2000 1800 1600 
T R Spectrum 
1400 1200 1000 
of 7 6 
800 600 400 
N 
lJ1 
-..1 
-I 
BIBLIOGRAPHY 
1. Arens, J. F.; van Dorp, D. A. Nature (London) 1946, 
157, 190. 
2. Aszalos, A., Ed.; Antitumor Compounds .2..f Natural 
Orgin: Chemistry and Biochemistry, CRC, Florida, 
1981, Vo1.2, pp 101-128. 
3. Arbuzov, B. A. Pure Appl. Chern. 1964, 2, 307-335. 
4. Ariens, E. J. In Drug Design, Ariens, E. J. Ed., 
Academic Press, New York, 1971, pp 109-114. 
5. Asato, A. E.; Matsumoto, H.; Denny, M.; Liu, R. S. H. 
~Am. Chern. Soc. 1978, 100, 5957. 
6. Baukzis, P.; Baukzis, M. L. F • .:I:_~ Che!h 1981, 
i§_, 235-239. 
7. Baumann, C. A.; Steenbock, H. Science 1932, 1£, 
417-420. 
8. Behrens, N.H.; Leloir, L. F. Proc. Natl. Acad. Sci. 
U.S.A. 1970, ~' 153-159. 
9. Berretti, B.; Grupper, C.; Edelson, Y.; Bermejo, D. 
In Retinoids: Advances in Basic Research and Therapy 
Orfanos, C. E., Ed., 1981, pp 397-399. 
10. Bhat, P. V.; DeLuca, L. M.; Adamo, S.; Akalovsky, I.; 
Silverman-Jones, C. S.; Peck, G. L. J. Lipid Res. 
1979, 20, 357. 
11. Blake, C. C. F.; Geisow, M. J.; Oatley, S. J.; 
Rerat, B.; Rerat, C. ~Mol. Biol. 1978, 121, 339. 
12. Bollag, w. Experientia 1971, 1]_, 90-92. 
13. Bollag, w. Eur. J. Cancer 1972, .§., 689-693. 
14. Bollag, w. Eur. ~ Cancer 1974, lQ, 731-737. 
15. Bollag, w. ; Hartmann, H. R. Cancer Survey 1983, 1_, 
293. 
16. Bollag, w. The La net 1983, 860. 
258 
17. Bollag, W.; Geiger, J .-M. , Retinoid Therapy, 
Cunliffe, W. J.; Miller, A. J.; Ed., MPT Press 
Limited, Lancaster, 1984, pp 1-7. 
18. Brownbridge, P.; Warren, S. J. Chern. Soc. Perkins 
Trans. l 1977, 2272-2285. --
259 
19. Burt, C. T.; Moore, R. R.; Roberts, M. F.; Brady, T. 
J. Biochim. Biophys. Acta 1984, 805, 375-381. 
20. Cohen, S. G.; Wolosinski, H. T.; Schever, P. J. J. 
Am. Chern. Soc., 1949 11, 3439-3440. 
21. Conaradie, W. J.; Garbers, C. F.; Steyn, P. S. J. 
Chern Soc. 1964, 594-597. 
22. Conner, M. J. Life Sciences 1986, 38, 1807. 
23. Cunliffe, W. J.; Miller, A. J.; Ed., Retinoid 
Therapy, MTP Press Limited, Lancaster, 1984. 
24. Curley, R. W.; DeLuca, H. F.~~ Chern. 1984, 
±2.., 1944-1946. Schwieter, U.; Planta, C. V.; Ruegg, 
R.; Isler, 0. Helv. Chim. Acta 1962, ~. 541-548. 
25. Curley, R. W.; SilvC!_, D. P.; DeLuca, H. F. Archives. 
Biochem. Biophys. 1985, 238, 484-489. 
26. Dawson, M. I.; Hobbs, P. D.; Chan, R. L.; 
27. 
Chao, W.-R.; Fung, V. A • .::L_ J:!ed. Che..!!!..:.. 1981, li• 
583-592. 
Dawson, M. 
Chao, W .-R. 
I.; Hobbs, P. D.; Chan, R. L.-S.; 
~ Med. Chern. 1981, li, 1214-1223. 
28. Dawson, M. I.; Chan, R. L.; Hobbs, P. D.; 
Chao, W. R.;Schiff, L. J . .::L_ J:!ed. Che..!!!..:.. 1983, ~. 
1282-1293. 
29. Dawson, M. I.; Hobbs, P. D.; Derdzinshki, K.; 
Chan, R. L.-S.; Gruber, J.; Chao, W.-R.; Smith, S.; 
Thies, R. W.; Schiff, L. J. J. Med. Chern. 1984, 27, 
1516-1531. Butsugan, Y.; Tsukamoto, H.; Morita,~; 
Bito, T. Chern. Lett. 1976, 523-524. 
30. Dawson, M. I.; Hobbs, P. D.; Chan, R.; Derdzinski, 
K.; Helmes, C. T.; Chao, W.; Mierhenry, E.; Schiff, 
L. J. ,In ~mposium on Retinoids, Differentiation and 
Disease, Nugent, J.; Clark, S. Ed., Pittman 
Publishing Ltd., (London, UK), 1985. 
31. DeLuca, H. F., In Retinoids: New Trends in Research 
and Therapy, Saura t, Eds, Karger, Basel ,1985, 
pp 12-19. 
32. Diamond, L.; O'Brien, T. G.; Baird, W. M. Adv. 
Cancer Res. 1980, ].1, 1-74. 
33. Dicken, C. H.; Connolly, S. M. Mayo. Clin. Proc. 
1982, 21_, 51. 
260 
3 4 • Do y 1 e , T • W • ; K a n e k o , T • A n n. ~ M e d. C h e.!!!..!.. 1 9 8 5 , 
20, 169. 
35. Dummound, J. C. Biochem. ~ 1920, ~. 660. 
36. Dunagin, P. E.; Zachman, R. D.; Olson, J. A. Biochim. 
Biophys. Acta 1964, 90, 432. 
37. Englert, G. Helv. Chim. Acta. 1975, ~. 2367~2390. 
38. Ernst, L.: Hopf, H.; Natsias, K. 2..!:...&...:_ !:!_~Res. 
1984, 11· 296-300. 
39. Fidge, N.H.; Shiratori, T.; Ganguly, J., Goodman, 
D. S. J. Lipid Res. 1968, 2, 103. 
40. Frolik, C. A.; Roller, P. P.; Roberts, A. B.; Sporn, 
M. B. J. Biol. Chern. 1980, 255, 8057. 
41. Frot-Coutaz, J. P.; Silverman-Jones, C. S.; Deluca, 
L. M • .:L._ Lipid Res. 1976, 11., 220. 
42. Fujimaki, Y. J. Cancer Res. 1926, lQ, !•69-477. 
43. Geiger, J.; Ott, F.; Bollag, W. Current Therapeutic 
Res. 1984, ]j_, 735. 
44. Goodman, D. S.; Hung, H. S.; Shiratori, T. J. Lipid 
Res. 1965, Q• 390-396. 
45. Goodman, D. S.; Huang, H. S.; Shiratori, T. J. Biol. 
Chern. 1966, 241, 1929-1932. 
46. Goodman, D. S.; Kanai, S.; Raz, A. J. Clin. Invest. 
1968, !:!]_, 2025. 
47. Goodman, D. S. ~Engl.~ Med. 1984, 310, 1023. 
48. Gray, G. A.; Ellis, P. D.; Traficante, D. D.; Maciel, 
G. E. J. ~Res. 1969, 1, 41-54. 
49. Gray, G. A. ~ ~ Reson. 1983, 1£, 111. 
50. Hall, R. H.; Stern, E. S • .:L_ Che.!!!..:.. Soc. 1949, 2035-
3037. 
261 
51. Hanawa, Y.; Kawagoe, K.; Kobayashi, N.; Oshima, T.; 
Kobayashi, Y. Tetrahedron Lett. 1985, 1£, 2881-2884. 
52. Hanni, R.; Bigler, F. Helv. Chim. Acta 1976, 22, 
2221-2227. 
53. Hanzawa, Y.; Yamada, A.; Kobayashi, Y. Tetrahedron 
Lett. 1985, 1£, 2881-2884. 
54. Heller, J. ~ Biol. Chern. 1975, 250, 3613. 
55. Heller, J.; Chen, C-C. J. Biol. Chern. 1977, 252, 
5216. 
56. Isler, 0. W.; Rubber, A.; Ronco A.; Kofler, M. 
Helv. Chim. Acta 1947, 30, 1911. 
57. Iwai, K.; Kosugi, H.; Miyazaki, A: Uda, H. ~.Y.~ 
Commun. 1976, ~. 357-363 • 
. 58. Kajiwara, T.; Nakatomi, T.; Sasaki, K.; Hatanaka, A. 
Agric. Biol. Chern. 1980, 44, 2099-2104. 
59. Kalin, J. R.; Mitton, E. S.; Hill, D. L. Drug Met. 
and Disp. 1981, .2_, 196. 
60. Kanda, Y.; Goodman, D. S.; Canfield, R. E.; 
Morgan, F. J. ~ Biol. Chern. 1974, 249, 6796. 
61. Karrer, P.; Helfenstein, A.; Wehrli, H.; 
Wettstein, A. Helv. Chim. Acta 1930, 11., 1084. 
62. Karrer, P.; Helfenstein, A.; Wehrli, H.; Wettstein, A. 
Helv. Chim. Acta, 1931, 1!, 614-632. 
63. Karrer, P.; Morf, R. Helv. Chim. Acta 1933, .l§., 557. 
64. Lee, K. H.; Tong, T. G. J. Pharm. Sci. 1969, 58, 
773-774. 
65. Lee, K. H.: Fu, C-C; Spencer, M. R.; Tong, T. G.; 
Poon, R. ~ Pharm. Sci. 1973, Ql, 895-899. 
66. Lewis, A. J.; Capetola, R. J.; Mezick, J. A. Ann. 
~ Med. Chern. 1983, ~' 181. 
67. Liu, R. S. J.; Asato, A. E. Tetrahedron 1984, 1Q, 
1931-1969. 
262 
68. Loeliger, P.; Bollag, W.; Mayer, H. Eur. ;L_ k!_ed. 
Chern. 1980, 12, 9-15. 
69. Longnecker, D. S.; Kuhlmann, E. T.; Curphey, T. J. 
Cancer Res. 1983, 43, 3219. 
70. MacNiol, D. D.; McKendrick, J. J. J. ~h~m. ~Q~ 
Perkins Trans. l 1974, 2593-2496. 
70a. March, J., In Advanced Organic Chemistry; Wiley-
Interscience: New York, 1986, pp 331. 
71. Mathews-Roth, M. M. Pure & Appl. Chern. 1985, ll• 
717. 
72. Mayer, H.; Bollag, W.; Hanni, R.; Ruegg, R. 
Experientia 1978, 34, 1105-1119. 
73. Mayer, H. Pure & Appl. Chern. 1979, 2l_, 535-534. 
74. McCollum, E. V., Davis, M. J. Biol. Che.!!!...!_ 1913, 12• 
181. 
75. McCollum, E. V., Davis, M. J. Biol. Chern. 1915, ll· 
167. 
-
76. McCormick, A. M.; Napoli, J. L.; Schnoes, M. K.; 
DeLuca, H. F. Biochemistry 1978, lZ· 4085. 
77. Mead, D.; Loh, R.; Asto, A. E.; Liu, R. S. H. 
Tetrahedron Lett. 1985, IQ, 2873-2876. 
78. Mehta, R. G.; Schiff, L. J.; Moore, S. J.; 
Buckley, A. M.; Dawson, M. I. l.!! Vivo Cellular & 
Developmental Biology 1986, 11, 164. 
79. Moon, P. C.; Thompson, H. J.; Becci, P. J.; Grubbs, 
C. J.; Gander, R • .J.; Newton, D. L.; Smith, J. M.; 
Phillips~ S. L.; Henderson, W. R.; Mullen, L. T.; 
Brown, C. C.; Sporn, M. B. Cancer Res. 1979, 39, 
1339-1346. 
80. Newcomer, M. E.; Jones, T. A.; Aqvist, J.; 
Sundelin, J.; Eriksson, U.; Rask, L.; Peterson, P. A. 
EMBO ~ 1984, l• 1451. 
81. Newton, D. L.; Henderson, W. R.; Sporn, M. B. Cancer 
Res. 1980, 40, 3412-3425. 
82. Nugent, J.; Clark, S. Ed., Symposium on Retinoids, 
Differtiation and Disease, Pittman Publishing Ltd., 
London, Uk, 1985. 
83. Pawson, B. A.; Chan, K.-K.; DeNoble, J.; 
84. 
Nan, R.-J. L.; Pipermattie, V.; Specian, A. C.; 
Srisethail, S.; Trown, P. W.; Bohoslawec, 0.; 
Machlin, L. J.; Gabriel, E. J. Med. Chern. 1979, 
11_, 1059-1067. - --
Pawson, B. A.; 
Sherman, M. I. 
Ehmann, C. A.; Itri, L. M.; 
1.:_ Med. Chern., 1982 25, 1269-1277. 
85. Payne, G. B. ~~Chern. 1967, 1£, 3351-3355. 
86. Peck, G. L.; Olsen, T. G.; Yoder, F. W.; 
Strauss, J. S.; Downing, D. T.; Pandya, M.; 
Butkus, D.; Arnaud-Battandier, J. ~Engl. J. Med. 
1979, 300, 329. 
87. Peck, G. L. Drugs 1982, ~. 341. 
88. Plewig, G.; Ruhfus, M.; Klorekorn, W. J. J. Invest 
Dermatol. 1983, 80, 357. 
89. Pommer, H. Angew. Chern. 1960, ].1:.., 811. 
263 
90. Pugsley, L. I.; Wills, G.; Crandall, W. A. J. Nutri. 
1944, ~. 365-379. 
91. Quander, R. V.; Lear-y, S. L.; Strandberg J.D.; 
Y a r b o u g h , B • A • ; S q u i r e , R • A . C a nc e r R e s • , 1 9 8 5 , 4 5 , 
5235. 
92. Rask, L.; Peteron, P. S. J. Biol. Che.!!!.!_, 1976, 251, 
6360. 
93. Rask, L.; Anundi, H.; Pertson, P. A. FEBS Letters 
1979, 104, 55. 
94. Rietz, L.; Anundi, H.; Pertson, P. A. FEES Letters 
1974, 1£, 237. 
95. Roberts, A. B.; Sporn, M. B. The Retinoids, 
Sporn, M. B.; Roberts, A. B.; Goodman, D. S. Ed., 
Academic Press: New York, 1984, Vol 2, pp 209-286. 
96. Ruban, G.; Zobel, D.; Kossmehl, G.; Nuck, R. Che.!!!..:._ 
Ber. 1980, 113, 3384-3388. 
97. Rustin, G. J. S.; Eccles, S. A. Brit. J. Cancer 1985, 
g, 443. 
98. Saffioth, U.; Montesano, R.; Sellakumar, A. R.; 
Borg, S. A. Cancer Res. 1967, 1Q, 857-864. 
99. Sani, B. P.; Dawson, M. I.; Hobbs, P. D.; 
Chan, R. L.-S.; Schiff, L. J. Cancer Res. 1984, 
44, 190-195. 
100. Schlichting, D. A.; Wooding, W. M.; Brown, M. J. 
~ Pharm. Sci. 1973, 62, 388. 
101. Schwieter, U., Englert, G.; Rigassi, N.; Vetter, W. 
Pure ! Appl. Chern. 1969, lQ, 365-420. 
102. Seyferth, D.; Stone, F. G. A.~ Am. Chern. Soc. 
1957' J..2..., 515-517. 
103. Seyferth, D. Coll ~ ~ 19 , !, 258-260. 
104. Sherman, M. I. Ed., Retinoids and Cell 
Differentiation, CRC: Florida, 1986. 
264 
105. Sibel'Dina, L.A.; Kayushin, L. P.; Zvonkova, E. N.; 
Skalaran, T. D.; Khristoforov, V. A.; Evstigneeva, R. 
P. Studia Biophysica 1978, 187-193. 
106. Sietsema, W. K.; DeLuca, H. F. J. Nutr. 1982, 112, 
1481-1489. 
107. Simons, J. H.; Ramle~, E. D. J. Am. Chern. Soc. 
1943, Q2, 389-392. 
108. Smith, J. E.; Milch, P.O.; Muto, Y.; Goodman, D. S. 
Biochem. ~ 1973, 132, 821-827. 
109. Sporn, M. B.; Roberts, A. B.; Goodman D. S. Ed;, The 
Retinoids, Academic Press: New York, Vol. 1, 1984-.--
110. Sporn, M. B.; Roberts, A. B.; Goodman D. S. Ed., The 
Retinoid s , Academic Press : New York , V o 1 . 2 , 1 9 8 4-.-
111. Sporn, M. B.; Roberts, A. B.; Goodman D. S. Ed., The 
Retinoids, Academic Press: New York, Vol. 1, 1984--
pp 244-261. 
112. Sporn, M. B.; Roberts, A. B.; Goodman D. S. Ed., The 
Retinoids, Academic Press: New York, Vol. 1, 1984 
pp 262-271. 
113. Sporn, M. B.; Roberts, A. B., In Symposium ..2.f Retinoids, 
Differentiation and Disease, Nugent, J.; Clark, S. 
Ed., Pitman Publishing Ltd: London, UK, 1985, pp 1-5. 
114. Stec, W. J. Ace. Chern. Res. 1983, 1£, 411-417. 
115. Stephenss-Jarnagin, A.; Sietsema, W. K.; Miller, 
D.A.; DeLuca, H. F. Archives. Biochem. Biophys. 
1983, 220, 502-508. 
116. Stepp, W. Biochem. ~ 1909, 11, 452. 
Chern. Abstr. 1910, !, 485. 
117. Stepp, W. ~ Biol., 1911, 135. Chern. Abstr. 
1912, .§., 103. 
265 
118. Stephens-Jarnagin, A.; Sietsema, H. K.; DeLuca, H. F. 
Arch. Biochem. Biophys. 1983, 220, 502. 
119. Strickland, D.; Breitman, T. R.; Frickel F.; 
Nurrenbach, A.; Hadicke, E.; Sporn, M. B., Cancer 
Res. 1983, ~. 5268-5272. 
120. Taguchi, T.; Hosoda, A.; Kobayashi, Y. Tetrahedron 
Lett., 1985, 1§., 6209-6212. 
1 21 • Takas e, S.; 0 n g, D. E.; C h y t i 1, F. Arc h. B i o c hem. 
Biophys. 1986, 247, 328. 
122. Verma, A. K. ; Boutwell, R. K. Cancer Res. 1977, ]]_, 
2196-2101. 
-
123. Verma, A. K.; Boutwell, R. K. Cancer Res. 1978, 1..§_, 
793-801. 
124. Verma, A. K. ; Shapas, B. G. ; Rice, H. M. i Boutwell, 
R. K. Cancer Res. 1979, 39, 419-425. 
125. Wald, G. J. Gen. Physiol. 1935, 1..2_, 351. 
126. Wald, G. J. Gen. Physiol. 1935, 1..2_, 781. 
12 7. Wald, G. Science 1968, 162, 230. 
128. Waugh, K. M.; Berlin, K. D.; Ford, W. T.; 
Holt, E. M.; Carroll, J. P.; Schamber, P. R.; 
Thompson, M. D.; Schiff, L. J • .:L_ ~ed. Che.!!!..:.. 1985, 
1.§_, 116-124. 
129. Welch, S.C.; Gruber, J. M • .:L_ ~ed. Che.!!!..:.. 1982, 47, 285-
389. 
130. Wolback, S. B.; Howe, R. R. ~ ~ Med. 125, 
_g, 753-777. 
131. Wittig, G.; Schollkopf, U. Che.!!!...!_Ber. 1954, .§1_, 
1318. 
266 
132. Wu, R.; Wu, M. M. J. ~Cell Phys. 1986, 127, 73. 
133. Zile, M.; DeLuca, H. F. J. Nutri. 1968, 302-308. 
-= 
f\i 
y·· 
VITA 
LYLE w. SPRUCE 
Candidate for the Degree of 
Doctor of Philosophy 
Thesis: SYNTHESES, STRUCTURAL ELUCIDATION AND BIOLOGICAL 
ACTIVITY OF NEW HETEROAROTINOIDS 
Major Field: Chemistry 
Biographical: 
Personal Data: Born in Denver, Colorado, May 28, 
1959, the son of Norman and Alice Spruce. 
Education: High School; Abraham Lincoln High School; 
Denver, Colorado, June, 1977; B.S., Metropolitan 
State College; Denver, Colorado, 1982; completed 
requirements for the Doctor of Philosophy degree 
at Oklahoma State University, May, 1987. 
Professional Experience: Teaching Assistant, 
Oklahoma State University, 1982-85. Research 
Assistant, 1985-86. 
